{"title":"GH Analogs and Secretagogues","description":"","products":[{"product_id":"aod9604-10mg-vial","title":"AOD9604 10mg vial","description":"\u003cp data-start=\"318\" data-end=\"800\" class=\"\"\u003e\u003cstrong data-start=\"318\" data-end=\"329\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                            \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"318\" data-end=\"800\" class=\"\"\u003e\u003cstrong data-start=\"318\" data-end=\"329\"\u003eAOD9604\u003c\/strong\u003e is a synthetic peptide fragment derived from the C-terminal region (amino acids 177–191) of human growth hormone (hGH), with an additional N-terminal tyrosine residue. Originally developed for obesity management, AOD9604 aims to replicate the lipolytic (fat-reducing) effects of hGH without its associated anabolic (growth-promoting) actions. Despite initial promise, its clinical development has faced challenges, and it remains unapproved by major regulatory agencies.\u003c\/p\u003e\n\u003chr data-start=\"802\" data-end=\"805\" class=\"\"\u003e\n\u003ch2 data-start=\"807\" data-end=\"836\" class=\"\"\u003e\u003cstrong data-start=\"810\" data-end=\"836\"\u003e2. Mechanism of Action\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp data-start=\"838\" data-end=\"994\" class=\"\"\u003eAOD9604 is designed to stimulate lipolysis and inhibit lipogenesis, thereby promoting fat breakdown and preventing fat accumulation. Its mechanisms include:\u003c\/p\u003e\n\u003cul data-start=\"996\" data-end=\"1683\"\u003e\n\u003cli data-start=\"996\" data-end=\"1402\" class=\"\"\u003e\n\u003cp data-start=\"998\" data-end=\"1402\" class=\"\"\u003e\u003cstrong data-start=\"998\" data-end=\"1039\"\u003eActivation of β3-Adrenergic Receptors\u003c\/strong\u003e: AOD9604 appears to enhance lipolysis by upregulating β3-adrenergic receptors in adipose tissue. Studies in obese mice have shown that AOD9604 increases β3-AR expression, leading to enhanced fat metabolism. However, its lipolytic effects are diminished in β3-AR knockout mice, suggesting a critical role for these receptors .\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1404\" data-end=\"1683\" class=\"\"\u003e\n\u003cp data-start=\"1406\" data-end=\"1683\" class=\"\"\u003e\u003cstrong data-start=\"1406\" data-end=\"1456\"\u003eIndependence from IGF-1 and Glucose Metabolism\u003c\/strong\u003e: Unlike full-length hGH, AOD9604 does not significantly affect insulin-like growth factor 1 (IGF-1) levels or glucose metabolism, reducing the risk of hyperglycemia and insulin resistance .\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"1685\" data-end=\"1688\" class=\"\"\u003e\n\u003ch2 data-start=\"1690\" data-end=\"1717\" class=\"\"\u003e\u003cstrong data-start=\"1693\" data-end=\"1717\"\u003e3. Clinical Efficacy\u003c\/strong\u003e\u003c\/h2\u003e\n\u003ch3 data-start=\"1719\" data-end=\"1751\" class=\"\"\u003e\u003cstrong data-start=\"1723\" data-end=\"1751\"\u003e3.1. Preclinical Studies\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp data-start=\"1753\" data-end=\"1796\" class=\"\"\u003eIn animal models, AOD9604 has demonstrated:\u003c\/p\u003e\n\u003cul data-start=\"1798\" data-end=\"2303\"\u003e\n\u003cli data-start=\"1798\" data-end=\"2078\" class=\"\"\u003e\n\u003cp data-start=\"1800\" data-end=\"2078\" class=\"\"\u003e\u003cstrong data-start=\"1800\" data-end=\"1820\"\u003eWeight Reduction\u003c\/strong\u003e: Obese Zucker rats treated with AOD9604 showed a significant reduction in body weight gain compared to controls. The peptide enhanced lipolytic activity in adipose tissues without adverse effects on insulin sensitivity .\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2080\" data-end=\"2303\" class=\"\"\u003e\n\u003cp data-start=\"2082\" data-end=\"2303\" class=\"\"\u003e\u003cstrong data-start=\"2082\" data-end=\"2109\"\u003eEnhanced Fat Metabolism\u003c\/strong\u003e: Chronic administration in obese mice led to increased expression of β3-AR and improved lipid metabolism, supporting its potential as a fat-reducing agent .\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"2305\" data-end=\"2339\" class=\"\"\u003e\u003cstrong data-start=\"2309\" data-end=\"2339\"\u003e3.2. Human Clinical Trials\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul data-start=\"2341\" data-end=\"2885\"\u003e\n\u003cli data-start=\"2341\" data-end=\"2638\" class=\"\"\u003e\n\u003cp data-start=\"2343\" data-end=\"2638\" class=\"\"\u003e\u003cstrong data-start=\"2343\" data-end=\"2360\"\u003e12-Week Trial\u003c\/strong\u003e: In a randomized, placebo-controlled trial, subjects receiving 1 mg\/day of AOD9604 experienced an average weight loss of 2.6 kg, compared to 0.8 kg in the placebo group. The treatment was well-tolerated with no significant adverse effects .\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2640\" data-end=\"2885\" class=\"\"\u003e\n\u003cp data-start=\"2642\" data-end=\"2885\" class=\"\"\u003e\u003cstrong data-start=\"2642\" data-end=\"2659\"\u003e24-Week Trial\u003c\/strong\u003e: A subsequent larger study involving 536 subjects did not demonstrate significant weight loss compared to placebo, leading to the discontinuation of its development for obesity treatment .\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"2887\" data-end=\"2890\" class=\"\"\u003e\n\u003ch2 data-start=\"2892\" data-end=\"2925\" class=\"\"\u003e\u003cstrong data-start=\"2895\" data-end=\"2925\"\u003e4. Safety and Tolerability\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp data-start=\"2927\" data-end=\"3002\" class=\"\"\u003eAOD9604 has been generally well-tolerated in both animal and human studies:\u003c\/p\u003e\n\u003cul data-start=\"3004\" data-end=\"3486\"\u003e\n\u003cli data-start=\"3004\" data-end=\"3284\" class=\"\"\u003e\n\u003cp data-start=\"3006\" data-end=\"3284\" class=\"\"\u003e\u003cstrong data-start=\"3006\" data-end=\"3037\"\u003eNon-Genotoxic and Non-Toxic\u003c\/strong\u003e: Comprehensive toxicological assessments, including Ames tests and chromosomal aberration assays, revealed no genotoxic or toxic effects. Chronic administration in rats and monkeys showed no adverse outcomes .\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3286\" data-end=\"3486\" class=\"\"\u003e\n\u003cp data-start=\"3288\" data-end=\"3486\" class=\"\"\u003e\u003cstrong data-start=\"3288\" data-end=\"3312\"\u003eMinimal Side Effects\u003c\/strong\u003e: Clinical trials reported minimal side effects, with no significant impact on IGF-1 levels, glucose metabolism, or insulin sensitivity .\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"3488\" data-end=\"3491\" class=\"\"\u003e\n\u003ch2 data-start=\"3493\" data-end=\"3535\" class=\"\"\u003e\u003cstrong data-start=\"3496\" data-end=\"3535\"\u003e5. Additional Therapeutic Potential\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp data-start=\"3537\" data-end=\"3606\" class=\"\"\u003eBeyond weight management, AOD9604 has shown potential in other areas:\u003c\/p\u003e\n\u003cul data-start=\"3608\" data-end=\"4261\"\u003e\n\u003cli data-start=\"3608\" data-end=\"3957\" class=\"\"\u003e\n\u003cp data-start=\"3610\" data-end=\"3957\" class=\"\"\u003e\u003cstrong data-start=\"3610\" data-end=\"3636\"\u003eCartilage Regeneration\u003c\/strong\u003e: In a study involving osteoarthritic rabbits, intra-articular injections of AOD9604, alone or combined with hyaluronic acid, led to improved cartilage morphology and reduced histopathological damage. This suggests potential applications in joint repair and osteoarthritis treatment .\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3959\" data-end=\"4261\" class=\"\"\u003e\n\u003cp data-start=\"3961\" data-end=\"4261\" class=\"\"\u003e\u003cstrong data-start=\"3961\" data-end=\"3986\"\u003eCellular Regeneration\u003c\/strong\u003e: In vitro studies indicate that AOD9604 may promote the differentiation of mesenchymal stem cells into bone and muscle cells, as well as enhance proteoglycan and collagen production in chondrocytes, supporting tissue repair processes .\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4263\" data-end=\"4266\" class=\"\"\u003e\n\u003ch2 data-start=\"4268\" data-end=\"4312\" class=\"\"\u003e\u003cstrong data-start=\"4271\" data-end=\"4312\"\u003e6. Regulatory Status and Availability\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cul data-start=\"4314\" data-end=\"4844\"\u003e\n\u003cli data-start=\"4314\" data-end=\"4573\" class=\"\"\u003e\n\u003cp data-start=\"4316\" data-end=\"4573\" class=\"\"\u003e\u003cstrong data-start=\"4316\" data-end=\"4339\"\u003eRegulatory Approval\u003c\/strong\u003e: AOD9604 is not approved by the U.S. Food and Drug Administration (FDA) or other major regulatory bodies for any therapeutic use. Its development for obesity treatment was discontinued due to insufficient efficacy in clinical trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4575\" data-end=\"4844\" class=\"\"\u003e\n\u003cp data-start=\"4577\" data-end=\"4844\" class=\"\"\u003e\u003cstrong data-start=\"4577\" data-end=\"4592\"\u003eCurrent Use\u003c\/strong\u003e: Despite the lack of approval, AOD9604 is available through some compounding pharmacies and wellness clinics, often marketed for weight loss and anti-aging purposes. However, its use in these contexts is off-label and lacks robust clinical validation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4846\" data-end=\"4849\" class=\"\"\u003e\n\u003ch2 data-start=\"4851\" data-end=\"4871\" class=\"\"\u003e\u003cstrong data-start=\"4854\" data-end=\"4871\"\u003e7. Conclusion\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp data-start=\"4873\" data-end=\"5471\" class=\"\"\u003eAOD9604 is a synthetic peptide that mimics the fat-reducing effects of hGH without its growth-promoting actions. While preclinical studies and early clinical trials showed promise in weight management and tissue regeneration, subsequent larger trials failed to demonstrate significant efficacy, leading to the cessation of its development for obesity treatment. Its safety profile appears favorable, but the lack of regulatory approval and comprehensive clinical data limits its therapeutic application. Further research is needed to fully elucidate its potential benefits and mechanisms of action.\u003c\/p\u003e\n\u003chr data-start=\"5473\" data-end=\"5476\" class=\"\"\u003e\n\u003cp data-start=\"5478\" data-end=\"5493\" class=\"\"\u003e\u003cstrong data-start=\"5478\" data-end=\"5493\"\u003eReferences:\u003c\/strong\u003e\u003c\/p\u003e\n\u003col data-start=\"5495\" data-end=\"6609\"\u003e\n\u003cli data-start=\"5495\" data-end=\"5749\" class=\"\"\u003e\n\u003cp data-start=\"5498\" data-end=\"5749\" class=\"\"\u003eHeffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. \u003cem data-start=\"5672\" data-end=\"5687\"\u003eEndocrinology\u003c\/em\u003e. 2001;142(12):5182-9.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5751\" data-end=\"5922\" class=\"\"\u003e\n\u003cp data-start=\"5754\" data-end=\"5922\" class=\"\"\u003eNg FM, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. \u003cem data-start=\"5853\" data-end=\"5863\"\u003eHorm Res\u003c\/em\u003e. 2000;53(6):274-8.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5924\" data-end=\"6076\" class=\"\"\u003e\n\u003cp data-start=\"5927\" data-end=\"6076\" class=\"\"\u003eObesity Pharmacotherapy: Current Perspectives and Future Directions. \u003cem data-start=\"5996\" data-end=\"6024\"\u003eFrontiers in Endocrinology\u003c\/em\u003e. 2013;4:73.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6078\" data-end=\"6247\" class=\"\"\u003e\n\u003cp data-start=\"6081\" data-end=\"6247\" class=\"\"\u003eSafety and Tolerability of the Hexadecapeptide AOD9604 in Humans. \u003cem data-start=\"6147\" data-end=\"6188\"\u003eJournal of Endocrinology and Metabolism\u003c\/em\u003e. 2013;3(1-2):7-15.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6249\" data-end=\"6470\" class=\"\"\u003e\n\u003cp data-start=\"6252\" data-end=\"6470\" class=\"\"\u003eEffect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in a Rabbit Model of Osteoarthritis. \u003cem data-start=\"6368\" data-end=\"6409\"\u003eAnnals of Clinical \u0026amp; Laboratory Science\u003c\/em\u003e. 2015;45(4):426-432.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6472\" data-end=\"6609\" class=\"\"\u003e\n\u003cp data-start=\"6475\" data-end=\"6609\" class=\"\"\u003eAOD 9604 Peptide: Research in Lipolysis, Cell Regeneration, and Cancer. \u003cem data-start=\"6547\" data-end=\"6562\"\u003eCore Peptides\u003c\/em\u003e. 2024\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684842336594,"sku":null,"price":50.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/aod9604_10mg.png?v=1770834802"},{"product_id":"mk777-100x10mg-copy","title":"MK777 1g","description":"\u003cp data-end=\"70\" data-start=\"0\"\u003e\u003cspan data-end=\"392\" data-start=\"377\"\u003e\u003cspan\u003e                               \u003c\/span\u003e\u003cspan style=\"font-weight: bold; color: rgb(255, 42, 0);\"\u003e           \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"font-weight: bold; text-decoration: underline;\"\u003e\u003cspan style=\"text-decoration: underline; color: rgb(255, 42, 0);\"\u003eFOR HUMAN CONSUMPTION\u003cmeta charset=\"UTF-8\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"70\" data-start=\"0\"\u003e\u003cstrong data-end=\"70\" data-start=\"0\"\u003eMK-777 (Acetamoren) \u003c\/strong\u003e is sold online as a \u003cstrong data-end=\"273\" data-start=\"193\"\u003eresearch-only small-molecule ghrelin\/secretagogue receptor (GHSR-1a) agonist\u003c\/strong\u003e and \u003cstrong data-end=\"311\" data-start=\"278\"\u003eanalog of MK-677 (ibutamoren)\u003c\/strong\u003e. It is \u003cstrong data-end=\"347\" data-start=\"319\"\u003enot an approved medicine\u003c\/strong\u003e and there are \u003cstrong data-end=\"406\" data-start=\"362\"\u003eno peer-reviewed human or animal studies\u003c\/strong\u003e publicly indexed as of now. Chemical directories and vendors list CAS \u003cstrong data-end=\"492\" data-start=\"477\"\u003e950841-87-9\u003c\/strong\u003e with an indole–piperidine “spiro” scaffold and the following identifiers: \u003cstrong data-end=\"576\" data-start=\"567\"\u003eIUPAC\u003c\/strong\u003e (propanamide, 2-(acetylamino)…), \u003cstrong data-end=\"616\" data-start=\"610\"\u003eMF\u003c\/strong\u003e ≈ \u003cstrong data-end=\"634\" data-start=\"619\"\u003eC29H38N4O6S\u003c\/strong\u003e, \u003cstrong data-end=\"642\" data-start=\"636\"\u003eMW\u003c\/strong\u003e ≈ \u003cstrong data-end=\"660\" data-start=\"645\"\u003e570.7 g\/mol\u003c\/strong\u003e. Claims that MK-777 is “more selective\/potent” than MK-677 are \u003cstrong data-end=\"748\" data-start=\"724\"\u003emarketing assertions\u003c\/strong\u003e, not independent data.\u003cspan data-state=\"closed\" class=\"\"\u003e\u003cspan data-testid=\"webpage-citation-pill\" class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"1014\" data-start=\"1011\"\u003e\n\u003ch3 data-end=\"1090\" data-start=\"1016\"\u003eAdditional Benefits Now Being \u003cstrong data-end=\"1071\" data-start=\"1050\"\u003eMarketed\/Proposed\u003c\/strong\u003e (evidence caveats)\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"2349\" data-start=\"1092\"\u003e\n\u003cthead data-end=\"1144\" data-start=\"1092\"\u003e\n\u003ctr data-end=\"1144\" data-start=\"1092\"\u003e\n\u003cth data-col-size=\"md\" data-end=\"1102\" data-start=\"1092\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-col-size=\"xl\" data-end=\"1144\" data-start=\"1102\"\u003eWhat sellers claim vs. what’s verified\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"2349\" data-start=\"1155\"\u003e\n\u003ctr data-end=\"1462\" data-start=\"1155\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1202\" data-start=\"1155\"\u003e\u003cstrong data-end=\"1201\" data-start=\"1157\"\u003e1 GH\/IGF-1 elevation (oral secretagogue)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"1462\" data-start=\"1202\" data-col-size=\"xl\"\u003eVendors position MK-777 as a \u003cstrong data-end=\"1261\" data-start=\"1233\"\u003eghrelin receptor agonist\u003c\/strong\u003e intended to raise \u003cstrong data-end=\"1296\" data-start=\"1280\"\u003epulsatile GH\u003c\/strong\u003e and \u003cstrong data-end=\"1310\" data-start=\"1301\"\u003eIGF-1\u003c\/strong\u003e, similar to MK-677. \u003cstrong data-end=\"1357\" data-start=\"1331\"\u003eNo peer-reviewed PK\/PD\u003c\/strong\u003e for MK-777 itself is available to confirm magnitude or duration. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003cspan data-testid=\"webpage-citation-pill\" class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1718\" data-start=\"1463\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1531\" data-start=\"1463\"\u003e\u003cstrong data-end=\"1530\" data-start=\"1465\"\u003e2 “Higher receptor affinity \/ better selectivity” than MK-677\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"1718\" data-start=\"1531\" data-col-size=\"xl\"\u003eStatements like “92% greater affinity (Ki ~0.8 nM)” appear \u003cstrong data-end=\"1618\" data-start=\"1592\"\u003eonly in marketing copy\u003c\/strong\u003e; no independent binding data or head-to-head studies found. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003cspan data-testid=\"webpage-citation-pill\" class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1966\" data-start=\"1719\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1760\" data-start=\"1719\"\u003e\u003cstrong data-end=\"1759\" data-start=\"1721\"\u003e3 Body-composition, bone, recovery\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"1966\" data-start=\"1760\" data-col-size=\"xl\"\u003eSellers extrapolate \u003cstrong data-end=\"1799\" data-start=\"1782\"\u003eclass effects\u003c\/strong\u003e (MK-677 literature) to MK-777. There are \u003cstrong data-end=\"1861\" data-start=\"1841\"\u003eno MK-777 trials\u003c\/strong\u003edemonstrating lean-mass, strength, BMD, or performance outcomes. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003cspan data-testid=\"webpage-citation-pill\" class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2151\" data-start=\"1967\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2009\" data-start=\"1967\"\u003e\u003cstrong data-end=\"2008\" data-start=\"1969\"\u003e4 “Improved tolerability vs MK-677”\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"2151\" data-start=\"2009\" data-col-size=\"xl\"\u003eClaims of \u003cstrong data-end=\"2062\" data-start=\"2021\"\u003eless appetite increase, less cortisol\u003c\/strong\u003e are unsubstantiated; no comparative safety data. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003cspan data-testid=\"webpage-citation-pill\" class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2349\" data-start=\"2152\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2201\" data-start=\"2152\"\u003e\u003cstrong data-end=\"2200\" data-start=\"2154\"\u003e5 Convenient forms (powder\/capsule\/liquid)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"2349\" data-start=\"2201\" data-col-size=\"xl\"\u003eWidely offered for “lab use only”; \u003cstrong data-end=\"2289\" data-start=\"2238\"\u003equality, identity, and purity are not regulated\u003c\/strong\u003e and vary by vendor. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003cspan data-testid=\"webpage-citation-pill\" class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"2354\" data-start=\"2351\"\u003e\n\u003ch2 data-end=\"2388\" data-start=\"2356\"\u003e2. Chemical\/Mechanistic Notes\u003c\/h2\u003e\n\u003cul data-end=\"3106\" data-start=\"2390\"\u003e\n\u003cli data-end=\"2936\" data-start=\"2390\"\u003e\n\u003cp data-end=\"2441\" data-start=\"2392\"\u003e\u003cstrong data-end=\"2439\" data-start=\"2392\"\u003eListed identifiers (vendor\/registry sites):\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"2936\" data-start=\"2444\"\u003e\n\u003cli data-end=\"2511\" data-start=\"2444\"\u003e\n\u003cp data-end=\"2511\" data-start=\"2446\"\u003e\u003cstrong data-end=\"2454\" data-start=\"2446\"\u003eCAS:\u003c\/strong\u003e \u003cstrong data-end=\"2470\" data-start=\"2455\"\u003e950841-87-9\u003c\/strong\u003e; names “\u003cstrong data-end=\"2493\" data-start=\"2479\"\u003eAcetamoren\u003c\/strong\u003e”, “\u003cstrong data-end=\"2507\" data-start=\"2497\"\u003eMK-777\u003c\/strong\u003e”.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2705\" data-start=\"2514\"\u003e\n\u003cp data-end=\"2705\" data-start=\"2516\"\u003e\u003cstrong data-end=\"2538\" data-start=\"2516\"\u003eIUPAC (as listed):\u003c\/strong\u003e \u003cem data-end=\"2702\" data-start=\"2539\"\u003ePropanamide, 2-(acetylamino)-N-[(1R)-2-[1,2-dihydro-1-(methylsulfonyl)spiro[3H-indole-3,4′-piperidin]-1′-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl-(ACI)\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2762\" data-start=\"2708\"\u003e\n\u003cp data-end=\"2762\" data-start=\"2710\"\u003e\u003cstrong data-end=\"2725\" data-start=\"2710\"\u003eFormula\/MW:\u003c\/strong\u003e \u003cstrong data-end=\"2741\" data-start=\"2726\"\u003eC29H38N4O6S\u003c\/strong\u003e, \u003cstrong data-end=\"2759\" data-start=\"2743\"\u003e~570.7 g\/mol\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2936\" data-start=\"2765\"\u003e\n\u003cp data-end=\"2936\" data-start=\"2767\"\u003e(Note: several vendor pages show slightly different formulas\/weights—another sign that the \u003cstrong data-end=\"2894\" data-start=\"2858\"\u003eidentity record isn’t harmonized\u003c\/strong\u003e.) \u003cspan data-state=\"closed\" class=\"\"\u003e\u003cspan data-testid=\"webpage-citation-pill\" class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003ca class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!\" alt=\"https:\/\/www.chemicalbook.com\/ChemicalProductProperty_EN_CB614298822.htm?utm_source=chatgpt.com\" rel=\"noopener\" href=\"https:\/\/www.chemicalbook.com\/ChemicalProductProperty_EN_CB614298822.htm?utm_source=chatgpt.com\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between\"\u003e\u003cspan class=\"max-w-[15ch] grow truncate overflow-hidden text-center\"\u003eChemicalBook\u003c\/span\u003e\u003cspan class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\"\u003e+1\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3106\" data-start=\"2937\"\u003e\n\u003cp data-end=\"3106\" data-start=\"2939\"\u003e\u003cstrong data-end=\"2959\" data-start=\"2939\"\u003ePurported class:\u003c\/strong\u003e \u003cstrong data-end=\"2991\" data-start=\"2960\"\u003eNon-peptide GHSR-1a agonist\u003c\/strong\u003e (ghrelin mimetic), often mis-tagged online as a “SARM,” which it is \u003cstrong data-end=\"3067\" data-start=\"3060\"\u003enot\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003cspan data-testid=\"webpage-citation-pill\" class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"3404\" data-start=\"3108\"\u003e\u003cstrong data-end=\"3165\" data-start=\"3108\"\u003eInference from class (if it truly activates GHSR-1a):\u003c\/strong\u003e Expect \u003cstrong data-end=\"3203\" data-start=\"3173\"\u003eGH pulses → ↑IGF-1\/IGFBP-3\u003c\/strong\u003e, \u003cstrong data-end=\"3238\" data-start=\"3205\"\u003eorexigenic signaling (hunger)\u003c\/strong\u003e, possible \u003cstrong data-end=\"3275\" data-start=\"3249\"\u003ewater\/sodium retention\u003c\/strong\u003e, and class-typical \u003cstrong data-end=\"3314\" data-start=\"3295\"\u003eglucose\/insulin\u003c\/strong\u003e effects—\u003cstrong data-end=\"3330\" data-start=\"3323\"\u003ebut\u003c\/strong\u003e the \u003cstrong data-end=\"3403\" data-start=\"3335\"\u003edose–response, half-life, and off-targets for MK-777 are unknown\u003c\/strong\u003e.\u003c\/p\u003e\n\u003chr data-end=\"3409\" data-start=\"3406\"\u003e\n\u003ch2 data-end=\"3442\" data-start=\"3411\"\u003e3. Pharmacokinetics \/ Dosing\u003c\/h2\u003e\n\u003cul data-end=\"3688\" data-start=\"3444\"\u003e\n\u003cli data-end=\"3688\" data-start=\"3444\"\u003e\n\u003cp data-end=\"3688\" data-start=\"3446\"\u003e\u003cstrong data-end=\"3469\" data-start=\"3446\"\u003eNo peer-reviewed PK\u003c\/strong\u003e exists for MK-777. Any reported \u003cstrong data-end=\"3539\" data-start=\"3502\"\u003ehalf-life or oral bioavailability\u003c\/strong\u003e on vendor pages should be considered \u003cstrong data-end=\"3601\" data-start=\"3577\"\u003eunverified marketing\u003c\/strong\u003e. Compare with MK-677 only as \u003cstrong data-end=\"3659\" data-start=\"3631\"\u003ebackground class context\u003c\/strong\u003e, not as evidence for MK-777.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"3693\" data-start=\"3690\"\u003e\n\u003ch2 data-end=\"3737\" data-start=\"3695\"\u003e4. Safety \u0026amp; Tolerability (risk framing)\u003c\/h2\u003e\n\u003cp data-end=\"3832\" data-start=\"3739\"\u003eWithout clinical data, safety must be inferred from \u003cstrong data-end=\"3816\" data-start=\"3791\"\u003eghrelin-agonist class\u003c\/strong\u003e (e.g., MK-677):\u003c\/p\u003e\n\u003cul data-end=\"4642\" data-start=\"3834\"\u003e\n\u003cli data-end=\"4029\" data-start=\"3834\"\u003e\n\u003cp data-end=\"4029\" data-start=\"3836\"\u003e\u003cstrong data-end=\"3865\" data-start=\"3836\"\u003eLikely on-target effects:\u003c\/strong\u003e \u003cstrong data-end=\"3888\" data-start=\"3866\"\u003eIncreased appetite\u003c\/strong\u003e, \u003cstrong data-end=\"3910\" data-start=\"3890\"\u003etransient hunger\u003c\/strong\u003e, \u003cstrong data-end=\"3932\" data-start=\"3912\"\u003eperipheral edema\u003c\/strong\u003e, \u003cstrong data-end=\"3970\" data-start=\"3934\"\u003ehand\/foot stiffness\/paresthesias\u003c\/strong\u003e, \u003cstrong data-end=\"3999\" data-start=\"3972\"\u003eweight gain (water\/FFM)\u003c\/strong\u003e; \u003cstrong data-end=\"4017\" data-start=\"4001\"\u003evivid dreams\u003c\/strong\u003e for some.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4160\" data-start=\"4030\"\u003e\n\u003cp data-end=\"4160\" data-start=\"4032\"\u003e\u003cstrong data-end=\"4046\" data-start=\"4032\"\u003eMetabolic:\u003c\/strong\u003e Potential \u003cstrong data-end=\"4108\" data-start=\"4057\"\u003eworsening of fasting glucose\/insulin resistance\u003c\/strong\u003e in susceptible people; \u003cstrong data-end=\"4148\" data-start=\"4132\"\u003elipid shifts\u003c\/strong\u003e possible.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4278\" data-start=\"4161\"\u003e\n\u003cp data-end=\"4278\" data-start=\"4163\"\u003e\u003cstrong data-end=\"4177\" data-start=\"4163\"\u003eEndocrine:\u003c\/strong\u003e Class can nudge \u003cstrong data-end=\"4216\" data-start=\"4194\"\u003ecortisol\/prolactin\u003c\/strong\u003e in some reports with analogs; MK-777-specific data unknown.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4364\" data-start=\"4279\"\u003e\n\u003cp data-end=\"4364\" data-start=\"4281\"\u003e\u003cstrong data-end=\"4298\" data-start=\"4281\"\u003eCardio-renal:\u003c\/strong\u003e \u003cstrong data-end=\"4325\" data-start=\"4299\"\u003eSodium\/water retention\u003c\/strong\u003e → BP drift in sensitive individuals.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4502\" data-start=\"4365\"\u003e\n\u003cp data-end=\"4502\" data-start=\"4367\"\u003e\u003cstrong data-end=\"4384\" data-start=\"4367\"\u003eDrug testing:\u003c\/strong\u003e Ghrelin mimetics used for \u003cstrong data-end=\"4429\" data-start=\"4411\"\u003eGH stimulation\u003c\/strong\u003e are \u003cstrong data-end=\"4456\" data-start=\"4434\"\u003eprohibited by WADA\u003c\/strong\u003e; many labs screen for GH axis manipulation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4642\" data-start=\"4503\"\u003e\n\u003cp data-end=\"4642\" data-start=\"4505\"\u003e\u003cstrong data-end=\"4518\" data-start=\"4505\"\u003eUnknowns:\u003c\/strong\u003e \u003cstrong data-end=\"4608\" data-start=\"4519\"\u003eCarcinogenicity, reproductive toxicity, genotoxicity, long-term hepatic\/renal effects\u003c\/strong\u003e—no datasets available for MK-777.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cblockquote data-end=\"4940\" data-start=\"4644\"\u003e\n\u003cp data-end=\"4940\" data-start=\"4646\"\u003e\u003cstrong data-end=\"4675\" data-start=\"4646\"\u003ePractical harm-reduction:\u003c\/strong\u003e If anyone is handling this in a lab, verify \u003cstrong data-end=\"4739\" data-start=\"4720\"\u003eidentity\/purity\u003c\/strong\u003e by independent \u003cstrong data-end=\"4768\" data-start=\"4755\"\u003eNMR\/LC-MS\u003c\/strong\u003e, maintain \u003cstrong data-end=\"4799\" data-start=\"4779\"\u003echain-of-custody\u003c\/strong\u003e, and avoid human exposure. “For research only” vendors explicitly state \u003cstrong data-end=\"4901\" data-start=\"4872\"\u003enot for human consumption\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003cspan data-testid=\"webpage-citation-pill\" class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003ca class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!\" alt=\"https:\/\/kimerachems.co\/product\/product-mk-777-research-compound\/?utm_source=chatgpt.com\" rel=\"noopener\" href=\"https:\/\/kimerachems.co\/product\/product-mk-777-research-compound\/?utm_source=chatgpt.com\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between overflow-hidden\"\u003e\u003cspan class=\"max-w-[15ch] grow truncate overflow-hidden text-center\"\u003eKimera Chems\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-end=\"4945\" data-start=\"4942\"\u003e\n\u003ch2 data-end=\"4982\" data-start=\"4947\"\u003e5. Regulatory \u0026amp; Sourcing Reality\u003c\/h2\u003e\n\u003cul data-end=\"5466\" data-start=\"4984\"\u003e\n\u003cli data-end=\"5363\" data-start=\"4984\"\u003e\n\u003cp data-end=\"5363\" data-start=\"4986\"\u003eMK-777\/“Acetamoren” appears \u003cstrong data-end=\"5073\" data-start=\"5014\"\u003eonly on vendor\/marketplace and chemical-trader listings\u003c\/strong\u003e(Amazon\/eBay\/Alibaba\/chem directories); it is \u003cstrong data-end=\"5179\" data-start=\"5120\"\u003eabsent from major curated drug\/chemical knowledge bases\u003c\/strong\u003e with peer-reviewed data (e.g., no public PubChem compound page tied to this CAS at time of checking). Treat the CAS\/structure as \u003cstrong data-end=\"5324\" data-start=\"5309\"\u003eprovisional\u003c\/strong\u003e. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003cspan data-testid=\"webpage-citation-pill\" class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003ca class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!\" alt=\"https:\/\/www.chemicalbook.com\/ChemicalProductProperty_EN_CB614298822.htm?utm_source=chatgpt.com\" rel=\"noopener\" href=\"https:\/\/www.chemicalbook.com\/ChemicalProductProperty_EN_CB614298822.htm?utm_source=chatgpt.com\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between\"\u003e\u003cspan class=\"max-w-[15ch] grow truncate overflow-hidden text-center\"\u003eChemicalBook\u003c\/span\u003e\u003cspan class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\"\u003e+2\u003c\/span\u003e\u003c\/span\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between absolute\"\u003e\u003cspan class=\"max-w-[15ch] grow truncate overflow-hidden text-center\"\u003eeBay\u003c\/span\u003e\u003cspan class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\"\u003e+2\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5466\" data-start=\"5364\"\u003e\n\u003cp data-end=\"5466\" data-start=\"5366\"\u003eSellers label it \u003cstrong data-end=\"5426\" data-start=\"5383\"\u003e“research chemical, not for human use.”\u003c\/strong\u003e \u003cspan data-state=\"closed\" class=\"\"\u003e\u003cspan data-testid=\"webpage-citation-pill\" class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003ca class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!\" alt=\"https:\/\/kimerachems.co\/product\/product-mk-777-research-compound\/?utm_source=chatgpt.com\" rel=\"noopener\" href=\"https:\/\/kimerachems.co\/product\/product-mk-777-research-compound\/?utm_source=chatgpt.com\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between overflow-hidden\"\u003e\u003cspan class=\"max-w-[15ch] grow truncate overflow-hidden text-center\"\u003eKimera Chems\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"5471\" data-start=\"5468\"\u003e\n\u003ch2 data-end=\"5536\" data-start=\"5473\"\u003e6. How it compares (based on class, not head-to-head trials)\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"6042\" data-start=\"5538\"\u003e\n\u003cthead data-end=\"5601\" data-start=\"5538\"\u003e\n\u003ctr data-end=\"5601\" data-start=\"5538\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5548\" data-start=\"5538\"\u003eFeature\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"5574\" data-start=\"5548\"\u003e\u003cstrong data-end=\"5573\" data-start=\"5550\"\u003eMK-777 (Acetamoren)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"5601\" data-start=\"5574\"\u003e\u003cstrong data-end=\"5599\" data-start=\"5576\"\u003eMK-677 (ibutamoren)\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"6042\" data-start=\"5616\"\u003e\n\u003ctr data-end=\"5758\" data-start=\"5616\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5632\" data-start=\"5616\"\u003eEvidence base\u003c\/td\u003e\n\u003ctd data-end=\"5677\" data-start=\"5632\" data-col-size=\"md\"\u003e\u003cstrong data-end=\"5676\" data-start=\"5634\"\u003eNone (no peer-reviewed PK\/PD\/clinical)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"5758\" data-start=\"5677\" data-col-size=\"md\"\u003e\n\u003cstrong data-end=\"5704\" data-start=\"5679\"\u003eHuman and animal data\u003c\/strong\u003e for GH\/IGF-1 rise, appetite, edema, glucose effects\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5875\" data-start=\"5759\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5774\" data-start=\"5759\"\u003eLegal status\u003c\/td\u003e\n\u003ctd data-end=\"5817\" data-start=\"5774\" data-col-size=\"md\"\u003eUnapproved; research-only vendor product\u003c\/td\u003e\n\u003ctd data-end=\"5875\" data-start=\"5817\" data-col-size=\"md\"\u003eUnapproved; studied investigationally, widely profiled\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5970\" data-start=\"5876\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5892\" data-start=\"5876\"\u003eVendor claims\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5939\" data-start=\"5892\"\u003e“More selective, higher affinity, better PK”\u003c\/td\u003e\n\u003ctd data-end=\"5970\" data-start=\"5939\" data-col-size=\"md\"\u003eBaseline reference compound\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6042\" data-start=\"5971\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5985\" data-start=\"5971\"\u003eSafety data\u003c\/td\u003e\n\u003ctd data-end=\"5999\" data-start=\"5985\" data-col-size=\"md\"\u003e\u003cstrong data-end=\"5998\" data-start=\"5987\"\u003eUnknown\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"6042\" data-start=\"5999\" data-col-size=\"md\"\u003eClass-typical AEs documented in studies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"6047\" data-start=\"6044\"\u003e\n\u003ch2 data-end=\"6085\" data-start=\"6049\"\u003e7. Bottom line (clear \u0026amp; cautious)\u003c\/h2\u003e\n\u003cul data-end=\"6694\" data-start=\"6087\"\u003e\n\u003cli data-end=\"6383\" data-start=\"6087\"\u003e\n\u003cp data-end=\"6383\" data-start=\"6089\"\u003e\u003cstrong data-end=\"6151\" data-start=\"6089\"\u003eCAS 950841-87-9 corresponds online to “Acetamoren\/MK-777,”\u003c\/strong\u003e a \u003cstrong data-end=\"6173\" data-start=\"6154\"\u003emarketed analog\u003c\/strong\u003e of MK-677 with \u003cstrong data-end=\"6218\" data-start=\"6189\"\u003eno independent literature\u003c\/strong\u003e confirming pharmacology, efficacy, PK, or safety. Chemical identifiers posted by sellers\/registries may not be harmonized. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003cspan data-testid=\"webpage-citation-pill\" class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003ca class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!\" alt=\"https:\/\/www.chemicalbook.com\/ChemicalProductProperty_EN_CB614298822.htm?utm_source=chatgpt.com\" rel=\"noopener\" href=\"https:\/\/www.chemicalbook.com\/ChemicalProductProperty_EN_CB614298822.htm?utm_source=chatgpt.com\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between overflow-hidden\"\u003e\u003cspan class=\"max-w-[15ch] grow truncate overflow-hidden text-center\"\u003eChemicalBook\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6694\" data-start=\"6384\"\u003e\n\u003cp data-end=\"6694\" data-start=\"6386\"\u003eIf you’re evaluating it scientifically, treat it like any \u003cstrong data-end=\"6481\" data-start=\"6444\"\u003enovel, unvalidated small molecule\u003c\/strong\u003e: confirm \u003cstrong data-end=\"6503\" data-start=\"6491\"\u003eidentity\u003c\/strong\u003e, \u003cstrong data-end=\"6515\" data-start=\"6505\"\u003epurity\u003c\/strong\u003e, and \u003cstrong data-end=\"6534\" data-start=\"6521\"\u003estability\u003c\/strong\u003e yourself, and \u003cstrong data-end=\"6573\" data-start=\"6549\"\u003edo not use in humans\u003c\/strong\u003e. Vendor claims about superiority to MK-677 are \u003cstrong data-end=\"6640\" data-start=\"6621\"\u003eunsubstantiated\u003c\/strong\u003eat this time.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684849185106,"sku":null,"price":55.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/mk777_1g.png?v=1770834836"},{"product_id":"mk777-10ng","title":"MK777 100x10mg","description":"\u003cp data-start=\"0\" data-end=\"70\"\u003e\u003cspan data-start=\"377\" data-end=\"392\"\u003e\u003cspan\u003e                             \u003c\/span\u003e\u003cspan style=\"font-weight: bold; color: rgb(255, 42, 0);\"\u003e           \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"font-weight: bold; text-decoration: underline;\"\u003e\u003cspan style=\"text-decoration: underline; color: rgb(255, 42, 0);\"\u003eFOR HUMAN CONSUMPTION\u003cmeta charset=\"UTF-8\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"0\" data-end=\"70\"\u003e\u003cstrong data-start=\"0\" data-end=\"70\"\u003eMK-777 (Acetamoren) \u003c\/strong\u003e is sold online as a \u003cstrong data-start=\"193\" data-end=\"273\"\u003eresearch-only small-molecule ghrelin\/secretagogue receptor (GHSR-1a) agonist\u003c\/strong\u003e and \u003cstrong data-start=\"278\" data-end=\"311\"\u003eanalog of MK-677 (ibutamoren)\u003c\/strong\u003e. It is \u003cstrong data-start=\"319\" data-end=\"347\"\u003enot an approved medicine\u003c\/strong\u003e and there are \u003cstrong data-start=\"362\" data-end=\"406\"\u003eno peer-reviewed human or animal studies\u003c\/strong\u003e publicly indexed as of now. Chemical directories and vendors list CAS \u003cstrong data-start=\"477\" data-end=\"492\"\u003e950841-87-9\u003c\/strong\u003e with an indole–piperidine “spiro” scaffold and the following identifiers: \u003cstrong data-start=\"567\" data-end=\"576\"\u003eIUPAC\u003c\/strong\u003e (propanamide, 2-(acetylamino)…), \u003cstrong data-start=\"610\" data-end=\"616\"\u003eMF\u003c\/strong\u003e ≈ \u003cstrong data-start=\"619\" data-end=\"634\"\u003eC29H38N4O6S\u003c\/strong\u003e, \u003cstrong data-start=\"636\" data-end=\"642\"\u003eMW\u003c\/strong\u003e ≈ \u003cstrong data-start=\"645\" data-end=\"660\"\u003e570.7 g\/mol\u003c\/strong\u003e. Claims that MK-777 is “more selective\/potent” than MK-677 are \u003cstrong data-start=\"724\" data-end=\"748\"\u003emarketing assertions\u003c\/strong\u003e, not independent data.\u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"1011\" data-end=\"1014\"\u003e\n\u003ch3 data-start=\"1016\" data-end=\"1090\"\u003eAdditional Benefits Now Being \u003cstrong data-start=\"1050\" data-end=\"1071\"\u003eMarketed\/Proposed\u003c\/strong\u003e (evidence caveats)\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"1092\" data-end=\"2349\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"1092\" data-end=\"1144\"\u003e\n\u003ctr data-start=\"1092\" data-end=\"1144\"\u003e\n\u003cth data-start=\"1092\" data-end=\"1102\" data-col-size=\"md\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-start=\"1102\" data-end=\"1144\" data-col-size=\"xl\"\u003eWhat sellers claim vs. what’s verified\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"1155\" data-end=\"2349\"\u003e\n\u003ctr data-start=\"1155\" data-end=\"1462\"\u003e\n\u003ctd data-start=\"1155\" data-end=\"1202\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1157\" data-end=\"1201\"\u003e1 GH\/IGF-1 elevation (oral secretagogue)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"1202\" data-end=\"1462\"\u003eVendors position MK-777 as a \u003cstrong data-start=\"1233\" data-end=\"1261\"\u003eghrelin receptor agonist\u003c\/strong\u003e intended to raise \u003cstrong data-start=\"1280\" data-end=\"1296\"\u003epulsatile GH\u003c\/strong\u003e and \u003cstrong data-start=\"1301\" data-end=\"1310\"\u003eIGF-1\u003c\/strong\u003e, similar to MK-677. \u003cstrong data-start=\"1331\" data-end=\"1357\"\u003eNo peer-reviewed PK\/PD\u003c\/strong\u003e for MK-777 itself is available to confirm magnitude or duration. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1463\" data-end=\"1718\"\u003e\n\u003ctd data-start=\"1463\" data-end=\"1531\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1465\" data-end=\"1530\"\u003e2 “Higher receptor affinity \/ better selectivity” than MK-677\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"1531\" data-end=\"1718\"\u003eStatements like “92% greater affinity (Ki ~0.8 nM)” appear \u003cstrong data-start=\"1592\" data-end=\"1618\"\u003eonly in marketing copy\u003c\/strong\u003e; no independent binding data or head-to-head studies found. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1719\" data-end=\"1966\"\u003e\n\u003ctd data-start=\"1719\" data-end=\"1760\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1721\" data-end=\"1759\"\u003e3 Body-composition, bone, recovery\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"1760\" data-end=\"1966\"\u003eSellers extrapolate \u003cstrong data-start=\"1782\" data-end=\"1799\"\u003eclass effects\u003c\/strong\u003e (MK-677 literature) to MK-777. There are \u003cstrong data-start=\"1841\" data-end=\"1861\"\u003eno MK-777 trials\u003c\/strong\u003edemonstrating lean-mass, strength, BMD, or performance outcomes. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1967\" data-end=\"2151\"\u003e\n\u003ctd data-start=\"1967\" data-end=\"2009\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1969\" data-end=\"2008\"\u003e4 “Improved tolerability vs MK-677”\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"2009\" data-end=\"2151\"\u003eClaims of \u003cstrong data-start=\"2021\" data-end=\"2062\"\u003eless appetite increase, less cortisol\u003c\/strong\u003e are unsubstantiated; no comparative safety data. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2152\" data-end=\"2349\"\u003e\n\u003ctd data-start=\"2152\" data-end=\"2201\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2154\" data-end=\"2200\"\u003e5 Convenient forms (powder\/capsule\/liquid)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"2201\" data-end=\"2349\"\u003eWidely offered for “lab use only”; \u003cstrong data-start=\"2238\" data-end=\"2289\"\u003equality, identity, and purity are not regulated\u003c\/strong\u003e and vary by vendor. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"2351\" data-end=\"2354\"\u003e\n\u003ch2 data-start=\"2356\" data-end=\"2388\"\u003e2. Chemical\/Mechanistic Notes\u003c\/h2\u003e\n\u003cul data-start=\"2390\" data-end=\"3106\"\u003e\n\u003cli data-start=\"2390\" data-end=\"2936\"\u003e\n\u003cp data-start=\"2392\" data-end=\"2441\"\u003e\u003cstrong data-start=\"2392\" data-end=\"2439\"\u003eListed identifiers (vendor\/registry sites):\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"2444\" data-end=\"2936\"\u003e\n\u003cli data-start=\"2444\" data-end=\"2511\"\u003e\n\u003cp data-start=\"2446\" data-end=\"2511\"\u003e\u003cstrong data-start=\"2446\" data-end=\"2454\"\u003eCAS:\u003c\/strong\u003e \u003cstrong data-start=\"2455\" data-end=\"2470\"\u003e950841-87-9\u003c\/strong\u003e; names “\u003cstrong data-start=\"2479\" data-end=\"2493\"\u003eAcetamoren\u003c\/strong\u003e”, “\u003cstrong data-start=\"2497\" data-end=\"2507\"\u003eMK-777\u003c\/strong\u003e”.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2514\" data-end=\"2705\"\u003e\n\u003cp data-start=\"2516\" data-end=\"2705\"\u003e\u003cstrong data-start=\"2516\" data-end=\"2538\"\u003eIUPAC (as listed):\u003c\/strong\u003e \u003cem data-start=\"2539\" data-end=\"2702\"\u003ePropanamide, 2-(acetylamino)-N-[(1R)-2-[1,2-dihydro-1-(methylsulfonyl)spiro[3H-indole-3,4′-piperidin]-1′-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl-(ACI)\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2708\" data-end=\"2762\"\u003e\n\u003cp data-start=\"2710\" data-end=\"2762\"\u003e\u003cstrong data-start=\"2710\" data-end=\"2725\"\u003eFormula\/MW:\u003c\/strong\u003e \u003cstrong data-start=\"2726\" data-end=\"2741\"\u003eC29H38N4O6S\u003c\/strong\u003e, \u003cstrong data-start=\"2743\" data-end=\"2759\"\u003e~570.7 g\/mol\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2765\" data-end=\"2936\"\u003e\n\u003cp data-start=\"2767\" data-end=\"2936\"\u003e(Note: several vendor pages show slightly different formulas\/weights—another sign that the \u003cstrong data-start=\"2858\" data-end=\"2894\"\u003eidentity record isn’t harmonized\u003c\/strong\u003e.) \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003ca href=\"https:\/\/www.chemicalbook.com\/ChemicalProductProperty_EN_CB614298822.htm?utm_source=chatgpt.com\" rel=\"noopener\" alt=\"https:\/\/www.chemicalbook.com\/ChemicalProductProperty_EN_CB614298822.htm?utm_source=chatgpt.com\" class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between\"\u003e\u003cspan class=\"max-w-[15ch] grow truncate overflow-hidden text-center\"\u003eChemicalBook\u003c\/span\u003e\u003cspan class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\"\u003e+1\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2937\" data-end=\"3106\"\u003e\n\u003cp data-start=\"2939\" data-end=\"3106\"\u003e\u003cstrong data-start=\"2939\" data-end=\"2959\"\u003ePurported class:\u003c\/strong\u003e \u003cstrong data-start=\"2960\" data-end=\"2991\"\u003eNon-peptide GHSR-1a agonist\u003c\/strong\u003e (ghrelin mimetic), often mis-tagged online as a “SARM,” which it is \u003cstrong data-start=\"3060\" data-end=\"3067\"\u003enot\u003c\/strong\u003e. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"3108\" data-end=\"3404\"\u003e\u003cstrong data-start=\"3108\" data-end=\"3165\"\u003eInference from class (if it truly activates GHSR-1a):\u003c\/strong\u003e Expect \u003cstrong data-start=\"3173\" data-end=\"3203\"\u003eGH pulses → ↑IGF-1\/IGFBP-3\u003c\/strong\u003e, \u003cstrong data-start=\"3205\" data-end=\"3238\"\u003eorexigenic signaling (hunger)\u003c\/strong\u003e, possible \u003cstrong data-start=\"3249\" data-end=\"3275\"\u003ewater\/sodium retention\u003c\/strong\u003e, and class-typical \u003cstrong data-start=\"3295\" data-end=\"3314\"\u003eglucose\/insulin\u003c\/strong\u003e effects—\u003cstrong data-start=\"3323\" data-end=\"3330\"\u003ebut\u003c\/strong\u003e the \u003cstrong data-start=\"3335\" data-end=\"3403\"\u003edose–response, half-life, and off-targets for MK-777 are unknown\u003c\/strong\u003e.\u003c\/p\u003e\n\u003chr data-start=\"3406\" data-end=\"3409\"\u003e\n\u003ch2 data-start=\"3411\" data-end=\"3442\"\u003e3. Pharmacokinetics \/ Dosing\u003c\/h2\u003e\n\u003cul data-start=\"3444\" data-end=\"3688\"\u003e\n\u003cli data-start=\"3444\" data-end=\"3688\"\u003e\n\u003cp data-start=\"3446\" data-end=\"3688\"\u003e\u003cstrong data-start=\"3446\" data-end=\"3469\"\u003eNo peer-reviewed PK\u003c\/strong\u003e exists for MK-777. Any reported \u003cstrong data-start=\"3502\" data-end=\"3539\"\u003ehalf-life or oral bioavailability\u003c\/strong\u003e on vendor pages should be considered \u003cstrong data-start=\"3577\" data-end=\"3601\"\u003eunverified marketing\u003c\/strong\u003e. Compare with MK-677 only as \u003cstrong data-start=\"3631\" data-end=\"3659\"\u003ebackground class context\u003c\/strong\u003e, not as evidence for MK-777.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"3690\" data-end=\"3693\"\u003e\n\u003ch2 data-start=\"3695\" data-end=\"3737\"\u003e4. Safety \u0026amp; Tolerability (risk framing)\u003c\/h2\u003e\n\u003cp data-start=\"3739\" data-end=\"3832\"\u003eWithout clinical data, safety must be inferred from \u003cstrong data-start=\"3791\" data-end=\"3816\"\u003eghrelin-agonist class\u003c\/strong\u003e (e.g., MK-677):\u003c\/p\u003e\n\u003cul data-start=\"3834\" data-end=\"4642\"\u003e\n\u003cli data-start=\"3834\" data-end=\"4029\"\u003e\n\u003cp data-start=\"3836\" data-end=\"4029\"\u003e\u003cstrong data-start=\"3836\" data-end=\"3865\"\u003eLikely on-target effects:\u003c\/strong\u003e \u003cstrong data-start=\"3866\" data-end=\"3888\"\u003eIncreased appetite\u003c\/strong\u003e, \u003cstrong data-start=\"3890\" data-end=\"3910\"\u003etransient hunger\u003c\/strong\u003e, \u003cstrong data-start=\"3912\" data-end=\"3932\"\u003eperipheral edema\u003c\/strong\u003e, \u003cstrong data-start=\"3934\" data-end=\"3970\"\u003ehand\/foot stiffness\/paresthesias\u003c\/strong\u003e, \u003cstrong data-start=\"3972\" data-end=\"3999\"\u003eweight gain (water\/FFM)\u003c\/strong\u003e; \u003cstrong data-start=\"4001\" data-end=\"4017\"\u003evivid dreams\u003c\/strong\u003e for some.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4030\" data-end=\"4160\"\u003e\n\u003cp data-start=\"4032\" data-end=\"4160\"\u003e\u003cstrong data-start=\"4032\" data-end=\"4046\"\u003eMetabolic:\u003c\/strong\u003e Potential \u003cstrong data-start=\"4057\" data-end=\"4108\"\u003eworsening of fasting glucose\/insulin resistance\u003c\/strong\u003e in susceptible people; \u003cstrong data-start=\"4132\" data-end=\"4148\"\u003elipid shifts\u003c\/strong\u003e possible.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4161\" data-end=\"4278\"\u003e\n\u003cp data-start=\"4163\" data-end=\"4278\"\u003e\u003cstrong data-start=\"4163\" data-end=\"4177\"\u003eEndocrine:\u003c\/strong\u003e Class can nudge \u003cstrong data-start=\"4194\" data-end=\"4216\"\u003ecortisol\/prolactin\u003c\/strong\u003e in some reports with analogs; MK-777-specific data unknown.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4279\" data-end=\"4364\"\u003e\n\u003cp data-start=\"4281\" data-end=\"4364\"\u003e\u003cstrong data-start=\"4281\" data-end=\"4298\"\u003eCardio-renal:\u003c\/strong\u003e \u003cstrong data-start=\"4299\" data-end=\"4325\"\u003eSodium\/water retention\u003c\/strong\u003e → BP drift in sensitive individuals.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4365\" data-end=\"4502\"\u003e\n\u003cp data-start=\"4367\" data-end=\"4502\"\u003e\u003cstrong data-start=\"4367\" data-end=\"4384\"\u003eDrug testing:\u003c\/strong\u003e Ghrelin mimetics used for \u003cstrong data-start=\"4411\" data-end=\"4429\"\u003eGH stimulation\u003c\/strong\u003e are \u003cstrong data-start=\"4434\" data-end=\"4456\"\u003eprohibited by WADA\u003c\/strong\u003e; many labs screen for GH axis manipulation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4503\" data-end=\"4642\"\u003e\n\u003cp data-start=\"4505\" data-end=\"4642\"\u003e\u003cstrong data-start=\"4505\" data-end=\"4518\"\u003eUnknowns:\u003c\/strong\u003e \u003cstrong data-start=\"4519\" data-end=\"4608\"\u003eCarcinogenicity, reproductive toxicity, genotoxicity, long-term hepatic\/renal effects\u003c\/strong\u003e—no datasets available for MK-777.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cblockquote data-start=\"4644\" data-end=\"4940\"\u003e\n\u003cp data-start=\"4646\" data-end=\"4940\"\u003e\u003cstrong data-start=\"4646\" data-end=\"4675\"\u003ePractical harm-reduction:\u003c\/strong\u003e If anyone is handling this in a lab, verify \u003cstrong data-start=\"4720\" data-end=\"4739\"\u003eidentity\/purity\u003c\/strong\u003e by independent \u003cstrong data-start=\"4755\" data-end=\"4768\"\u003eNMR\/LC-MS\u003c\/strong\u003e, maintain \u003cstrong data-start=\"4779\" data-end=\"4799\"\u003echain-of-custody\u003c\/strong\u003e, and avoid human exposure. “For research only” vendors explicitly state \u003cstrong data-start=\"4872\" data-end=\"4901\"\u003enot for human consumption\u003c\/strong\u003e. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003ca href=\"https:\/\/kimerachems.co\/product\/product-mk-777-research-compound\/?utm_source=chatgpt.com\" rel=\"noopener\" alt=\"https:\/\/kimerachems.co\/product\/product-mk-777-research-compound\/?utm_source=chatgpt.com\" class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between overflow-hidden\"\u003e\u003cspan class=\"max-w-[15ch] grow truncate overflow-hidden text-center\"\u003eKimera Chems\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-start=\"4942\" data-end=\"4945\"\u003e\n\u003ch2 data-start=\"4947\" data-end=\"4982\"\u003e5. Regulatory \u0026amp; Sourcing Reality\u003c\/h2\u003e\n\u003cul data-start=\"4984\" data-end=\"5466\"\u003e\n\u003cli data-start=\"4984\" data-end=\"5363\"\u003e\n\u003cp data-start=\"4986\" data-end=\"5363\"\u003eMK-777\/“Acetamoren” appears \u003cstrong data-start=\"5014\" data-end=\"5073\"\u003eonly on vendor\/marketplace and chemical-trader listings\u003c\/strong\u003e(Amazon\/eBay\/Alibaba\/chem directories); it is \u003cstrong data-start=\"5120\" data-end=\"5179\"\u003eabsent from major curated drug\/chemical knowledge bases\u003c\/strong\u003e with peer-reviewed data (e.g., no public PubChem compound page tied to this CAS at time of checking). Treat the CAS\/structure as \u003cstrong data-start=\"5309\" data-end=\"5324\"\u003eprovisional\u003c\/strong\u003e. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003ca href=\"https:\/\/www.chemicalbook.com\/ChemicalProductProperty_EN_CB614298822.htm?utm_source=chatgpt.com\" rel=\"noopener\" alt=\"https:\/\/www.chemicalbook.com\/ChemicalProductProperty_EN_CB614298822.htm?utm_source=chatgpt.com\" class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between\"\u003e\u003cspan class=\"max-w-[15ch] grow truncate overflow-hidden text-center\"\u003eChemicalBook\u003c\/span\u003e\u003cspan class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\"\u003e+2\u003c\/span\u003e\u003c\/span\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between absolute\"\u003e\u003cspan class=\"max-w-[15ch] grow truncate overflow-hidden text-center\"\u003eeBay\u003c\/span\u003e\u003cspan class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\"\u003e+2\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5364\" data-end=\"5466\"\u003e\n\u003cp data-start=\"5366\" data-end=\"5466\"\u003eSellers label it \u003cstrong data-start=\"5383\" data-end=\"5426\"\u003e“research chemical, not for human use.”\u003c\/strong\u003e \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003ca href=\"https:\/\/kimerachems.co\/product\/product-mk-777-research-compound\/?utm_source=chatgpt.com\" rel=\"noopener\" alt=\"https:\/\/kimerachems.co\/product\/product-mk-777-research-compound\/?utm_source=chatgpt.com\" class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between overflow-hidden\"\u003e\u003cspan class=\"max-w-[15ch] grow truncate overflow-hidden text-center\"\u003eKimera Chems\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"5468\" data-end=\"5471\"\u003e\n\u003ch2 data-start=\"5473\" data-end=\"5536\"\u003e6. How it compares (based on class, not head-to-head trials)\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"group _tableWrapper_1rjym_13 flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"5538\" data-end=\"6042\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"5538\" data-end=\"5601\"\u003e\n\u003ctr data-start=\"5538\" data-end=\"5601\"\u003e\n\u003cth data-start=\"5538\" data-end=\"5548\" data-col-size=\"sm\"\u003eFeature\u003c\/th\u003e\n\u003cth data-start=\"5548\" data-end=\"5574\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"5550\" data-end=\"5573\"\u003eMK-777 (Acetamoren)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"5574\" data-end=\"5601\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"5576\" data-end=\"5599\"\u003eMK-677 (ibutamoren)\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"5616\" data-end=\"6042\"\u003e\n\u003ctr data-start=\"5616\" data-end=\"5758\"\u003e\n\u003ctd data-start=\"5616\" data-end=\"5632\" data-col-size=\"sm\"\u003eEvidence base\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"5632\" data-end=\"5677\"\u003e\u003cstrong data-start=\"5634\" data-end=\"5676\"\u003eNone (no peer-reviewed PK\/PD\/clinical)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"5677\" data-end=\"5758\"\u003e\n\u003cstrong data-start=\"5679\" data-end=\"5704\"\u003eHuman and animal data\u003c\/strong\u003e for GH\/IGF-1 rise, appetite, edema, glucose effects\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5759\" data-end=\"5875\"\u003e\n\u003ctd data-start=\"5759\" data-end=\"5774\" data-col-size=\"sm\"\u003eLegal status\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"5774\" data-end=\"5817\"\u003eUnapproved; research-only vendor product\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"5817\" data-end=\"5875\"\u003eUnapproved; studied investigationally, widely profiled\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5876\" data-end=\"5970\"\u003e\n\u003ctd data-start=\"5876\" data-end=\"5892\" data-col-size=\"sm\"\u003eVendor claims\u003c\/td\u003e\n\u003ctd data-start=\"5892\" data-end=\"5939\" data-col-size=\"md\"\u003e“More selective, higher affinity, better PK”\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"5939\" data-end=\"5970\"\u003eBaseline reference compound\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5971\" data-end=\"6042\"\u003e\n\u003ctd data-start=\"5971\" data-end=\"5985\" data-col-size=\"sm\"\u003eSafety data\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"5985\" data-end=\"5999\"\u003e\u003cstrong data-start=\"5987\" data-end=\"5998\"\u003eUnknown\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"5999\" data-end=\"6042\"\u003eClass-typical AEs documented in studies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"6044\" data-end=\"6047\"\u003e\n\u003ch2 data-start=\"6049\" data-end=\"6085\"\u003e7. Bottom line (clear \u0026amp; cautious)\u003c\/h2\u003e\n\u003cul data-start=\"6087\" data-end=\"6694\"\u003e\n\u003cli data-start=\"6087\" data-end=\"6383\"\u003e\n\u003cp data-start=\"6089\" data-end=\"6383\"\u003e\u003cstrong data-start=\"6089\" data-end=\"6151\"\u003eCAS 950841-87-9 corresponds online to “Acetamoren\/MK-777,”\u003c\/strong\u003e a \u003cstrong data-start=\"6154\" data-end=\"6173\"\u003emarketed analog\u003c\/strong\u003e of MK-677 with \u003cstrong data-start=\"6189\" data-end=\"6218\"\u003eno independent literature\u003c\/strong\u003e confirming pharmacology, efficacy, PK, or safety. Chemical identifiers posted by sellers\/registries may not be harmonized. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\" data-testid=\"webpage-citation-pill\"\u003e\u003ca href=\"https:\/\/www.chemicalbook.com\/ChemicalProductProperty_EN_CB614298822.htm?utm_source=chatgpt.com\" rel=\"noopener\" alt=\"https:\/\/www.chemicalbook.com\/ChemicalProductProperty_EN_CB614298822.htm?utm_source=chatgpt.com\" class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium transition-colors duration-150 ease-in-out text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]!\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between overflow-hidden\"\u003e\u003cspan class=\"max-w-[15ch] grow truncate overflow-hidden text-center\"\u003eChemicalBook\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6384\" data-end=\"6694\"\u003e\n\u003cp data-start=\"6386\" data-end=\"6694\"\u003eIf you’re evaluating it scientifically, treat it like any \u003cstrong data-start=\"6444\" data-end=\"6481\"\u003enovel, unvalidated small molecule\u003c\/strong\u003e: confirm \u003cstrong data-start=\"6491\" data-end=\"6503\"\u003eidentity\u003c\/strong\u003e, \u003cstrong data-start=\"6505\" data-end=\"6515\"\u003epurity\u003c\/strong\u003e, and \u003cstrong data-start=\"6521\" data-end=\"6534\"\u003estability\u003c\/strong\u003e yourself, and \u003cstrong data-start=\"6549\" data-end=\"6573\"\u003edo not use in humans\u003c\/strong\u003e. Vendor claims about superiority to MK-677 are \u003cstrong data-start=\"6621\" data-end=\"6640\"\u003eunsubstantiated\u003c\/strong\u003eat this time.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684850987346,"sku":null,"price":70.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/mk777.png?v=1770834839"},{"product_id":"mk677ibutamoren-100x10mgg","title":"MK677(Ibutamoren) 100x10mg","description":"\u003cp style=\"text-align: center;\"\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eNOT FOR HUMAN CONSUMPTION\u003cmeta charset=\"UTF-8\"\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"607\" data-start=\"53\"\u003e\u003cstrong\u003eMK677 \u003c\/strong\u003e(ibutamoren) is an oral, non-peptide \u003cstrong data-end=\"168\" data-start=\"130\"\u003eghrelin-receptor (GHSR-1a) agonist\u003c\/strong\u003e that provokes \u003cstrong data-end=\"224\" data-start=\"183\"\u003epulsatile growth-hormone (GH) release\u003c\/strong\u003e and raises circulating \u003cstrong data-end=\"257\" data-start=\"248\"\u003eIGF-1\u003c\/strong\u003e. Unlike injectable secretagogues (GHRP-2\/hexarelin), MK-677 is \u003cstrong data-end=\"340\" data-start=\"321\"\u003eonce-daily oral\u003c\/strong\u003e, engages central orexigenic circuits (NPY\/AgRP), and modestly elevates \u003cstrong data-end=\"424\" data-start=\"412\"\u003ecortisol\u003c\/strong\u003e and \u003cstrong data-end=\"442\" data-start=\"429\"\u003eprolactin\u003c\/strong\u003e. It does \u003cstrong data-end=\"459\" data-start=\"452\"\u003enot\u003c\/strong\u003e activate the androgen receptor and is \u003cstrong data-end=\"512\" data-start=\"498\"\u003enot a SARM\u003c\/strong\u003e. MK-677 is \u003cstrong data-end=\"548\" data-start=\"524\"\u003enot FDA\/EMA-approved\u003c\/strong\u003e and is \u003cstrong data-end=\"578\" data-start=\"556\"\u003eprohibited by WADA\u003c\/strong\u003e as a GH-releasing substance.\u003c\/p\u003e\n\u003chr data-end=\"612\" data-start=\"609\"\u003e\n\u003ch3 data-end=\"671\" data-start=\"614\"\u003eAdditional Benefits of MK-677 Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"2885\" data-start=\"673\"\u003e\n\u003cthead data-end=\"701\" data-start=\"673\"\u003e\n\u003ctr data-end=\"701\" data-start=\"673\"\u003e\n\u003cth data-col-size=\"md\" data-end=\"683\" data-start=\"673\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-col-size=\"xl\" data-end=\"701\" data-start=\"683\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"2885\" data-start=\"712\"\u003e\n\u003ctr data-end=\"1010\" data-start=\"712\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"754\" data-start=\"712\"\u003e\u003cstrong data-end=\"753\" data-start=\"714\"\u003e1 Lean-mass accrual in older adults\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"1010\" data-start=\"754\" data-col-size=\"xl\"\u003eDaily MK-677 \u003cstrong data-end=\"796\" data-start=\"769\"\u003eincreases fat-free mass\u003c\/strong\u003e over months with parallel \u003cstrong data-end=\"838\" data-start=\"823\"\u003eIGF-1 rises\u003c\/strong\u003e, approximating youthful GH\/IGF-1 levels; strength\/function show supportive trends when combined with resistance training. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Annals of Internal Medicine; JCEM\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1280\" data-start=\"1011\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1047\" data-start=\"1011\"\u003e\u003cstrong data-end=\"1046\" data-start=\"1013\"\u003e2 Bone-turnover \u0026amp; BMD signals\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"1280\" data-start=\"1047\" data-col-size=\"xl\"\u003eIncreases \u003cstrong data-end=\"1085\" data-start=\"1059\"\u003ebone-formation markers\u003c\/strong\u003e (e.g., P1NP, osteocalcin) and \u003cstrong data-end=\"1146\" data-start=\"1116\"\u003ereduces resorption markers\u003c\/strong\u003e; longer-term cohorts report \u003cstrong data-end=\"1195\" data-start=\"1175\"\u003eBMD improvements\u003c\/strong\u003e, supporting anti-frailty potential. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Bone; Osteoporosis International\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1487\" data-start=\"1281\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1308\" data-start=\"1281\"\u003e\u003cstrong data-end=\"1307\" data-start=\"1283\"\u003e3 Sleep architecture\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"1487\" data-start=\"1308\" data-col-size=\"xl\"\u003e\n\u003cstrong data-end=\"1335\" data-start=\"1310\"\u003eSlow-wave sleep (SWS)\u003c\/strong\u003e and REM density improve with bedtime dosing, aligning with physiologic GH pulses and next-day vitality. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Sleep; Psychoneuroendocrinology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1734\" data-start=\"1488\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1534\" data-start=\"1488\"\u003e\u003cstrong data-end=\"1533\" data-start=\"1490\"\u003e4 Appetite \u0026amp; weight in catabolic states\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"1734\" data-start=\"1534\" data-col-size=\"xl\"\u003eRobust \u003cstrong data-end=\"1564\" data-start=\"1543\"\u003eorexigenic effect\u003c\/strong\u003e increases caloric intake; cachexia\/rehab pilots show \u003cstrong data-end=\"1642\" data-start=\"1618\"\u003eweight and FFM gains\u003c\/strong\u003ewith acceptable tolerability. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Clinical Nutrition; Supportive Care in Cancer\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1989\" data-start=\"1735\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1768\" data-start=\"1735\"\u003e\u003cstrong data-end=\"1767\" data-start=\"1737\"\u003e5 Glucose handling (mixed)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"1989\" data-start=\"1768\" data-col-size=\"xl\"\u003eSome studies show \u003cstrong data-end=\"1817\" data-start=\"1788\"\u003einsulin-sensitivity drift\u003c\/strong\u003e (↑ fasting glucose\/insulin); others report \u003cstrong data-end=\"1881\" data-start=\"1861\"\u003eneutral outcomes\u003c\/strong\u003e with lifestyle control—underscores need for glycaemic monitoring. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Diabetes Care; Metabolism\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2253\" data-start=\"1990\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2039\" data-start=\"1990\"\u003e\u003cstrong data-end=\"2038\" data-start=\"1992\"\u003e6 Functional recovery after illness\/injury\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"2253\" data-start=\"2039\" data-col-size=\"xl\"\u003eEarly programs evaluate MK-677 to \u003cstrong data-end=\"2099\" data-start=\"2075\"\u003espeed rehabilitation\u003c\/strong\u003e, leveraging appetite + anabolic endocrine support. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Geriatrics \u0026amp; Gerontology International; Archives of Physical Medicine \u0026amp; Rehabilitation\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2456\" data-start=\"2254\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2305\" data-start=\"2254\"\u003e\u003cstrong data-end=\"2304\" data-start=\"2256\"\u003e7 GH-axis restoration in age-related decline\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"2456\" data-start=\"2305\" data-col-size=\"xl\"\u003eElevates \u003cstrong data-end=\"2333\" data-start=\"2316\"\u003eIGF-1\/IGFBP-3\u003c\/strong\u003e toward youthful ranges without exogenous GH injections; preserves \u003cstrong data-end=\"2415\" data-start=\"2400\"\u003epulsatility\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Endocrine Reviews; JCEM\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2683\" data-start=\"2457\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2489\" data-start=\"2457\"\u003e\u003cstrong data-end=\"2488\" data-start=\"2459\"\u003e8 Quality-of-life domains\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"2683\" data-start=\"2489\" data-col-size=\"xl\"\u003eParticipants frequently report \u003cstrong data-end=\"2570\" data-start=\"2522\"\u003ebetter sleep quality, appetite, and recovery\u003c\/strong\u003e; validated PROs are being incorporated into trials. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Endocrine Practice; Quality of Life Research\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2885\" data-start=\"2684\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2716\" data-start=\"2684\"\u003e\u003cstrong data-end=\"2715\" data-start=\"2686\"\u003e9 Convenience \u0026amp; adherence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"2885\" data-start=\"2716\" data-col-size=\"xl\"\u003e\n\u003cstrong data-end=\"2737\" data-start=\"2718\"\u003eOnce-daily oral\u003c\/strong\u003e regimen improves persistence versus injectable GH or peptide secretagogues. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Clinical Therapeutics; Patient Preference and Adherence\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"2890\" data-start=\"2887\"\u003e\n\u003ch2 data-end=\"2927\" data-start=\"2892\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-end=\"2964\" data-start=\"2929\"\u003e2.1 Receptor Pharmacodynamics\u003c\/h3\u003e\n\u003cp data-end=\"3291\" data-start=\"2965\"\u003eMK-677 binds \u003cstrong data-end=\"2989\" data-start=\"2978\"\u003eGHSR-1a\u003c\/strong\u003e (GPCR) on hypothalamic neurons and pituitary somatotrophs → \u003cstrong data-end=\"3073\" data-start=\"3050\"\u003eGαq\/11–PLC–IP₃\/Ca²⁺\u003c\/strong\u003esignaling → GH vesicle exocytosis. It \u003cstrong data-end=\"3126\" data-start=\"3112\"\u003esynergizes\u003c\/strong\u003e with endogenous GHRH and is \u003cstrong data-end=\"3175\" data-start=\"3155\"\u003epartly countered\u003c\/strong\u003e by somatostatin. Central GHSR activation also drives \u003cstrong data-end=\"3241\" data-start=\"3229\"\u003eNPY\/AgRP\u003c\/strong\u003e orexigenic pathways and modulates sleep circuits.\u003c\/p\u003e\n\u003ch3 data-end=\"3320\" data-start=\"3293\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"3709\" data-start=\"3322\"\u003e\n\u003cthead data-end=\"3364\" data-start=\"3322\"\u003e\n\u003ctr data-end=\"3364\" data-start=\"3322\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3332\" data-start=\"3322\"\u003ePathway\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"3353\" data-start=\"3332\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3364\" data-start=\"3353\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"3709\" data-start=\"3379\"\u003e\n\u003ctr data-end=\"3485\" data-start=\"3379\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3405\" data-start=\"3379\"\u003eGH → \u003cstrong data-end=\"3404\" data-start=\"3386\"\u003eGHR–JAK2–STAT5\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3459\" data-start=\"3405\"\u003e↑ \u003cstrong data-end=\"3426\" data-start=\"3409\"\u003eIGF-1\/IGFBP-3\u003c\/strong\u003e, ↑ protein synthesis, lipolysis\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3485\" data-start=\"3459\"\u003eLiver, muscle, adipose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3560\" data-start=\"3486\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3508\" data-start=\"3486\"\u003eGHSR → \u003cstrong data-end=\"3507\" data-start=\"3495\"\u003eNPY\/AgRP\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3541\" data-start=\"3508\"\u003e↑ appetite, ↑ gastric motility\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3560\" data-start=\"3541\"\u003eHypothalamus\/GI\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3635\" data-start=\"3561\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3581\" data-start=\"3561\"\u003eSleep–GH coupling\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3628\" data-start=\"3581\"\u003e↑ SWS\/REM consolidation, nocturnal GH pulses\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3635\" data-start=\"3628\"\u003eCNS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3709\" data-start=\"3636\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3660\" data-start=\"3636\"\u003eBone turnover signals\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3697\" data-start=\"3660\"\u003e↑ formation markers; BMD over time\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3709\" data-start=\"3697\"\u003eSkeleton\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"3714\" data-start=\"3711\"\u003e\n\u003ch2 data-end=\"3738\" data-start=\"3716\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-end=\"4114\" data-start=\"3740\"\u003e\n\u003cli data-end=\"3773\" data-start=\"3740\"\u003e\n\u003cp data-end=\"3773\" data-start=\"3742\"\u003e\u003cstrong data-end=\"3752\" data-start=\"3742\"\u003eRoute:\u003c\/strong\u003e Oral (once daily).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3817\" data-start=\"3774\"\u003e\n\u003cp data-end=\"3817\" data-start=\"3776\"\u003e\u003cstrong data-end=\"3791\" data-start=\"3776\"\u003eAbsorption:\u003c\/strong\u003e Rapid; \u003cstrong data-end=\"3814\" data-start=\"3799\"\u003eTmax ~1–2 h\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3925\" data-start=\"3818\"\u003e\n\u003cp data-end=\"3925\" data-start=\"3820\"\u003e\u003cstrong data-end=\"3834\" data-start=\"3820\"\u003eHalf-life:\u003c\/strong\u003e \u003cstrong data-end=\"3845\" data-start=\"3835\"\u003e~4–6 h\u003c\/strong\u003e; \u003cstrong data-end=\"3880\" data-start=\"3847\"\u003eIGF-1 elevation persists 24 h\u003c\/strong\u003e with daily dosing due to GH-axis dynamics.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4044\" data-start=\"3926\"\u003e\n\u003cp data-end=\"4044\" data-start=\"3928\"\u003e\u003cstrong data-end=\"3943\" data-start=\"3928\"\u003eMetabolism:\u003c\/strong\u003e Hepatic; \u003cstrong data-end=\"3993\" data-start=\"3953\"\u003eCYP3A4 involvement reported in vitro\u003c\/strong\u003e (DDI potential with strong inhibitors\/inducers).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4114\" data-start=\"4045\"\u003e\n\u003cp data-end=\"4114\" data-start=\"4047\"\u003e\u003cstrong data-end=\"4063\" data-start=\"4047\"\u003eElimination:\u003c\/strong\u003e Hepatic\/renal metabolites; high protein binding.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"4119\" data-start=\"4116\"\u003e\n\u003ch2 data-end=\"4166\" data-start=\"4121\"\u003e4. Pre-clinical and Translational Evidence\u003c\/h2\u003e\n\u003ch3 data-end=\"4194\" data-start=\"4168\"\u003e4.1 Aging\/Sarcopenia\u003c\/h3\u003e\n\u003cp data-end=\"4407\" data-start=\"4195\"\u003eRandomized trials in older adults show \u003cstrong data-end=\"4263\" data-start=\"4234\"\u003esustained IGF-1 increases\u003c\/strong\u003e, \u003cstrong data-end=\"4278\" data-start=\"4265\"\u003eFFM gains\u003c\/strong\u003e, improved \u003cstrong data-end=\"4311\" data-start=\"4289\"\u003esleep architecture\u003c\/strong\u003e, and favorable trends in \u003cstrong data-end=\"4367\" data-start=\"4337\"\u003estrength and gait measures\u003c\/strong\u003e, particularly with structured exercise.\u003c\/p\u003e\n\u003ch3 data-end=\"4430\" data-start=\"4409\"\u003e4.2 Bone Health\u003c\/h3\u003e\n\u003cp data-end=\"4589\" data-start=\"4431\"\u003eMarkers of \u003cstrong data-end=\"4460\" data-start=\"4442\"\u003ebone formation\u003c\/strong\u003e rise within weeks; \u003cstrong data-end=\"4487\" data-start=\"4480\"\u003eBMD\u003c\/strong\u003e benefits emerge over longer courses—supporting evaluation for \u003cstrong data-end=\"4577\" data-start=\"4550\"\u003eosteopenia\/osteoporosis\u003c\/strong\u003e in frailty.\u003c\/p\u003e\n\u003ch3 data-end=\"4627\" data-start=\"4591\"\u003e4.3 Metabolism \u0026amp; Diabetes Risk\u003c\/h3\u003e\n\u003cp data-end=\"4828\" data-start=\"4628\"\u003eIn mixed-risk cohorts, MK-677 may \u003cstrong data-end=\"4695\" data-start=\"4662\"\u003eraise fasting glucose\/insulin\u003c\/strong\u003e and \u003cstrong data-end=\"4730\" data-start=\"4700\"\u003ereduce insulin sensitivity\u003c\/strong\u003e; effects are \u003cstrong data-end=\"4789\" data-start=\"4744\"\u003edose-, duration-, and phenotype-dependent\u003c\/strong\u003e, emphasizing \u003cstrong data-end=\"4827\" data-start=\"4803\"\u003eglycaemic monitoring\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cblockquote data-end=\"5016\" data-start=\"4830\"\u003e\n\u003cp data-end=\"5016\" data-start=\"4832\"\u003e\u003cstrong data-end=\"4858\" data-start=\"4832\"\u003eEvidence quality note:\u003c\/strong\u003e Human data include \u003cstrong data-end=\"4910\" data-start=\"4878\"\u003emultiple small–moderate RCTs\u003c\/strong\u003e and mechanistic studies; \u003cstrong data-end=\"4958\" data-start=\"4936\"\u003elong-term outcomes\u003c\/strong\u003e (fractures, disability, CV events) remain \u003cstrong data-end=\"5015\" data-start=\"5001\"\u003eunresolved\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-end=\"5021\" data-start=\"5018\"\u003e\n\u003ch2 data-end=\"5056\" data-start=\"5023\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"5588\" data-start=\"5058\"\u003e\n\u003cthead data-end=\"5096\" data-start=\"5058\"\u003e\n\u003ctr data-end=\"5096\" data-start=\"5058\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5066\" data-start=\"5058\"\u003eField\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"5078\" data-start=\"5066\"\u003eRationale\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"5096\" data-start=\"5078\"\u003eCurrent status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"5588\" data-start=\"5111\"\u003e\n\u003ctr data-end=\"5226\" data-start=\"5111\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5136\" data-start=\"5111\"\u003e\u003cstrong data-end=\"5135\" data-start=\"5113\"\u003eSarcopenia\/frailty\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5181\" data-start=\"5136\"\u003eOral anabolic + sleep and appetite support\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5226\" data-start=\"5181\"\u003ePhase 2–style signals; larger RCTs needed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5309\" data-start=\"5227\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5257\" data-start=\"5227\"\u003e\u003cstrong data-end=\"5256\" data-start=\"5229\"\u003eOsteopenia\/osteoporosis\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5294\" data-start=\"5257\"\u003eBone-turnover and BMD improvements\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5309\" data-start=\"5294\"\u003eExploratory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5398\" data-start=\"5310\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5343\" data-start=\"5310\"\u003e\u003cstrong data-end=\"5342\" data-start=\"5312\"\u003eCachexia (cancer\/COPD\/CHF)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5377\" data-start=\"5343\"\u003eOrexigenic + GH\/IGF-1 anabolism\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5398\" data-start=\"5377\"\u003ePilot\/feasibility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5488\" data-start=\"5399\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5422\" data-start=\"5399\"\u003e\u003cstrong data-end=\"5421\" data-start=\"5401\"\u003ePost-acute rehab\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5465\" data-start=\"5422\"\u003eAppetite\/FFM restoration to aid recovery\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5488\" data-start=\"5465\"\u003eEarly translational\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5588\" data-start=\"5489\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5525\" data-start=\"5489\"\u003e\u003cstrong data-end=\"5524\" data-start=\"5491\"\u003eSleep disorders (SWS decline)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5568\" data-start=\"5525\"\u003eSWS augmentation with endocrine coupling\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5588\" data-start=\"5568\"\u003eProof-of-concept\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"5593\" data-start=\"5590\"\u003e\n\u003ch2 data-end=\"5624\" data-start=\"5595\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-end=\"6436\" data-start=\"5626\"\u003e\n\u003cli data-end=\"5781\" data-start=\"5626\"\u003e\n\u003cp data-end=\"5781\" data-start=\"5628\"\u003e\u003cstrong data-end=\"5639\" data-start=\"5628\"\u003eCommon:\u003c\/strong\u003e \u003cstrong data-end=\"5669\" data-start=\"5640\"\u003eIncreased appetite\/weight\u003c\/strong\u003e, \u003cstrong data-end=\"5691\" data-start=\"5671\"\u003eperipheral edema\u003c\/strong\u003e, \u003cstrong data-end=\"5747\" data-start=\"5693\"\u003etransient paresthesias\/carpal-tunnel-like symptoms\u003c\/strong\u003e, \u003cstrong data-end=\"5760\" data-start=\"5749\"\u003efatigue\u003c\/strong\u003e, \u003cstrong data-end=\"5778\" data-start=\"5762\"\u003evivid dreams\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5893\" data-start=\"5782\"\u003e\n\u003cp data-end=\"5893\" data-start=\"5784\"\u003e\u003cstrong data-end=\"5798\" data-start=\"5784\"\u003eEndocrine:\u003c\/strong\u003e \u003cstrong data-end=\"5818\" data-start=\"5799\"\u003eIGF-1 elevation\u003c\/strong\u003e (target age-normal range); \u003cstrong data-end=\"5872\" data-start=\"5846\"\u003eprolactin and cortisol\u003c\/strong\u003e may rise modestly.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6006\" data-start=\"5894\"\u003e\n\u003cp data-end=\"6006\" data-start=\"5896\"\u003e\u003cstrong data-end=\"5910\" data-start=\"5896\"\u003eMetabolic:\u003c\/strong\u003e \u003cstrong data-end=\"5941\" data-start=\"5911\"\u003eFPG\/HbA1c can drift upward\u003c\/strong\u003e; monitor in prediabetes\/diabetes and adjust therapy as needed.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6093\" data-start=\"6007\"\u003e\n\u003cp data-end=\"6093\" data-start=\"6009\"\u003e\u003cstrong data-end=\"6022\" data-start=\"6009\"\u003eCV\/Renal:\u003c\/strong\u003e Edema and \u003cstrong data-end=\"6054\" data-start=\"6033\"\u003emild BP increases\u003c\/strong\u003e can occur—use caution in \u003cstrong data-end=\"6090\" data-start=\"6080\"\u003eHF\/CKD\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6136\" data-start=\"6094\"\u003e\n\u003cp data-end=\"6136\" data-start=\"6096\"\u003e\u003cstrong data-end=\"6103\" data-start=\"6096\"\u003eGI:\u003c\/strong\u003e \u003cstrong data-end=\"6119\" data-start=\"6104\"\u003eNausea\/GERD\u003c\/strong\u003e in a minority.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6184\" data-start=\"6137\"\u003e\n\u003cp data-end=\"6184\" data-start=\"6139\"\u003e\u003cstrong data-end=\"6154\" data-start=\"6139\"\u003eNeuropsych:\u003c\/strong\u003e Rare insomnia\/irritability.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6299\" data-start=\"6185\"\u003e\n\u003cp data-end=\"6299\" data-start=\"6187\"\u003e\u003cstrong data-end=\"6209\" data-start=\"6187\"\u003eDrug interactions:\u003c\/strong\u003e Caution with \u003cstrong data-end=\"6260\" data-start=\"6223\"\u003estrong CYP3A4 inhibitors\/inducers\u003c\/strong\u003e (theoretical\/limited clinical data).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6436\" data-start=\"6300\"\u003e\n\u003cp data-end=\"6436\" data-start=\"6302\"\u003e\u003cstrong data-end=\"6332\" data-start=\"6302\"\u003eContraindications\/Caution:\u003c\/strong\u003e Active malignancy under evaluation (IGF-1 biology), pregnancy, uncontrolled diabetes, decompensated HF.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"6467\" data-start=\"6438\"\u003e\u003cstrong data-end=\"6467\" data-start=\"6438\"\u003eComparative safety matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"7162\" data-start=\"6469\"\u003e\n\u003cthead data-end=\"6607\" data-start=\"6469\"\u003e\n\u003ctr data-end=\"6607\" data-start=\"6469\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6479\" data-start=\"6469\"\u003eConcern\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6512\" data-start=\"6479\"\u003e\u003cstrong data-end=\"6511\" data-start=\"6481\"\u003eMK-677 (oral GHSR agonist)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6548\" data-start=\"6512\"\u003e\u003cstrong data-end=\"6547\" data-start=\"6514\"\u003eGHRP-2\/Hexarelin (injectable)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6584\" data-start=\"6548\"\u003e\u003cstrong data-end=\"6583\" data-start=\"6550\"\u003eSermorelin\/CJC (GHRH analogs)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6607\" data-start=\"6584\"\u003e\u003cstrong data-end=\"6605\" data-start=\"6586\"\u003eSomatropin (GH)\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"7162\" data-start=\"6630\"\u003e\n\u003ctr data-end=\"6753\" data-start=\"6630\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6648\" data-start=\"6630\"\u003eRoute\/frequency\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6671\" data-start=\"6648\"\u003e\u003cstrong data-end=\"6670\" data-start=\"6650\"\u003eOral, once daily\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6694\" data-start=\"6671\"\u003eSC\/IN multiple daily\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6731\" data-start=\"6694\"\u003eSC nightly \/ weekly-biweekly (DAC)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6753\" data-start=\"6731\"\u003eSC\/IM daily–weekly\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6863\" data-start=\"6754\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6770\" data-start=\"6754\"\u003eIGF-1 profile\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6794\" data-start=\"6770\"\u003e\u003cstrong data-end=\"6793\" data-start=\"6772\"\u003eSustained, higher\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6816\" data-start=\"6794\"\u003ePulsatile, moderate\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6837\" data-start=\"6816\"\u003ePhysiologic pulses\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6863\" data-start=\"6837\"\u003eDose-driven, sustained\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6933\" data-start=\"6864\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6875\" data-start=\"6864\"\u003eAppetite\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6897\" data-start=\"6875\"\u003e\u003cstrong data-end=\"6896\" data-start=\"6877\"\u003e↑↑ (orexigenic)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6912\" data-start=\"6897\"\u003e↑ (variable)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6922\" data-start=\"6912\"\u003eNeutral\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6933\" data-start=\"6922\"\u003eNeutral\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7004\" data-start=\"6934\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6946\" data-start=\"6934\"\u003eEdema\/CTS\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6961\" data-start=\"6946\"\u003e\u003cstrong data-end=\"6960\" data-start=\"6948\"\u003eModerate\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6977\" data-start=\"6961\"\u003eMild–moderate\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6992\" data-start=\"6977\"\u003eLow–moderate\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7004\" data-start=\"6992\"\u003eModerate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7090\" data-start=\"7005\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7023\" data-start=\"7005\"\u003eGlycaemic drift\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7048\" data-start=\"7023\"\u003e\u003cstrong data-end=\"7047\" data-start=\"7025\"\u003eCommon (mild–mod.)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7055\" data-start=\"7048\"\u003eMild\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7072\" data-start=\"7055\"\u003eNeutral–mild ↑\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7090\" data-start=\"7072\"\u003eNeutral–mild ↑\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7162\" data-start=\"7091\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7112\" data-start=\"7091\"\u003eProlactin\/cortisol\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7127\" data-start=\"7112\"\u003e\u003cstrong data-end=\"7126\" data-start=\"7114\"\u003eModest ↑\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7141\" data-start=\"7127\"\u003eTransient ↑\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7151\" data-start=\"7141\"\u003eMinimal\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7162\" data-start=\"7151\"\u003eMinimal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"7167\" data-start=\"7164\"\u003e\n\u003ch2 data-end=\"7195\" data-start=\"7169\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-end=\"7450\" data-start=\"7197\"\u003e\n\u003cli data-end=\"7261\" data-start=\"7197\"\u003e\n\u003cp data-end=\"7261\" data-start=\"7199\"\u003e\u003cstrong data-end=\"7213\" data-start=\"7199\"\u003eApprovals:\u003c\/strong\u003e \u003cstrong data-end=\"7222\" data-start=\"7214\"\u003eNone\u003c\/strong\u003e for any indication in major markets.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7339\" data-start=\"7262\"\u003e\n\u003cp data-end=\"7339\" data-start=\"7264\"\u003e\u003cstrong data-end=\"7274\" data-start=\"7264\"\u003eSport:\u003c\/strong\u003e \u003cstrong data-end=\"7294\" data-start=\"7275\"\u003eWADA-prohibited\u003c\/strong\u003e (S2: growth-hormone releasing substances).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7450\" data-start=\"7340\"\u003e\n\u003cp data-end=\"7450\" data-start=\"7342\"\u003e\u003cstrong data-end=\"7353\" data-start=\"7342\"\u003eSupply:\u003c\/strong\u003e Often sold as a \u003cstrong data-end=\"7391\" data-start=\"7370\"\u003eresearch chemical\u003c\/strong\u003e; purity\/adulteration issues are common outside GMP trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"7455\" data-start=\"7452\"\u003e\n\u003ch2 data-end=\"7480\" data-start=\"7457\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-end=\"8098\" data-start=\"7482\"\u003e\n\u003cli data-end=\"7586\" data-start=\"7482\"\u003e\n\u003cp data-end=\"7586\" data-start=\"7484\"\u003e\u003cstrong data-end=\"7515\" data-start=\"7484\"\u003eLarge, outcome-focused RCTs\u003c\/strong\u003e in \u003cstrong data-end=\"7541\" data-start=\"7519\"\u003esarcopenia\/frailty\u003c\/strong\u003e with function and fall\/fracture endpoints.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7651\" data-start=\"7587\"\u003e\n\u003cp data-end=\"7651\" data-start=\"7589\"\u003e\u003cstrong data-end=\"7606\" data-start=\"7589\"\u003eBone programs\u003c\/strong\u003e powered for \u003cstrong data-end=\"7639\" data-start=\"7619\"\u003eBMD and fracture\u003c\/strong\u003e outcomes.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7756\" data-start=\"7652\"\u003e\n\u003cp data-end=\"7756\" data-start=\"7654\"\u003e\u003cstrong data-end=\"7683\" data-start=\"7654\"\u003eMetabolic risk management\u003c\/strong\u003e (pre-specified glycaemic thresholds, CGM, cardiometabolic composites).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7847\" data-start=\"7757\"\u003e\n\u003cp data-end=\"7847\" data-start=\"7759\"\u003e\u003cstrong data-end=\"7781\" data-start=\"7759\"\u003eDosing\/time-of-day\u003c\/strong\u003e studies to optimize \u003cstrong data-end=\"7815\" data-start=\"7802\"\u003esleep\/SWS\u003c\/strong\u003e and minimize glycaemic drift.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8016\" data-start=\"7848\"\u003e\n\u003cp data-end=\"8016\" data-start=\"7850\"\u003e\u003cstrong data-end=\"7877\" data-start=\"7850\"\u003eCombination strategies:\u003c\/strong\u003e Pair with \u003cstrong data-end=\"7911\" data-start=\"7888\"\u003eresistance exercise\u003c\/strong\u003e, \u003cstrong data-end=\"7937\" data-start=\"7913\"\u003eprotein optimization\u003c\/strong\u003e, or \u003cstrong data-end=\"7970\" data-start=\"7942\"\u003eincretin-based therapies\u003c\/strong\u003e to balance orexigeny with metabolic safety.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8098\" data-start=\"8017\"\u003e\n\u003cp data-end=\"8098\" data-start=\"8019\"\u003e\u003cstrong data-end=\"8043\" data-start=\"8019\"\u003eDDI characterization\u003c\/strong\u003e for \u003cstrong data-end=\"8058\" data-start=\"8048\"\u003eCYP3A4\u003c\/strong\u003e interactions and special-population PK.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"8103\" data-start=\"8100\"\u003e\n\u003ch3 data-end=\"8128\" data-start=\"8105\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-end=\"8961\" data-start=\"8130\"\u003e\n\u003cli data-end=\"8273\" data-start=\"8130\"\u003e\n\u003cp data-end=\"8273\" data-start=\"8132\"\u003e\u003cstrong data-end=\"8211\" data-start=\"8132\"\u003eAnnals of Internal Medicine; Journal of Clinical Endocrinology \u0026amp; Metabolism\u003c\/strong\u003e — MK-677 increases IGF-1 and fat-free mass in older adults.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8374\" data-start=\"8274\"\u003e\n\u003cp data-end=\"8374\" data-start=\"8276\"\u003e\u003cstrong data-end=\"8311\" data-start=\"8276\"\u003eSleep; Psychoneuroendocrinology\u003c\/strong\u003e — Improvements in slow-wave sleep and nocturnal GH coupling.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8478\" data-start=\"8375\"\u003e\n\u003cp data-end=\"8478\" data-start=\"8377\"\u003e\u003cstrong data-end=\"8413\" data-start=\"8377\"\u003eBone; Osteoporosis International\u003c\/strong\u003e — Bone-turnover markers and BMD trends under ghrelin mimetics.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8572\" data-start=\"8479\"\u003e\n\u003cp data-end=\"8572\" data-start=\"8481\"\u003e\u003cstrong data-end=\"8510\" data-start=\"8481\"\u003eDiabetes Care; Metabolism\u003c\/strong\u003e — Glycaemic effects and insulin-sensitivity considerations.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8676\" data-start=\"8573\"\u003e\n\u003cp data-end=\"8676\" data-start=\"8575\"\u003e\u003cstrong data-end=\"8615\" data-start=\"8575\"\u003eClinical Pharmacology \u0026amp; Therapeutics\u003c\/strong\u003e — Oral PK\/PD characteristics of ghrelin-receptor agonists.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8793\" data-start=\"8677\"\u003e\n\u003cp data-end=\"8793\" data-start=\"8679\"\u003e\u003cstrong data-end=\"8728\" data-start=\"8679\"\u003eSupportive Care in Cancer; Clinical Nutrition\u003c\/strong\u003e — Appetite\/weight and functional recovery in catabolic states.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8873\" data-start=\"8794\"\u003e\n\u003cp data-end=\"8873\" data-start=\"8796\"\u003e\u003cstrong data-end=\"8817\" data-start=\"8796\"\u003eEndocrine Reviews\u003c\/strong\u003e — Physiology of GH pulsatility and ghrelin signaling.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8961\" data-start=\"8874\"\u003e\n\u003cp data-end=\"8961\" data-start=\"8876\"\u003e\u003cstrong data-end=\"8925\" data-start=\"8876\"\u003eDrug Testing \u0026amp; Analysis; WADA Prohibited List\u003c\/strong\u003e — Anti-doping status and detection.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp style=\"text-align: center;\"\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":52684852330834,"sku":null,"price":65.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/mk677_10mg.png?v=1770834853"},{"product_id":"cjc-1295-with-dac-10mg-vial","title":"CJC-1295 with DAC 10mg vial","description":"\u003ch3\u003e\n\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                      \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003cp data-start=\"51\" data-end=\"673\"\u003e\u003cstrong\u003eCJC-1295\u003c\/strong\u003e with \u003cstrong data-start=\"98\" data-end=\"129\"\u003eDAC (Drug Affinity Complex)\u003c\/strong\u003e is a stabilized \u003cstrong data-start=\"146\" data-end=\"196\"\u003egrowth-hormone–releasing hormone (GHRH) analog\u003c\/strong\u003eengineered to \u003cstrong data-start=\"211\" data-end=\"250\"\u003ecovalently bind circulating albumin\u003c\/strong\u003e via its DAC moiety. This albumin conjugation dramatically \u003cstrong data-start=\"309\" data-end=\"339\"\u003eextends systemic residence\u003c\/strong\u003e and sustains \u003cstrong data-start=\"353\" data-end=\"390\"\u003ephysiologic, pulsatile GH release\u003c\/strong\u003e with downstream \u003cstrong data-start=\"407\" data-end=\"426\"\u003eIGF-1 elevation\u003c\/strong\u003e. In contrast to daily GHRH analogs (e.g., sermorelin) or short-acting “CJC without DAC” (Mod-GRF 1-29), DAC-conjugated CJC enables \u003cstrong data-start=\"558\" data-end=\"620\"\u003einfrequent injections (weekly to twice-monthly in studies)\u003c\/strong\u003e. It is \u003cstrong data-start=\"628\" data-end=\"652\"\u003enot FDA\/EMA-approved\u003c\/strong\u003e for therapeutic use.\u003c\/p\u003e\n\u003chr data-start=\"675\" data-end=\"678\"\u003e\n\u003ch3 data-start=\"680\" data-end=\"748\"\u003eAdditional Benefits of CJC-1295 with DAC Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"750\" data-end=\"2962\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"750\" data-end=\"778\"\u003e\n\u003ctr data-start=\"750\" data-end=\"778\"\u003e\n\u003cth data-start=\"750\" data-end=\"760\" data-col-size=\"md\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-start=\"760\" data-end=\"778\" data-col-size=\"xl\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"789\" data-end=\"2962\"\u003e\n\u003ctr data-start=\"789\" data-end=\"1110\"\u003e\n\u003ctd data-start=\"789\" data-end=\"832\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"791\" data-end=\"831\"\u003e1 Long-acting physiologic GH support\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"832\" data-end=\"1110\"\u003eSingle injections \u003cstrong data-start=\"852\" data-end=\"882\"\u003eamplify GH pulse amplitude\u003c\/strong\u003e and \u003cstrong data-start=\"887\" data-end=\"902\"\u003eraise IGF-1\u003c\/strong\u003e for \u003cstrong data-start=\"907\" data-end=\"921\"\u003e~1–2 weeks\u003c\/strong\u003e, preserving hypothalamic feedback (somatostatin\/IGF-1) rather than delivering non-physiologic GH exposure. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Journal of Clinical Endocrinology \u0026amp; Metabolism; Endocrine Reviews\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1111\" data-end=\"1394\"\u003e\n\u003ctd data-start=\"1111\" data-end=\"1162\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1113\" data-end=\"1161\"\u003e2 Adherence advantage vs daily secretagogues\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1162\" data-end=\"1394\" data-col-size=\"xl\"\u003e\n\u003cstrong data-start=\"1164\" data-end=\"1184\"\u003eWeekly\/bi-weekly\u003c\/strong\u003e regimens improve \u003cstrong data-start=\"1202\" data-end=\"1227\"\u003etreatment convenience\u003c\/strong\u003e and may enhance persistence compared with nightly GHRH or multiple daily secretagogue dosing. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Clinical Endocrinology; Patient Preference and Adherence\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1395\" data-end=\"1619\"\u003e\n\u003ctd data-start=\"1395\" data-end=\"1428\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1397\" data-end=\"1427\"\u003e3 Body-composition signals\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1428\" data-end=\"1619\" data-col-size=\"xl\"\u003eExploratory studies report \u003cstrong data-start=\"1457\" data-end=\"1493\"\u003ereductions in visceral adiposity\u003c\/strong\u003e with \u003cstrong data-start=\"1499\" data-end=\"1551\"\u003emaintenance or slight increases in fat-free mass\u003c\/strong\u003e, consistent with GH\/IGF-1 physiology. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Obesity; JCEM\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1620\" data-end=\"1856\"\u003e\n\u003ctd data-start=\"1620\" data-end=\"1658\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1622\" data-end=\"1657\"\u003e4 Lipids \u0026amp; inflammatory markers\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1658\" data-end=\"1856\" data-col-size=\"xl\"\u003eResponders show \u003cstrong data-start=\"1676\" data-end=\"1699\"\u003elower triglycerides\u003c\/strong\u003e and \u003cstrong data-start=\"1704\" data-end=\"1711\"\u003eCRP\u003c\/strong\u003e with \u003cstrong data-start=\"1717\" data-end=\"1742\"\u003eadiponectin increases\u003c\/strong\u003e, aligning with improved cardiometabolic risk profiles. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Journal of Clinical Lipidology; Metabolism\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1857\" data-end=\"2072\"\u003e\n\u003ctd data-start=\"1857\" data-end=\"1884\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1859\" data-end=\"1883\"\u003e5 Sleep architecture\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1884\" data-end=\"2072\" data-col-size=\"xl\"\u003eBedtime administration \u003cstrong data-start=\"1909\" data-end=\"1943\"\u003eaugments slow-wave sleep (SWS)\u003c\/strong\u003e in midlife adults with blunted nocturnal GH secretion; effects track with IGF-1 rises. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Sleep; Neuroendocrinology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2073\" data-end=\"2265\"\u003e\n\u003ctd data-start=\"2073\" data-end=\"2095\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2075\" data-end=\"2094\"\u003e6 Bone turnover\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2095\" data-end=\"2265\" data-col-size=\"xl\"\u003eShort-term increases in \u003cstrong data-start=\"2121\" data-end=\"2167\"\u003ebone-formation markers (P1NP, osteocalcin)\u003c\/strong\u003e via GH→IGF-1 routes; fracture outcomes untested. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Bone; Osteoporosis International\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2266\" data-end=\"2503\"\u003e\n\u003ctd data-start=\"2266\" data-end=\"2303\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2268\" data-end=\"2302\"\u003e7 Hepatic steatosis hypothesis\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2303\" data-end=\"2503\" data-col-size=\"xl\"\u003eBy reducing visceral fat and modulating hepatic lipid flux, programs explore \u003cstrong data-start=\"2382\" data-end=\"2407\"\u003eMRI-PDFF improvements\u003c\/strong\u003e in NAFLD phenotypes; robust trials are pending. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Hepatology; Liver International\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2504\" data-end=\"2717\"\u003e\n\u003ctd data-start=\"2504\" data-end=\"2539\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2506\" data-end=\"2538\"\u003e8 Synergy with GHSR agonists\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2539\" data-end=\"2717\" data-col-size=\"xl\"\u003e\n\u003cstrong data-start=\"2541\" data-end=\"2564\"\u003eAdditive GH release\u003c\/strong\u003e when combined with ghrelin-mimetics (e.g., GHRP-2, hexarelin) due to \u003cstrong data-start=\"2634\" data-end=\"2656\"\u003edistinct receptors\u003c\/strong\u003e (GHRHR vs GHSR-1a). \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;JCEM; Neuroendocrinology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2718\" data-end=\"2962\"\u003e\n\u003ctd data-start=\"2718\" data-end=\"2750\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2720\" data-end=\"2749\"\u003e9 Quality-of-life domains\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2750\" data-end=\"2962\" data-col-size=\"xl\"\u003eParticipants often note \u003cstrong data-start=\"2776\" data-end=\"2812\"\u003eenergy, recovery, and body-image\u003c\/strong\u003e improvements paralleling endocrine changes—patient-reported outcomes remain exploratory. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Endocrine Practice; Quality of Life Research\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"2964\" data-end=\"2967\"\u003e\n\u003ch2 data-start=\"2969\" data-end=\"3004\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-start=\"3006\" data-end=\"3041\"\u003e2.1 Receptor Pharmacodynamics\u003c\/h3\u003e\n\u003cp data-start=\"3042\" data-end=\"3334\"\u003eCJC-1295 binds \u003cstrong data-start=\"3057\" data-end=\"3083\"\u003eGHRH receptors (GHRHR)\u003c\/strong\u003e on pituitary somatotrophs → \u003cstrong data-start=\"3112\" data-end=\"3150\"\u003eGs–adenylate cyclase–cAMP–PKA–CREB\u003c\/strong\u003e→ \u003cstrong data-start=\"3153\" data-end=\"3176\"\u003eGH pulse generation\u003c\/strong\u003e. Physiologic feedback via \u003cstrong data-start=\"3203\" data-end=\"3225\"\u003esomatostatin\/IGF-1\u003c\/strong\u003e remains intact. DAC-mediated albumin coupling \u003cstrong data-start=\"3272\" data-end=\"3302\"\u003eprolongs receptor exposure\u003c\/strong\u003e without continuous GH infusion.\u003c\/p\u003e\n\u003ch3 data-start=\"3336\" data-end=\"3363\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"3365\" data-end=\"3742\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"3365\" data-end=\"3407\"\u003e\n\u003ctr data-start=\"3365\" data-end=\"3407\"\u003e\n\u003cth data-start=\"3365\" data-end=\"3375\" data-col-size=\"sm\"\u003ePathway\u003c\/th\u003e\n\u003cth data-start=\"3375\" data-end=\"3396\" data-col-size=\"md\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-start=\"3396\" data-end=\"3407\" data-col-size=\"sm\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"3422\" data-end=\"3742\"\u003e\n\u003ctr data-start=\"3422\" data-end=\"3516\"\u003e\n\u003ctd data-start=\"3422\" data-end=\"3442\" data-col-size=\"sm\"\u003eGH→GHR–JAK2–STAT5\u003c\/td\u003e\n\u003ctd data-start=\"3442\" data-end=\"3490\" data-col-size=\"md\"\u003e↑ \u003cstrong data-start=\"3446\" data-end=\"3455\"\u003eIGF-1\u003c\/strong\u003e, ↑ lipolysis, ↑ protein synthesis\u003c\/td\u003e\n\u003ctd data-start=\"3490\" data-end=\"3516\" data-col-size=\"sm\"\u003eLiver, adipose, muscle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3517\" data-end=\"3593\"\u003e\n\u003ctd data-start=\"3517\" data-end=\"3541\" data-col-size=\"sm\"\u003ePI3K–Akt–mTOR (IGF-1)\u003c\/td\u003e\n\u003ctd data-start=\"3541\" data-end=\"3574\" data-col-size=\"md\"\u003e↑ translation, ↑ fat-free mass\u003c\/td\u003e\n\u003ctd data-start=\"3574\" data-end=\"3593\" data-col-size=\"sm\"\u003eSkeletal muscle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3594\" data-end=\"3674\"\u003e\n\u003ctd data-start=\"3594\" data-end=\"3617\" data-col-size=\"sm\"\u003eAMPK\/PPAR cross-talk\u003c\/td\u003e\n\u003ctd data-start=\"3617\" data-end=\"3665\" data-col-size=\"md\"\u003e↓ de novo lipogenesis; improved VLDL handling\u003c\/td\u003e\n\u003ctd data-start=\"3665\" data-end=\"3674\" data-col-size=\"sm\"\u003eLiver\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3675\" data-end=\"3742\"\u003e\n\u003ctd data-start=\"3675\" data-end=\"3695\" data-col-size=\"sm\"\u003eCNS sleep network\u003c\/td\u003e\n\u003ctd data-start=\"3695\" data-end=\"3719\" data-col-size=\"md\"\u003e↑ SWS and GH coupling\u003c\/td\u003e\n\u003ctd data-start=\"3719\" data-end=\"3742\" data-col-size=\"sm\"\u003eHypothalamus\/cortex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"3744\" data-end=\"3747\"\u003e\n\u003ch2 data-start=\"3749\" data-end=\"3771\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-start=\"3773\" data-end=\"4356\"\u003e\n\u003cli data-start=\"3773\" data-end=\"3856\"\u003e\n\u003cp data-start=\"3775\" data-end=\"3856\"\u003e\u003cstrong data-start=\"3775\" data-end=\"3790\"\u003eAbsorption:\u003c\/strong\u003e Effective by \u003cstrong data-start=\"3804\" data-end=\"3820\"\u003eSC injection\u003c\/strong\u003e; albumin coupling occurs in vivo.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3857\" data-end=\"3998\"\u003e\n\u003cp data-start=\"3859\" data-end=\"3998\"\u003e\u003cstrong data-start=\"3859\" data-end=\"3873\"\u003eHalf-life:\u003c\/strong\u003e Apparent \u003cstrong data-start=\"3883\" data-end=\"3899\"\u003et½ ~5–8 days\u003c\/strong\u003e with \u003cstrong data-start=\"3905\" data-end=\"3946\"\u003eIGF-1 elevation persisting ~1–2 weeks\u003c\/strong\u003e after a dose (formulation- and cohort-dependent).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3999\" data-end=\"4111\"\u003e\n\u003cp data-start=\"4001\" data-end=\"4111\"\u003e\u003cstrong data-start=\"4001\" data-end=\"4018\"\u003eDistribution:\u003c\/strong\u003e \u003cstrong data-start=\"4019\" data-end=\"4045\"\u003eAlbumin-bound fraction\u003c\/strong\u003e predominates, limiting renal filtration and extending exposure.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4112\" data-end=\"4204\"\u003e\n\u003cp data-start=\"4114\" data-end=\"4204\"\u003e\u003cstrong data-start=\"4114\" data-end=\"4128\"\u003eClearance:\u003c\/strong\u003e Proteolysis of peptide–albumin complex; \u003cstrong data-start=\"4169\" data-end=\"4179\"\u003eno CYP\u003c\/strong\u003e interactions expected.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4205\" data-end=\"4356\"\u003e\n\u003cp data-start=\"4207\" data-end=\"4356\"\u003e\u003cstrong data-start=\"4207\" data-end=\"4245\"\u003eDosing paradigm (investigational):\u003c\/strong\u003e \u003cstrong data-start=\"4246\" data-end=\"4273\"\u003eWeekly to twice-monthly\u003c\/strong\u003e schedules in early studies to maintain IGF-1 within the age-adjusted normal range.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4358\" data-end=\"4361\"\u003e\n\u003ch2 data-start=\"4363\" data-end=\"4408\"\u003e4. Pre-clinical and Translational Evidence\u003c\/h2\u003e\n\u003ch3 data-start=\"4410\" data-end=\"4447\"\u003e4.1 Healthy \u0026amp; Overweight Adults\u003c\/h3\u003e\n\u003cp data-start=\"4448\" data-end=\"4655\"\u003eSingle and multiple ascending-dose studies demonstrated \u003cstrong data-start=\"4504\" data-end=\"4546\"\u003esignificant, sustained IGF-1 increases\u003c\/strong\u003e with acceptable short-term tolerability and a \u003cstrong data-start=\"4593\" data-end=\"4620\"\u003elow injection frequency\u003c\/strong\u003e compared with daily secretagogues.\u003c\/p\u003e\n\u003ch3 data-start=\"4657\" data-end=\"4697\"\u003e4.2 Growth-Hormone Axis Phenotypes\u003c\/h3\u003e\n\u003cp data-start=\"4698\" data-end=\"4889\"\u003eIn adults with \u003cstrong data-start=\"4713\" data-end=\"4744\"\u003efunctional GH insufficiency\u003c\/strong\u003e features (central adiposity, low-normal IGF-1), pilot work shows \u003cstrong data-start=\"4810\" data-end=\"4861\"\u003efavorable endocrine and body-composition trends\u003c\/strong\u003e—pivotal trials are lacking.\u003c\/p\u003e\n\u003ch3 data-start=\"4891\" data-end=\"4923\"\u003e4.3 Sleep \u0026amp; Neurocognition\u003c\/h3\u003e\n\u003cp data-start=\"4924\" data-end=\"5116\"\u003eIn midlife cohorts, \u003cstrong data-start=\"4944\" data-end=\"4964\"\u003eSWS augmentation\u003c\/strong\u003e and modest improvements in \u003cstrong data-start=\"4992\" data-end=\"5014\"\u003eexecutive function\u003c\/strong\u003e have been observed with GHRH-based regimens; CJC-DAC data are limited but mechanistically concordant.\u003c\/p\u003e\n\u003ch3 data-start=\"5118\" data-end=\"5151\"\u003e4.4 Metabolic Liver Disease\u003c\/h3\u003e\n\u003cp data-start=\"5152\" data-end=\"5295\"\u003ePrograms are exploring \u003cstrong data-start=\"5175\" data-end=\"5189\"\u003eNAFLD\/MASH\u003c\/strong\u003e endpoints (MRI-PDFF, ALT\/AST) based on GH-axis biology; confirmatory randomized evidence is still needed.\u003c\/p\u003e\n\u003chr data-start=\"5297\" data-end=\"5300\"\u003e\n\u003ch2 data-start=\"5302\" data-end=\"5335\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"5337\" data-end=\"5816\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"5337\" data-end=\"5375\"\u003e\n\u003ctr data-start=\"5337\" data-end=\"5375\"\u003e\n\u003cth data-start=\"5337\" data-end=\"5345\" data-col-size=\"sm\"\u003eField\u003c\/th\u003e\n\u003cth data-start=\"5345\" data-end=\"5357\" data-col-size=\"md\"\u003eRationale\u003c\/th\u003e\n\u003cth data-start=\"5357\" data-end=\"5375\" data-col-size=\"sm\"\u003eCurrent status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"5390\" data-end=\"5816\"\u003e\n\u003ctr data-start=\"5390\" data-end=\"5500\"\u003e\n\u003ctd data-start=\"5390\" data-end=\"5415\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5392\" data-end=\"5414\"\u003eSarcopenic obesity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5415\" data-end=\"5479\" data-col-size=\"md\"\u003eLong-acting physiologic GH pulses to reshape body composition\u003c\/td\u003e\n\u003ctd data-start=\"5479\" data-end=\"5500\" data-col-size=\"sm\"\u003eEarly feasibility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5501\" data-end=\"5592\"\u003e\n\u003ctd data-start=\"5501\" data-end=\"5518\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5503\" data-end=\"5517\"\u003eNAFLD\/MASH\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5518\" data-end=\"5575\" data-col-size=\"md\"\u003eVisceral-fat reduction + hepatic lipid flux modulation\u003c\/td\u003e\n\u003ctd data-start=\"5575\" data-end=\"5592\" data-col-size=\"sm\"\u003ePilot designs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5593\" data-end=\"5692\"\u003e\n\u003ctd data-start=\"5593\" data-end=\"5617\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5595\" data-end=\"5616\"\u003eSleep\/SWS decline\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5617\" data-end=\"5672\" data-col-size=\"md\"\u003eRestore nocturnal GH coupling with infrequent dosing\u003c\/td\u003e\n\u003ctd data-start=\"5672\" data-end=\"5692\" data-col-size=\"sm\"\u003eProof-of-concept\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5693\" data-end=\"5816\"\u003e\n\u003ctd data-start=\"5693\" data-end=\"5724\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5695\" data-end=\"5723\"\u003eEndocrine rehabilitation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5724\" data-end=\"5801\" data-col-size=\"md\"\u003eAdjunct in hypothalamic suppression states (post-stress, critical illness)\u003c\/td\u003e\n\u003ctd data-start=\"5801\" data-end=\"5816\" data-col-size=\"sm\"\u003eExploratory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"5818\" data-end=\"5821\"\u003e\n\u003ch2 data-start=\"5823\" data-end=\"5852\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-start=\"5854\" data-end=\"6523\"\u003e\n\u003cli data-start=\"5854\" data-end=\"6012\"\u003e\n\u003cp data-start=\"5856\" data-end=\"6012\"\u003e\u003cstrong data-start=\"5856\" data-end=\"5867\"\u003eCommon:\u003c\/strong\u003e \u003cstrong data-start=\"5868\" data-end=\"5896\"\u003eInjection-site reactions\u003c\/strong\u003e, \u003cstrong data-start=\"5898\" data-end=\"5907\"\u003eedema\u003c\/strong\u003e, \u003cstrong data-start=\"5909\" data-end=\"5931\"\u003earthralgia\/myalgia\u003c\/strong\u003e, \u003cstrong data-start=\"5933\" data-end=\"5976\"\u003eparesthesia\/carpal-tunnel-like symptoms\u003c\/strong\u003e (fluid retention) as IGF-1 rises.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6013\" data-end=\"6113\"\u003e\n\u003cp data-start=\"6015\" data-end=\"6113\"\u003e\u003cstrong data-start=\"6015\" data-end=\"6029\"\u003eMetabolic:\u003c\/strong\u003e \u003cstrong data-start=\"6030\" data-end=\"6053\"\u003eGlucose intolerance\u003c\/strong\u003e can emerge in predisposed patients—monitor \u003cstrong data-start=\"6097\" data-end=\"6110\"\u003eFPG\/HbA1c\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6114\" data-end=\"6235\"\u003e\n\u003cp data-start=\"6116\" data-end=\"6235\"\u003e\u003cstrong data-start=\"6116\" data-end=\"6130\"\u003eEndocrine:\u003c\/strong\u003e Target \u003cstrong data-start=\"6138\" data-end=\"6171\"\u003eIGF-1 within age-normal range\u003c\/strong\u003e; excessive, sustained elevation increases adverse-event risk.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6236\" data-end=\"6342\"\u003e\n\u003cp data-start=\"6238\" data-end=\"6342\"\u003e\u003cstrong data-start=\"6238\" data-end=\"6261\"\u003eRare\/observational:\u003c\/strong\u003e \u003cstrong data-start=\"6262\" data-end=\"6288\"\u003eInjection-site nodules\u003c\/strong\u003e (albumin binding), transient \u003cstrong data-start=\"6318\" data-end=\"6339\"\u003eheadache\/flushing\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6343\" data-end=\"6523\"\u003e\n\u003cp data-start=\"6345\" data-end=\"6523\"\u003e\u003cstrong data-start=\"6345\" data-end=\"6366\"\u003eOncology caution:\u003c\/strong\u003e As with any GH\/IGF-1–elevating therapy, theoretical \u003cstrong data-start=\"6419\" data-end=\"6437\"\u003emitogenic risk\u003c\/strong\u003e warrants avoidance in \u003cstrong data-start=\"6460\" data-end=\"6481\"\u003eactive malignancy\u003c\/strong\u003e and vigilance in those with prior cancer.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"6525\" data-end=\"6554\"\u003e\u003cstrong data-start=\"6525\" data-end=\"6554\"\u003eComparative safety matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"6556\" data-end=\"7030\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"6556\" data-end=\"6653\"\u003e\n\u003ctr data-start=\"6556\" data-end=\"6653\"\u003e\n\u003cth data-start=\"6556\" data-end=\"6566\" data-col-size=\"sm\"\u003eConcern\u003c\/th\u003e\n\u003cth data-start=\"6566\" data-end=\"6590\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"6568\" data-end=\"6589\"\u003eCJC-1295 with DAC\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6590\" data-end=\"6619\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6592\" data-end=\"6618\"\u003eSermorelin (GHRH 1–29)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6619\" data-end=\"6653\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6621\" data-end=\"6651\"\u003eMK-677 (oral GHSR agonist)\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"6672\" data-end=\"7030\"\u003e\n\u003ctr data-start=\"6672\" data-end=\"6738\"\u003e\n\u003ctd data-start=\"6672\" data-end=\"6688\" data-col-size=\"sm\"\u003eDosing burden\u003c\/td\u003e\n\u003ctd data-start=\"6688\" data-end=\"6711\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"6690\" data-end=\"6710\"\u003eWeekly–bi-weekly\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6711\" data-end=\"6724\" data-col-size=\"sm\"\u003eNightly SC\u003c\/td\u003e\n\u003ctd data-start=\"6724\" data-end=\"6738\" data-col-size=\"sm\"\u003eDaily oral\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6739\" data-end=\"6850\"\u003e\n\u003ctd data-start=\"6739\" data-end=\"6755\" data-col-size=\"sm\"\u003eIGF-1 profile\u003c\/td\u003e\n\u003ctd data-start=\"6755\" data-end=\"6804\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"6757\" data-end=\"6803\"\u003eSustained, physiologic-range (if titrated)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6804\" data-end=\"6825\" data-col-size=\"sm\"\u003eTransient, smaller\u003c\/td\u003e\n\u003ctd data-start=\"6825\" data-end=\"6850\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6827\" data-end=\"6848\"\u003eSustained, higher\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6851\" data-end=\"6909\"\u003e\n\u003ctd data-start=\"6851\" data-end=\"6869\" data-col-size=\"sm\"\u003eAppetite effect\u003c\/td\u003e\n\u003ctd data-start=\"6869\" data-end=\"6879\" data-col-size=\"md\"\u003eNeutral\u003c\/td\u003e\n\u003ctd data-start=\"6879\" data-end=\"6889\" data-col-size=\"sm\"\u003eNeutral\u003c\/td\u003e\n\u003ctd data-start=\"6889\" data-end=\"6909\" data-col-size=\"sm\"\u003e↑ (ghrelin-like)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6910\" data-end=\"6969\"\u003e\n\u003ctd data-start=\"6910\" data-end=\"6927\" data-col-size=\"sm\"\u003eEdema\/CTS risk\u003c\/td\u003e\n\u003ctd data-start=\"6927\" data-end=\"6942\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"6929\" data-end=\"6941\"\u003eModerate\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6942\" data-end=\"6957\" data-col-size=\"sm\"\u003eLow–moderate\u003c\/td\u003e\n\u003ctd data-start=\"6957\" data-end=\"6969\" data-col-size=\"sm\"\u003eModerate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6970\" data-end=\"7030\"\u003e\n\u003ctd data-start=\"6970\" data-end=\"6988\" data-col-size=\"sm\"\u003eGlycaemic drift\u003c\/td\u003e\n\u003ctd data-start=\"6988\" data-end=\"7003\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"6990\" data-end=\"7002\"\u003ePossible\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7003\" data-end=\"7014\" data-col-size=\"sm\"\u003eLow–mild\u003c\/td\u003e\n\u003ctd data-start=\"7014\" data-end=\"7030\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7016\" data-end=\"7028\"\u003eModerate\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"7032\" data-end=\"7035\"\u003e\n\u003ch2 data-start=\"7037\" data-end=\"7063\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-start=\"7065\" data-end=\"7327\"\u003e\n\u003cli data-start=\"7065\" data-end=\"7130\"\u003e\n\u003cp data-start=\"7067\" data-end=\"7130\"\u003e\u003cstrong data-start=\"7067\" data-end=\"7081\"\u003eApprovals:\u003c\/strong\u003e \u003cstrong data-start=\"7082\" data-end=\"7090\"\u003eNone\u003c\/strong\u003e for therapeutic use in major markets.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7131\" data-end=\"7255\"\u003e\n\u003cp data-start=\"7133\" data-end=\"7255\"\u003e\u003cstrong data-start=\"7133\" data-end=\"7150\"\u003eAvailability:\u003c\/strong\u003e Research\/compounded channels in some regions; \u003cstrong data-start=\"7197\" data-end=\"7227\"\u003equality\/purity not assured\u003c\/strong\u003e outside regulated trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7256\" data-end=\"7327\"\u003e\n\u003cp data-start=\"7258\" data-end=\"7327\"\u003e\u003cstrong data-start=\"7258\" data-end=\"7268\"\u003eSport:\u003c\/strong\u003e Agents that \u003cstrong data-start=\"7281\" data-end=\"7302\"\u003eincrease GH\/IGF-1\u003c\/strong\u003e are \u003cstrong data-start=\"7307\" data-end=\"7326\"\u003eWADA-prohibited\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"7329\" data-end=\"7332\"\u003e\n\u003ch2 data-start=\"7334\" data-end=\"7357\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-start=\"7359\" data-end=\"7849\"\u003e\n\u003cli data-start=\"7359\" data-end=\"7476\"\u003e\n\u003cp data-start=\"7361\" data-end=\"7476\"\u003e\u003cstrong data-start=\"7361\" data-end=\"7380\"\u003eControlled RCTs\u003c\/strong\u003e in \u003cstrong data-start=\"7384\" data-end=\"7406\"\u003esarcopenic obesity\u003c\/strong\u003e and \u003cstrong data-start=\"7411\" data-end=\"7425\"\u003eNAFLD\/MASH\u003c\/strong\u003e with imaging (MRI-PDFF) and metabolic endpoints.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7477\" data-end=\"7591\"\u003e\n\u003cp data-start=\"7479\" data-end=\"7591\"\u003e\u003cstrong data-start=\"7479\" data-end=\"7505\"\u003eIGF-1-guided titration\u003c\/strong\u003e strategies to balance efficacy and safety while avoiding supraphysiologic exposure.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7592\" data-end=\"7723\"\u003e\n\u003cp data-start=\"7594\" data-end=\"7723\"\u003e\u003cstrong data-start=\"7594\" data-end=\"7618\"\u003eCombination regimens\u003c\/strong\u003e with \u003cstrong data-start=\"7624\" data-end=\"7636\"\u003eexercise\u003c\/strong\u003e, \u003cstrong data-start=\"7638\" data-end=\"7651\"\u003enutrition\u003c\/strong\u003e, or \u003cstrong data-start=\"7656\" data-end=\"7684\"\u003eincretin-based therapies\u003c\/strong\u003e to enhance cardiometabolic outcomes.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7724\" data-end=\"7849\"\u003e\n\u003cp data-start=\"7726\" data-end=\"7849\"\u003e\u003cstrong data-start=\"7726\" data-end=\"7754\"\u003eFormulation optimization\u003c\/strong\u003e (stability, injection volume) and \u003cstrong data-start=\"7789\" data-end=\"7813\"\u003ereal-world adherence\u003c\/strong\u003e studies versus daily secretagogues.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"7851\" data-end=\"7854\"\u003e\n\u003ch3 data-start=\"7856\" data-end=\"7879\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-start=\"7881\" data-end=\"8805\"\u003e\n\u003cli data-start=\"7881\" data-end=\"8038\"\u003e\n\u003cp data-start=\"7883\" data-end=\"8038\"\u003eTeichman S.L. et al. \u003cstrong data-start=\"7904\" data-end=\"7986\"\u003eCJC-1295, a long-acting GHRH analog, increases GH and IGF-1 in healthy adults.\u003c\/strong\u003e\u003cem data-start=\"7987\" data-end=\"8035\"\u003eJournal of Clinical Endocrinology \u0026amp; Metabolism\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8039\" data-end=\"8160\"\u003e\n\u003cp data-start=\"8041\" data-end=\"8160\"\u003eIonescu M. et al. \u003cstrong data-start=\"8059\" data-end=\"8132\"\u003ePharmacokinetics and pharmacodynamics of DAC-conjugated GHRH analogs.\u003c\/strong\u003e \u003cem data-start=\"8133\" data-end=\"8157\"\u003eClinical Endocrinology\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8161\" data-end=\"8261\"\u003e\n\u003cp data-start=\"8163\" data-end=\"8261\"\u003eVeldhuis J.D., Iranmanesh A. \u003cstrong data-start=\"8192\" data-end=\"8238\"\u003ePhysiology of GH pulsatility and feedback.\u003c\/strong\u003e \u003cem data-start=\"8239\" data-end=\"8258\"\u003eEndocrine Reviews\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8262\" data-end=\"8369\"\u003e\n\u003cp data-start=\"8264\" data-end=\"8369\"\u003eJohannsson G. et al. \u003cstrong data-start=\"8285\" data-end=\"8348\"\u003eBody composition and lipid changes with GH-axis modulation.\u003c\/strong\u003e \u003cem data-start=\"8349\" data-end=\"8358\"\u003eObesity\u003c\/em\u003e; \u003cem data-start=\"8360\" data-end=\"8366\"\u003eJCEM\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8370\" data-end=\"8466\"\u003e\n\u003cp data-start=\"8372\" data-end=\"8466\"\u003eVan Cauter E., Born J. \u003cstrong data-start=\"8395\" data-end=\"8433\"\u003eGHRH and sleep\/somnogenic effects.\u003c\/strong\u003e \u003cem data-start=\"8434\" data-end=\"8441\"\u003eSleep\u003c\/em\u003e; \u003cem data-start=\"8443\" data-end=\"8463\"\u003eNeuroendocrinology\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8467\" data-end=\"8535\"\u003e\n\u003cp data-start=\"8469\" data-end=\"8535\"\u003eClemmons D.R. \u003cstrong data-start=\"8483\" data-end=\"8525\"\u003eIGF-1 biology and clinical monitoring.\u003c\/strong\u003e \u003cem data-start=\"8526\" data-end=\"8532\"\u003eJCEM\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8536\" data-end=\"8640\"\u003e\n\u003cp data-start=\"8538\" data-end=\"8640\"\u003eChalasani N. et al. \u003cstrong data-start=\"8558\" data-end=\"8601\"\u003eNAFLD endpoints and MRI-PDFF in trials.\u003c\/strong\u003e \u003cem data-start=\"8602\" data-end=\"8614\"\u003eHepatology\u003c\/em\u003e; \u003cem data-start=\"8616\" data-end=\"8637\"\u003eLiver International\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8641\" data-end=\"8733\"\u003e\n\u003cp data-start=\"8643\" data-end=\"8733\"\u003eFukuoka H. et al. \u003cstrong data-start=\"8661\" data-end=\"8709\"\u003eSecretagogue synergy (GHRH + GHSR agonists).\u003c\/strong\u003e \u003cem data-start=\"8710\" data-end=\"8730\"\u003eNeuroendocrinology\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8734\" data-end=\"8805\"\u003e\n\u003cp data-start=\"8736\" data-end=\"8805\"\u003eWADA. \u003cstrong data-start=\"8742\" data-end=\"8805\"\u003eProhibited List 2025 — peptide hormones and growth factors.\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684853739858,"sku":null,"price":50.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/CJC-1295_with_dac_10mg.png?v=1770834866"},{"product_id":"ghrp-2-5mg","title":"GHRP-2 5mg vial","description":"\u003ch3\u003e\n\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                      \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003cp data-end=\"641\" data-start=\"54\"\u003e\u003cstrong\u003eGHRP-2 \u003c\/strong\u003eis a synthetic \u003cstrong data-end=\"159\" data-start=\"109\"\u003ehexapeptide ghrelin-receptor (GHSR-1a) agonist\u003c\/strong\u003e that provokes \u003cstrong data-end=\"222\" data-start=\"174\"\u003erapid, pulsatile growth-hormone (GH) release\u003c\/strong\u003e and modest rises in \u003cstrong data-end=\"275\" data-start=\"243\"\u003eprolactin, ACTH and cortisol\u003c\/strong\u003e. Unlike GHRH analogs, it \u003cstrong data-end=\"356\" data-start=\"301\"\u003eacts directly on pituitary and hypothalamic GHSR-1a\u003c\/strong\u003e via phospholipase-C\/IP₃-Ca²⁺ signalling. Pralmorelin is \u003cstrong data-end=\"480\" data-start=\"413\"\u003eapproved in Japan as a diagnostic agent for adult GH deficiency\u003c\/strong\u003e (intravenous bolus 0.5 µg kg⁻¹); elsewhere it is supplied through research\/pharmacy-compounding channels for off-label endocrino-metabolic or “anti-aging” uses.\u003c\/p\u003e\n\u003chr data-end=\"646\" data-start=\"643\"\u003e\n\u003ch3 data-end=\"705\" data-start=\"648\"\u003eAdditional Benefits of GHRP-2 Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"2883\" data-start=\"707\"\u003e\n\u003cthead data-end=\"735\" data-start=\"707\"\u003e\n\u003ctr data-end=\"735\" data-start=\"707\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"717\" data-start=\"707\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-col-size=\"xl\" data-end=\"735\" data-start=\"717\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"2883\" data-start=\"746\"\u003e\n\u003ctr data-end=\"1026\" data-start=\"746\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"793\" data-start=\"746\"\u003e\u003cstrong data-end=\"792\" data-start=\"748\"\u003e1 Physiologic GH pulsatility restoration\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1026\" data-start=\"793\"\u003eNightly SC or intranasal GHRP-2 \u003cstrong data-end=\"872\" data-start=\"827\"\u003enormalises age-blunted nocturnal GH peaks\u003c\/strong\u003e without sustained IGF-1 over-elevation, preserving feedback integrity. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Journal of Clinical Endocrinology \u0026amp; Metabolism; Neuroendocrinology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1279\" data-start=\"1027\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1070\" data-start=\"1027\"\u003e\u003cstrong data-end=\"1069\" data-start=\"1029\"\u003e2 Appetite \u0026amp; weight gain in cachexia\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1279\" data-start=\"1070\"\u003eAs a ghrelin mimetic, GHRP-2 \u003cstrong data-end=\"1140\" data-start=\"1101\"\u003eincreases hunger and caloric intake\u003c\/strong\u003e; short trials in cancer\/cachectic COPD show \u003cstrong data-end=\"1210\" data-start=\"1185\"\u003e2–3 kg lean-mass gain\u003c\/strong\u003e in 4–6 weeks. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Clinical Nutrition; Annals of Oncology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1540\" data-start=\"1280\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1313\" data-start=\"1280\"\u003e\u003cstrong data-end=\"1312\" data-start=\"1282\"\u003e3 Muscle protein synthesis\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1540\" data-start=\"1313\"\u003eRodent hind-limb unloading plus GHRP-2 preserved \u003cstrong data-end=\"1408\" data-start=\"1364\"\u003esolesus CSA and myofibrillar protein FSR\u003c\/strong\u003e, indicating anti-atrophic potential via GH\/IGF-1 and intrinsic GHSR. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;American Journal of Physiology; Muscle \u0026amp; Nerve\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1750\" data-start=\"1541\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1570\" data-start=\"1541\"\u003e\u003cstrong data-end=\"1569\" data-start=\"1543\"\u003e4 Bone-density support\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1750\" data-start=\"1570\"\u003eDaily peptide raised \u003cstrong data-end=\"1614\" data-start=\"1593\"\u003eserum osteocalcin\u003c\/strong\u003e and improved \u003cstrong data-end=\"1642\" data-start=\"1628\"\u003etibial BMD\u003c\/strong\u003e by 6 % in ovariectomised rats—mirroring GH anabolic actions. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Bone; Journal of Endocrinology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1987\" data-start=\"1751\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1790\" data-start=\"1751\"\u003e\u003cstrong data-end=\"1789\" data-start=\"1753\"\u003e5 Sleep-architecture enhancement\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1987\" data-start=\"1790\"\u003eBedtime dosing augments \u003cstrong data-end=\"1841\" data-start=\"1816\"\u003eslow-wave sleep (SWS)\u003c\/strong\u003e and \u003cstrong data-end=\"1861\" data-start=\"1846\"\u003eREM density\u003c\/strong\u003e, correlating with GH surges and next-day vigilance in middle-aged volunteers. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Sleep; Psychoneuroendocrinology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2200\" data-start=\"1988\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2030\" data-start=\"1988\"\u003e\u003cstrong data-end=\"2029\" data-start=\"1990\"\u003e6 Gastro-intestinal mucosal healing\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2200\" data-start=\"2030\"\u003eGHRP-2 accelerates \u003cstrong data-end=\"2088\" data-start=\"2051\"\u003egastric and colonic ulcer closure\u003c\/strong\u003e via anti-apoptotic and angiogenic effects independent of GH. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Gut; American Journal of Pathology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2442\" data-start=\"2201\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2234\" data-start=\"2201\"\u003e\u003cstrong data-end=\"2233\" data-start=\"2203\"\u003e7 Cardio-protection signal\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2442\" data-start=\"2234\"\u003ePre-ischaemic infusion limits \u003cstrong data-end=\"2282\" data-start=\"2266\"\u003einfarct size\u003c\/strong\u003e and preserves ejection fraction in rat I\/R models, linked to \u003cstrong data-end=\"2361\" data-start=\"2344\"\u003ePI3K–Akt–eNOS\u003c\/strong\u003e activation. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Circulation Research; Cardiovascular Drugs \u0026amp; Therapy\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2646\" data-start=\"2443\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2469\" data-start=\"2443\"\u003e\u003cstrong data-end=\"2468\" data-start=\"2445\"\u003e8 Immune-modulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2646\" data-start=\"2469\"\u003ePeptide attenuates \u003cstrong data-end=\"2516\" data-start=\"2490\"\u003eLPS-induced TNF-α\/IL-6\u003c\/strong\u003e release while sparing anti-viral IFN pathways, suggesting sepsis-adjunct potential. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Shock; Critical Care Medicine\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2883\" data-start=\"2647\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2691\" data-start=\"2647\"\u003e\u003cstrong data-end=\"2690\" data-start=\"2649\"\u003e9 Insulin-sensitivity drift (caution)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2883\" data-start=\"2691\"\u003eRepeated dosing can \u003cstrong data-end=\"2751\" data-start=\"2713\"\u003eraise fasting glucose 5–10 mg dL⁻¹\u003c\/strong\u003e via counter-regulatory hormones—monitor glycaemia, especially in pre-diabetes. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Diabetes Care; Endocrine Connections\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"2888\" data-start=\"2885\"\u003e\n\u003ch2 data-end=\"2925\" data-start=\"2890\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-end=\"2962\" data-start=\"2927\"\u003e2.1 Receptor Pharmacodynamics\u003c\/h3\u003e\n\u003cp data-end=\"3196\" data-start=\"2963\"\u003eGHRP-2 binds \u003cstrong data-end=\"2987\" data-start=\"2976\"\u003eGHSR-1a\u003c\/strong\u003e (a GPCR) on hypothalamic neurons and pituitary somatotrophs → \u003cstrong data-end=\"3084\" data-start=\"3050\"\u003eGα\u0026lt;sub\u0026gt;q\/11\u0026lt;\/sub\u0026gt;–PLC–IP₃\/Ca²⁺\u003c\/strong\u003e cascade → GH vesicle exocytosis. It synergises with endogenous GHRH and is partially inhibited by somatostatin.\u003c\/p\u003e\n\u003ch3 data-end=\"3225\" data-start=\"3198\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"3569\" data-start=\"3227\"\u003e\n\u003cthead data-end=\"3269\" data-start=\"3227\"\u003e\n\u003ctr data-end=\"3269\" data-start=\"3227\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3237\" data-start=\"3227\"\u003ePathway\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"3258\" data-start=\"3237\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3269\" data-start=\"3258\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"3569\" data-start=\"3284\"\u003e\n\u003ctr data-end=\"3372\" data-start=\"3284\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3306\" data-start=\"3284\"\u003eGH → GHR–JAK2–STAT5\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3346\" data-start=\"3306\"\u003e↑ IGF-1, lipolysis, protein synthesis\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3372\" data-start=\"3346\"\u003eLiver, adipose, muscle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3457\" data-start=\"3373\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3388\" data-start=\"3373\"\u003eGhrelin–AMPK\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3431\" data-start=\"3388\"\u003e↑ appetite, gastric motility, GH release\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3457\" data-start=\"3431\"\u003eHypothalamus, GI tract\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3569\" data-start=\"3458\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3492\" data-start=\"3458\"\u003ePI3K–Akt–eNOS (extra-pituitary)\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3542\" data-start=\"3492\"\u003eAnti-apoptotic, vasodilatory, cardio-protective\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3569\" data-start=\"3542\"\u003eMyocardium, endothelium\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"3574\" data-start=\"3571\"\u003e\n\u003ch2 data-end=\"3598\" data-start=\"3576\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-end=\"3897\" data-start=\"3600\"\u003e\n\u003cli data-end=\"3698\" data-start=\"3600\"\u003e\n\u003cp data-end=\"3698\" data-start=\"3602\"\u003e\u003cstrong data-end=\"3617\" data-start=\"3602\"\u003eAbsorption:\u003c\/strong\u003e Effective \u003cstrong data-end=\"3662\" data-start=\"3628\"\u003eIV, SC, intranasal, sublingual\u003c\/strong\u003e; oral bioavailability negligible.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3805\" data-start=\"3699\"\u003e\n\u003cp data-end=\"3805\" data-start=\"3701\"\u003e\u003cstrong data-end=\"3715\" data-start=\"3701\"\u003eHalf-life:\u003c\/strong\u003e Plasma \u003cstrong data-end=\"3750\" data-start=\"3723\"\u003et\u0026lt;sub\u0026gt;½\u0026lt;\/sub\u0026gt; 20–30 min\u003c\/strong\u003e; GH peak ~30 min post-dose, back to baseline by 2 h.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3897\" data-start=\"3806\"\u003e\n\u003cp data-end=\"3897\" data-start=\"3808\"\u003e\u003cstrong data-end=\"3835\" data-start=\"3808\"\u003eDistribution\/Clearance:\u003c\/strong\u003e Rapid renal\/hepatic peptide degradation; no CYP interactions.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"3902\" data-start=\"3899\"\u003e\n\u003ch2 data-end=\"3949\" data-start=\"3904\"\u003e4. Pre-clinical and Translational Evidence\u003c\/h2\u003e\n\u003ch3 data-end=\"3982\" data-start=\"3951\"\u003e4.1 Cachexia \u0026amp; Sarcopenia\u003c\/h3\u003e\n\u003cp data-end=\"4133\" data-start=\"3983\"\u003ePhase 2 pilot in cancer cachexia showed \u003cstrong data-end=\"4059\" data-start=\"4023\"\u003e↑ caloric intake, lean mass, QOL\u003c\/strong\u003e over 30 days; COPD cohort mirrored gains with functional strength uptick.\u003c\/p\u003e\n\u003ch3 data-end=\"4166\" data-start=\"4135\"\u003e4.2 Endocrine Diagnostics\u003c\/h3\u003e\n\u003cp data-end=\"4311\" data-start=\"4167\"\u003e0.5 µg kg⁻¹ IV bolus provokes \u003cstrong data-end=\"4216\" data-start=\"4197\"\u003e≥3-fold GH rise\u003c\/strong\u003e in healthy adults; blunted response signals pituitary impairment—approved diagnostic in Japan.\u003c\/p\u003e\n\u003ch3 data-end=\"4340\" data-start=\"4313\"\u003e4.3 Sleep \u0026amp; Cognition\u003c\/h3\u003e\n\u003cp data-end=\"4476\" data-start=\"4341\"\u003eNightly intranasal GHRP-2 restored \u003cstrong data-end=\"4394\" data-start=\"4376\"\u003eSWS percentage\u003c\/strong\u003e and improved \u003cstrong data-end=\"4433\" data-start=\"4408\"\u003eStroop and digit-span\u003c\/strong\u003e performance after 3 weeks in adults \u0026gt;50 y.\u003c\/p\u003e\n\u003ch3 data-end=\"4514\" data-start=\"4478\"\u003e4.4 Metabolic \u0026amp; Cardiovascular\u003c\/h3\u003e\n\u003cp data-end=\"4703\" data-start=\"4515\"\u003eRodent DIO studies recorded \u003cstrong data-end=\"4569\" data-start=\"4543\"\u003evisceral-fat reduction\u003c\/strong\u003e despite appetite increase, attributed to GH-driven lipolysis; cardiac I\/R models showed \u003cstrong data-end=\"4678\" data-start=\"4658\"\u003esmaller infarcts\u003c\/strong\u003e and better hemodynamics.\u003c\/p\u003e\n\u003chr data-end=\"4708\" data-start=\"4705\"\u003e\n\u003ch2 data-end=\"4743\" data-start=\"4710\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"5189\" data-start=\"4745\"\u003e\n\u003cthead data-end=\"4783\" data-start=\"4745\"\u003e\n\u003ctr data-end=\"4783\" data-start=\"4745\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"4753\" data-start=\"4745\"\u003eField\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"4765\" data-start=\"4753\"\u003eRationale\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"4783\" data-start=\"4765\"\u003eCurrent status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"5189\" data-start=\"4798\"\u003e\n\u003ctr data-end=\"4897\" data-start=\"4798\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4825\" data-start=\"4798\"\u003e\u003cstrong data-end=\"4824\" data-start=\"4800\"\u003eCancer\/COPD cachexia\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4858\" data-start=\"4825\"\u003eAppetite + GH anabolic synergy\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"4897\" data-start=\"4858\"\u003ePhase 2 pilots; larger RCTs planned\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4987\" data-start=\"4898\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4923\" data-start=\"4898\"\u003e\u003cstrong data-end=\"4922\" data-start=\"4900\"\u003eSarcopenic obesity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4964\" data-start=\"4923\"\u003eGH pulses without chronic IGF-1 excess\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"4987\" data-start=\"4964\"\u003eExploratory studies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5084\" data-start=\"4988\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5030\" data-start=\"4988\"\u003e\u003cstrong data-end=\"5029\" data-start=\"4990\"\u003eSleep disorders (mid-life SWS loss)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5057\" data-start=\"5030\"\u003eGHRP-2 augments SWS \u0026amp; GH\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5084\" data-start=\"5057\"\u003eProof-of-concept trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5189\" data-start=\"5085\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5116\" data-start=\"5085\"\u003e\u003cstrong data-end=\"5115\" data-start=\"5087\"\u003eDiagnostic endocrinology\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5144\" data-start=\"5116\"\u003eRapid GH provocative test\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5189\" data-start=\"5144\"\u003eApproved in JP; investigational elsewhere\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"5194\" data-start=\"5191\"\u003e\n\u003ch2 data-end=\"5225\" data-start=\"5196\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-end=\"5710\" data-start=\"5227\"\u003e\n\u003cli data-end=\"5321\" data-start=\"5227\"\u003e\n\u003cp data-end=\"5321\" data-start=\"5229\"\u003e\u003cstrong data-end=\"5240\" data-start=\"5229\"\u003eCommon:\u003c\/strong\u003e Transient \u003cstrong data-end=\"5263\" data-start=\"5251\"\u003eflushing\u003c\/strong\u003e, \u003cstrong data-end=\"5280\" data-start=\"5265\"\u003eparesthesia\u003c\/strong\u003e, \u003cstrong data-end=\"5299\" data-start=\"5282\"\u003ehunger surges\u003c\/strong\u003e, mild \u003cstrong data-end=\"5318\" data-start=\"5306\"\u003eheadache\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5417\" data-start=\"5322\"\u003e\n\u003cp data-end=\"5417\" data-start=\"5324\"\u003e\u003cstrong data-end=\"5343\" data-start=\"5324\"\u003eHormonal drift:\u003c\/strong\u003e \u003cstrong data-end=\"5368\" data-start=\"5344\"\u003eProlactin \u0026amp; cortisol\u003c\/strong\u003e peaks (~1.5 × baseline 30 min) resolve by 2 h.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5509\" data-start=\"5418\"\u003e\n\u003cp data-end=\"5509\" data-start=\"5420\"\u003e\u003cstrong data-end=\"5434\" data-start=\"5420\"\u003eMetabolic:\u003c\/strong\u003e Watch for \u003cstrong data-end=\"5474\" data-start=\"5445\"\u003emild fasting-glucose rise\u003c\/strong\u003e; adjust antidiabetics if needed.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5595\" data-start=\"5510\"\u003e\n\u003cp data-end=\"5595\" data-start=\"5512\"\u003e\u003cstrong data-end=\"5519\" data-start=\"5512\"\u003eCV:\u003c\/strong\u003e Occasional \u003cstrong data-end=\"5547\" data-start=\"5531\"\u003epalpitations\u003c\/strong\u003e; no sustained QT issues in studies \u0026lt;12 weeks.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5710\" data-start=\"5596\"\u003e\n\u003cp data-end=\"5710\" data-start=\"5598\"\u003e\u003cstrong data-end=\"5621\" data-start=\"5598\"\u003eContra-indications:\u003c\/strong\u003e Active malignancy under anabolic-sensitive evaluation, uncontrolled diabetes, pregnancy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"5741\" data-start=\"5712\"\u003e\u003cstrong data-end=\"5741\" data-start=\"5712\"\u003eComparative safety matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"6165\" data-start=\"5743\"\u003e\n\u003cthead data-end=\"5835\" data-start=\"5743\"\u003e\n\u003ctr data-end=\"5835\" data-start=\"5743\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5753\" data-start=\"5743\"\u003eConcern\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5777\" data-start=\"5753\"\u003eGHRP-2 (GHSR agonist)\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5805\" data-start=\"5777\"\u003eTesamorelin (GHRH analog)\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5835\" data-start=\"5805\"\u003eMK-677 (oral GHSR agonist)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"6165\" data-start=\"5854\"\u003e\n\u003ctr data-end=\"5938\" data-start=\"5854\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5872\" data-start=\"5854\"\u003eIGF-1 elevation\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5898\" data-start=\"5872\"\u003e\u003cstrong data-end=\"5897\" data-start=\"5874\"\u003eModerate, pulsatile\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5913\" data-start=\"5898\"\u003ePhysio-range\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5938\" data-start=\"5913\"\u003e\u003cstrong data-end=\"5936\" data-start=\"5915\"\u003eHigher, sustained\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5994\" data-start=\"5939\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5957\" data-start=\"5939\"\u003eAppetite impact\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5979\" data-start=\"5957\"\u003e\u003cstrong data-end=\"5978\" data-start=\"5959\"\u003e↑↑ (orexigenic)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5989\" data-start=\"5979\"\u003eNeutral\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5994\" data-start=\"5989\"\u003e↑\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6051\" data-start=\"5995\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6011\" data-start=\"5995\"\u003eGlucose drift\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6020\" data-start=\"6011\"\u003eMild ↑\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6037\" data-start=\"6020\"\u003eNeutral–mild ↑\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6051\" data-start=\"6037\"\u003eModerate ↑\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6114\" data-start=\"6052\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6079\" data-start=\"6052\"\u003eProlactin\/cortisol spike\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6097\" data-start=\"6079\"\u003eYes (transient)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6107\" data-start=\"6097\"\u003eMinimal\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6114\" data-start=\"6107\"\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6165\" data-start=\"6115\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6129\" data-start=\"6115\"\u003eAdmin route\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6140\" data-start=\"6129\"\u003eIV\/SC\/IN\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6151\" data-start=\"6140\"\u003eSC daily\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6165\" data-start=\"6151\"\u003eOral daily\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"6170\" data-start=\"6167\"\u003e\n\u003ch2 data-end=\"6198\" data-start=\"6172\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-end=\"6450\" data-start=\"6200\"\u003e\n\u003cli data-end=\"6280\" data-start=\"6200\"\u003e\n\u003cp data-end=\"6280\" data-start=\"6202\"\u003e\u003cstrong data-end=\"6212\" data-start=\"6202\"\u003eJapan:\u003c\/strong\u003e \u003cstrong data-end=\"6231\" data-start=\"6213\"\u003ePralmorelin IV\u003c\/strong\u003e approved (1999) for GH-deficiency diagnostics.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6384\" data-start=\"6281\"\u003e\n\u003cp data-end=\"6384\" data-start=\"6283\"\u003e\u003cstrong data-end=\"6293\" data-start=\"6283\"\u003eUS\/EU:\u003c\/strong\u003e Investigational\/research use only; compounded peptides circulate without FDA evaluation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6450\" data-start=\"6385\"\u003e\n\u003cp data-end=\"6450\" data-start=\"6387\"\u003e\u003cstrong data-end=\"6397\" data-start=\"6387\"\u003eSport:\u003c\/strong\u003e \u003cstrong data-end=\"6417\" data-start=\"6398\"\u003eWADA-prohibited\u003c\/strong\u003e as a GH-secretagogue (S2 class).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"6455\" data-start=\"6452\"\u003e\n\u003ch2 data-end=\"6480\" data-start=\"6457\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-end=\"7006\" data-start=\"6482\"\u003e\n\u003cli data-end=\"6566\" data-start=\"6482\"\u003e\n\u003cp data-end=\"6566\" data-start=\"6484\"\u003e\u003cstrong data-end=\"6507\" data-start=\"6484\"\u003eLong-acting analogs\u003c\/strong\u003e or \u003cstrong data-end=\"6531\" data-start=\"6511\"\u003elipidated depots\u003c\/strong\u003e to minimise injection frequency.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6673\" data-start=\"6567\"\u003e\n\u003cp data-end=\"6673\" data-start=\"6569\"\u003e\u003cstrong data-end=\"6593\" data-start=\"6569\"\u003eCombination regimens\u003c\/strong\u003e with \u003cstrong data-end=\"6622\" data-start=\"6599\"\u003eresistance exercise\u003c\/strong\u003e or \u003cstrong data-end=\"6651\" data-start=\"6626\"\u003eanti-catabolic agents\u003c\/strong\u003e in cachexia trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6784\" data-start=\"6674\"\u003e\n\u003cp data-end=\"6784\" data-start=\"6676\"\u003e\u003cstrong data-end=\"6697\" data-start=\"6676\"\u003eMetabolic tuning:\u003c\/strong\u003e Co-administration with GLP-1RA to offset orexigenic effect while retaining GH surge.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6899\" data-start=\"6785\"\u003e\n\u003cp data-end=\"6899\" data-start=\"6787\"\u003e\u003cstrong data-end=\"6815\" data-start=\"6787\"\u003eBiomarker-guided dosing:\u003c\/strong\u003e Use \u003cstrong data-end=\"6833\" data-start=\"6820\"\u003eIGF-1 SDS\u003c\/strong\u003e and \u003cstrong data-end=\"6871\" data-start=\"6838\"\u003econtinuous glucose monitoring\u003c\/strong\u003e to individualise therapy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7006\" data-start=\"6900\"\u003e\n\u003cp data-end=\"7006\" data-start=\"6902\"\u003e\u003cstrong data-end=\"6933\" data-start=\"6902\"\u003eCardio-metabolic endpoints:\u003c\/strong\u003e Larger animal → human translation for \u003cstrong data-end=\"6995\" data-start=\"6972\"\u003epost-MI remodelling\u003c\/strong\u003e and HFpEF.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"7011\" data-start=\"7008\"\u003e\n\u003ch3 data-end=\"7036\" data-start=\"7013\"\u003eSelected References\u003c\/h3\u003e\n\u003cp data-end=\"7807\" data-start=\"7038\"\u003eBlum W.F. et al. \u003cem data-end=\"7114\" data-start=\"7055\"\u003eDiagnostic utility of pralmorelin in adult GH deficiency.\u003c\/em\u003e \u003cstrong data-end=\"7165\" data-start=\"7115\"\u003eJournal of Clinical Endocrinology \u0026amp; Metabolism\u003c\/strong\u003e.\u003cbr data-end=\"7169\" data-start=\"7166\"\u003eZhang W. et al. \u003cem data-end=\"7245\" data-start=\"7185\"\u003eGHRP-2 improves appetite and lean mass in cancer cachexia.\u003c\/em\u003e \u003cstrong data-end=\"7268\" data-start=\"7246\"\u003eClinical Nutrition\u003c\/strong\u003e.\u003cbr data-end=\"7272\" data-start=\"7269\"\u003eNagaya N. et al. \u003cem data-end=\"7361\" data-start=\"7289\"\u003eCardio-protective effects of ghrelin analogs in ischaemia–reperfusion.\u003c\/em\u003e \u003cstrong data-end=\"7386\" data-start=\"7362\"\u003eCirculation Research\u003c\/strong\u003e.\u003cbr data-end=\"7390\" data-start=\"7387\"\u003evan den Berghe G. et al. \u003cem data-end=\"7481\" data-start=\"7415\"\u003eEndocrine and metabolic responses to GHRP-2 in critical illness.\u003c\/em\u003e \u003cstrong data-end=\"7508\" data-start=\"7482\"\u003eCritical Care Medicine\u003c\/strong\u003e.\u003cbr data-end=\"7512\" data-start=\"7509\"\u003eFitch M., Howard A. \u003cem data-end=\"7583\" data-start=\"7532\"\u003eSlow-wave sleep enhancement by intranasal GHRP-2.\u003c\/em\u003e \u003cstrong data-end=\"7593\" data-start=\"7584\"\u003eSleep\u003c\/strong\u003e.\u003cbr data-end=\"7597\" data-start=\"7594\"\u003eYokoya S. et al. \u003cem data-end=\"7662\" data-start=\"7614\"\u003ePhase 1\/2 AAV1-FS344 safety in muscle disease.\u003c\/em\u003e \u003cstrong data-end=\"7684\" data-start=\"7663\"\u003eMolecular Therapy\u003c\/strong\u003e (context for GH-axis modulation).\u003cbr data-end=\"7721\" data-start=\"7718\"\u003eWorld Anti-Doping Agency. \u003cstrong data-end=\"7771\" data-start=\"7747\"\u003eProhibited List 2025\u003c\/strong\u003e — S2 peptide hormone secretagogues.\u003c\/p\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684855312722,"sku":null,"price":20.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/GHRP-2_5mg.png?v=1770834874"},{"product_id":"tesamorelin-10mg-vial","title":"Tesamorelin 10mg vial","description":"\u003ch3\u003e\n\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                       \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003cp data-end=\"3265\" data-start=\"2930\"\u003e\u003cstrong\u003eTesamorelin\u003c\/strong\u003e binds \u003cstrong data-end=\"2974\" data-start=\"2948\"\u003eGHRH receptors (GHRHR)\u003c\/strong\u003e on pituitary somatotrophs → \u003cstrong data-end=\"3023\" data-start=\"3003\"\u003eGs–cAMP–PKA–CREB\u003c\/strong\u003e signaling → \u003cstrong data-end=\"3059\" data-start=\"3036\"\u003eGH pulse generation\u003c\/strong\u003e. Peripheral \u003cstrong data-end=\"3078\" data-start=\"3072\"\u003eGH\u003c\/strong\u003e activates \u003cstrong data-end=\"3107\" data-start=\"3089\"\u003eGHR–JAK2–STAT5\u003c\/strong\u003e in liver and adipose, boosting \u003cstrong data-end=\"3148\" data-start=\"3139\"\u003eIGF-1\u003c\/strong\u003e and lipid-flux enzymes; \u003cstrong data-end=\"3189\" data-start=\"3173\"\u003esomatostatin\u003c\/strong\u003e and \u003cstrong data-end=\"3203\" data-start=\"3194\"\u003eIGF-1\u003c\/strong\u003e provide negative feedback that preserves physiologic rhythms.\u003c\/p\u003e\n\u003ch3 data-end=\"3294\" data-start=\"3267\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"3719\" data-start=\"3296\"\u003e\n\u003cthead data-end=\"3338\" data-start=\"3296\"\u003e\n\u003ctr data-end=\"3338\" data-start=\"3296\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3306\" data-start=\"3296\"\u003ePathway\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"3327\" data-start=\"3306\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3338\" data-start=\"3327\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"3719\" data-start=\"3353\"\u003e\n\u003ctr data-end=\"3450\" data-start=\"3353\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3371\" data-start=\"3353\"\u003eJAK2–STAT5 (GH)\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3432\" data-start=\"3371\"\u003e↑ IGF-1, ↑ hormone-sensitive lipase, ↓ de novo lipogenesis\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3450\" data-start=\"3432\"\u003eLiver, adipose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3533\" data-start=\"3451\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3475\" data-start=\"3451\"\u003ePI3K–Akt–mTOR (IGF-1)\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3514\" data-start=\"3475\"\u003e↑ protein synthesis, ↑ fat-free mass\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3533\" data-start=\"3514\"\u003eSkeletal muscle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3612\" data-start=\"3534\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3557\" data-start=\"3534\"\u003eAMPK\/PPAR cross-talk\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3603\" data-start=\"3557\"\u003e↓ hepatic steatosis, improved VLDL handling\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3612\" data-start=\"3603\"\u003eLiver\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3719\" data-start=\"3613\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3639\" data-start=\"3613\"\u003eCNS neuroendocrine axes\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3691\" data-start=\"3639\"\u003eModulates sleep–metabolism–cognition via GH\/IGF-1\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3719\" data-start=\"3691\"\u003eHypothalamus\/hippocampus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"3724\" data-start=\"3721\"\u003e\n\u003ch2 data-end=\"3748\" data-start=\"3726\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cp data-end=\"4267\" data-start=\"3750\"\u003e\u003cstrong data-end=\"3765\" data-start=\"3750\"\u003eAbsorption:\u003c\/strong\u003e Rapid after SC injection; \u003cstrong data-end=\"3805\" data-start=\"3792\"\u003eTmax ~1 h\u003c\/strong\u003e.\u003cbr data-end=\"3809\" data-start=\"3806\"\u003e\u003cstrong data-end=\"3832\" data-start=\"3809\"\u003eHalf-life (parent):\u003c\/strong\u003e \u003cstrong data-end=\"3843\" data-start=\"3833\"\u003e~1–2 h\u003c\/strong\u003e; pharmacodynamic effects persist via induced \u003cstrong data-end=\"3902\" data-start=\"3889\"\u003eGH pulses\u003c\/strong\u003e and \u003cstrong data-end=\"3916\" data-start=\"3907\"\u003eIGF-1\u003c\/strong\u003e (24–48 h).\u003cbr data-end=\"3930\" data-start=\"3927\"\u003e\u003cstrong data-end=\"3947\" data-start=\"3930\"\u003eDistribution:\u003c\/strong\u003e Primary site of action is pituitary; systemic effects mediated by GH\/IGF-1; minimal direct BBB penetration.\u003cbr data-end=\"4058\" data-start=\"4055\"\u003e\u003cstrong data-end=\"4072\" data-start=\"4058\"\u003eClearance:\u003c\/strong\u003e Peptidase degradation; no known CYP interactions.\u003cbr data-end=\"4125\" data-start=\"4122\"\u003e\u003cstrong data-end=\"4136\" data-start=\"4125\"\u003eDosing:\u003c\/strong\u003e Daily SC abdomen; rotate sites. \u003cstrong data-end=\"4188\" data-start=\"4169\"\u003eEGRIFTA SV 2 mg\u003c\/strong\u003e vs \u003cstrong data-end=\"4214\" data-start=\"4192\"\u003eEGRIFTA WR 1.28 mg\u003c\/strong\u003e—\u003cstrong data-end=\"4238\" data-start=\"4215\"\u003enot interchangeable\u003c\/strong\u003e. FDA Prescribing Information\u003c\/p\u003e\n\u003chr data-end=\"4272\" data-start=\"4269\"\u003e\n\u003ch2 data-end=\"4319\" data-start=\"4274\"\u003e4. Pre-clinical and Translational Evidence\u003c\/h2\u003e\n\u003ch3 data-end=\"4377\" data-start=\"4321\"\u003e4.1 HIV-Associated Lipodystrophy (core indication)\u003c\/h3\u003e\n\u003cp data-end=\"4595\" data-start=\"4378\"\u003eMultiple RCTs demonstrate \u003cstrong data-end=\"4438\" data-start=\"4404\"\u003eclinically meaningful VAT loss\u003c\/strong\u003e, \u003cstrong data-end=\"4466\" data-start=\"4440\"\u003etriglyceride reduction\u003c\/strong\u003e, and improved adipokines over \u003cstrong data-end=\"4512\" data-start=\"4497\"\u003e26–52 weeks\u003c\/strong\u003e, with \u003cstrong data-end=\"4543\" data-start=\"4519\"\u003eVAT rebound off-drug\u003c\/strong\u003e and re-response upon \u003cstrong data-end=\"4581\" data-start=\"4565\"\u003ere-treatment\u003c\/strong\u003e. \u003cem data-end=\"4595\" data-start=\"4583\"\u003eNEJM; AIDS\u003c\/em\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"4638\" data-start=\"4597\"\u003e4.2 Hepatic Steatosis \/ MASH in HIV\u003c\/h3\u003e\n\u003cp data-end=\"4866\" data-start=\"4639\"\u003e12-month randomized data show \u003cstrong data-end=\"4692\" data-start=\"4669\"\u003ereduced hepatic fat\u003c\/strong\u003e and \u003cstrong data-end=\"4732\" data-start=\"4697\"\u003elower fibrosis-progression risk\u003c\/strong\u003e; mechanisms likely include \u003cstrong data-end=\"4787\" data-start=\"4760\"\u003eGH-dependent lipid flux\u003c\/strong\u003e and \u003cstrong data-end=\"4825\" data-start=\"4792\"\u003eIGF-1 anti-fibrotic signaling\u003c\/strong\u003e. \u003cem data-end=\"4866\" data-start=\"4827\"\u003eLancet HIV; Hepatology Communications\u003c\/em\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"4893\" data-start=\"4868\"\u003e4.3 Cognitive Aging\u003c\/h3\u003e\n\u003cp data-end=\"5149\" data-start=\"4894\"\u003eA 20-week placebo-controlled trial in \u003cstrong data-end=\"4975\" data-start=\"4932\"\u003ehealthy older adults and those with MCI\u003c\/strong\u003e reported \u003cstrong data-end=\"5027\" data-start=\"4985\"\u003eimproved executive function and memory\u003c\/strong\u003e with tesamorelin-class GHRH analog therapy, correlating with \u003cstrong data-end=\"5098\" data-start=\"5089\"\u003eIGF-1\u003c\/strong\u003e increases. \u003cem data-end=\"5149\" data-start=\"5110\"\u003eArchives of Neurology; JAMA Neurology\u003c\/em\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"5181\" data-start=\"5151\"\u003e4.4 Cardiometabolic Risk\u003c\/h3\u003e\n\u003cp data-end=\"5371\" data-start=\"5182\"\u003eVAT responders show \u003cstrong data-end=\"5226\" data-start=\"5202\"\u003ehigher HDL, lower TG\u003c\/strong\u003e, and \u003cstrong data-end=\"5264\" data-start=\"5232\"\u003ereduced inflammatory markers\u003c\/strong\u003e; risk modeling suggests \u003cstrong data-end=\"5331\" data-start=\"5289\"\u003efavorable shifts in 10-year ASCVD risk\u003c\/strong\u003e. \u003cem data-end=\"5371\" data-start=\"5333\"\u003eJCEM; Journal of Clinical Lipidology\u003c\/em\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"5419\" data-start=\"5373\"\u003e4.5 Body Composition \u0026amp; Physical Function\u003c\/h3\u003e\n\u003cp data-end=\"5588\" data-start=\"5420\"\u003eDXA\/CT sub-studies indicate \u003cstrong data-end=\"5482\" data-start=\"5448\"\u003epreferential visceral-fat loss\u003c\/strong\u003e with \u003cstrong data-end=\"5531\" data-start=\"5488\"\u003emaintenance or slight gain of lean mass\u003c\/strong\u003e and improved abdominal comfort\/mobility. \u003cem data-end=\"5588\" data-start=\"5573\"\u003eObesity; AIDS\u003c\/em\u003e\u003c\/p\u003e\n\u003chr data-end=\"5593\" data-start=\"5590\"\u003e\n\u003ch2 data-end=\"5628\" data-start=\"5595\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"6121\" data-start=\"5630\"\u003e\n\u003cthead data-end=\"5668\" data-start=\"5630\"\u003e\n\u003ctr data-end=\"5668\" data-start=\"5630\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5638\" data-start=\"5630\"\u003eField\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"5650\" data-start=\"5638\"\u003eRationale\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"5668\" data-start=\"5650\"\u003eCurrent status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"6121\" data-start=\"5683\"\u003e\n\u003ctr data-end=\"5811\" data-start=\"5683\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5704\" data-start=\"5683\"\u003e\u003cstrong data-end=\"5703\" data-start=\"5685\"\u003eHIV-NAFLD\/MASH\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5759\" data-start=\"5704\"\u003eVAT–liver axis; anti-steatotic\/anti-fibrotic signals\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5811\" data-start=\"5759\"\u003ePhase 2–3 translational work; label not expanded\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5928\" data-start=\"5812\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5837\" data-start=\"5812\"\u003e\u003cstrong data-end=\"5836\" data-start=\"5814\"\u003eSarcopenic obesity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5888\" data-start=\"5837\"\u003eIGF-1–mediated anabolism with selective VAT loss\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5928\" data-start=\"5888\"\u003eEarly feasibility; no pivotal trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6035\" data-start=\"5929\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5955\" data-start=\"5929\"\u003e\u003cstrong data-end=\"5954\" data-start=\"5931\"\u003eCognitive aging\/MCI\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5993\" data-start=\"5955\"\u003eGHRH→GH→IGF-1 neurotrophic pathways\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6035\" data-start=\"5993\"\u003eSmall RCT signal; larger trials needed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6121\" data-start=\"6036\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6060\" data-start=\"6036\"\u003e\u003cstrong data-end=\"6059\" data-start=\"6038\"\u003eNAFLD without HIV\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6095\" data-start=\"6060\"\u003eGH-deficiency phenotype in NAFLD\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"6121\" data-start=\"6095\"\u003ePilot studies proposed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"6126\" data-start=\"6123\"\u003e\n\u003ch2 data-end=\"6157\" data-start=\"6128\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cp data-end=\"6698\" data-start=\"6159\"\u003e\u003cstrong data-end=\"6170\" data-start=\"6159\"\u003eCommon:\u003c\/strong\u003e Injection-site reactions, \u003cstrong data-end=\"6206\" data-start=\"6197\"\u003eedema\u003c\/strong\u003e, \u003cstrong data-end=\"6230\" data-start=\"6208\"\u003earthralgia\/myalgia\u003c\/strong\u003e, \u003cstrong data-end=\"6275\" data-start=\"6232\"\u003eparesthesia\/carpal-tunnel-like symptoms\u003c\/strong\u003e (fluid retention).\u003cbr data-end=\"6297\" data-start=\"6294\"\u003e\u003cstrong data-end=\"6311\" data-start=\"6297\"\u003eEndocrine:\u003c\/strong\u003e \u003cstrong data-end=\"6331\" data-start=\"6312\"\u003eIGF-1 elevation\u003c\/strong\u003e—monitor; \u003cstrong data-end=\"6364\" data-start=\"6341\"\u003eglucose intolerance\u003c\/strong\u003e can emerge (check FPG\/HbA1c; adjust antidiabetics).\u003cbr data-end=\"6419\" data-start=\"6416\"\u003e\u003cstrong data-end=\"6441\" data-start=\"6419\"\u003eContraindications:\u003c\/strong\u003e \u003cstrong data-end=\"6455\" data-start=\"6442\"\u003ePregnancy\u003c\/strong\u003e, \u003cstrong data-end=\"6478\" data-start=\"6457\"\u003eactive malignancy\u003c\/strong\u003e, hypersensitivity (e.g., mannitol).\u003cbr data-end=\"6517\" data-start=\"6514\"\u003e\u003cstrong data-end=\"6530\" data-start=\"6517\"\u003eOncology:\u003c\/strong\u003e Theoretical \u003cstrong data-end=\"6574\" data-start=\"6543\"\u003eIGF-1-driven mitogenic risk\u003c\/strong\u003e; discontinue if malignancy occurs.\u003cbr data-end=\"6612\" data-start=\"6609\"\u003e\u003cstrong data-end=\"6631\" data-start=\"6612\"\u003eOphthalmic\/OSA:\u003c\/strong\u003e Fluid shifts may unmask\/worsen \u003cstrong data-end=\"6678\" data-start=\"6663\"\u003eretinopathy\u003c\/strong\u003e or \u003cstrong data-end=\"6697\" data-start=\"6682\"\u003esleep apnea\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp data-end=\"6729\" data-start=\"6700\"\u003e\u003cstrong data-end=\"6729\" data-start=\"6700\"\u003eComparative safety matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"7214\" data-start=\"6731\"\u003e\n\u003cthead data-end=\"6788\" data-start=\"6731\"\u003e\n\u003ctr data-end=\"6788\" data-start=\"6731\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6741\" data-start=\"6731\"\u003eConcern\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6769\" data-start=\"6741\"\u003eTesamorelin (GHRH analog)\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6788\" data-start=\"6769\"\u003eSomatropin (GH)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"7214\" data-start=\"6803\"\u003e\n\u003ctr data-end=\"6898\" data-start=\"6803\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6817\" data-start=\"6803\"\u003eGH dynamics\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6856\" data-start=\"6817\"\u003e\u003cstrong data-end=\"6855\" data-start=\"6819\"\u003ePhysiologic pulses via pituitary\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6898\" data-start=\"6856\"\u003e\u003cstrong data-end=\"6896\" data-start=\"6858\"\u003eNon-physiologic exogenous exposure\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6962\" data-start=\"6899\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6915\" data-start=\"6899\"\u003eIGF-1 control\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6938\" data-start=\"6915\"\u003e\u003cstrong data-end=\"6937\" data-start=\"6917\"\u003eFeedback-limited\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6962\" data-start=\"6938\"\u003eDirectly dose-driven\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7048\" data-start=\"6963\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6982\" data-start=\"6963\"\u003eEdema\/arthralgia\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7009\" data-start=\"6982\"\u003eModerate, dose-dependent\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7048\" data-start=\"7009\"\u003eModerate–higher at equipotent IGF-1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7132\" data-start=\"7049\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7066\" data-start=\"7049\"\u003eGlucose impact\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7103\" data-start=\"7066\"\u003eNeutral → mild worsening (monitor)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7132\" data-start=\"7103\"\u003eSimilar or slightly worse\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"7214\" data-start=\"7133\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7152\" data-start=\"7133\"\u003eEvidence for VAT\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7187\" data-start=\"7152\"\u003eRobust RCTs in HIV lipodystrophy\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"7214\" data-start=\"7187\"\u003eMixed in non-GHD adults\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"7219\" data-start=\"7216\"\u003e\n\u003ch2 data-end=\"7247\" data-start=\"7221\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cp data-end=\"7600\" data-start=\"7249\"\u003e\u003cstrong data-end=\"7266\" data-start=\"7249\"\u003eApproved use:\u003c\/strong\u003e Reduction of excess abdominal fat in \u003cstrong data-end=\"7336\" data-start=\"7304\"\u003eHIV-associated lipodystrophy\u003c\/strong\u003e.\u003cbr data-end=\"7340\" data-start=\"7337\"\u003e\u003cstrong data-end=\"7362\" data-start=\"7340\"\u003eFormulations (US):\u003c\/strong\u003e \u003cstrong data-end=\"7382\" data-start=\"7363\"\u003eEGRIFTA SV 2 mg\u003c\/strong\u003e and \u003cstrong data-end=\"7409\" data-start=\"7387\"\u003eEGRIFTA WR 1.28 mg\u003c\/strong\u003e once daily SC; \u003cstrong data-end=\"7448\" data-start=\"7425\"\u003enot interchangeable\u003c\/strong\u003e.\u003cbr data-end=\"7452\" data-start=\"7449\"\u003e\u003cstrong data-end=\"7475\" data-start=\"7452\"\u003eLimitations of use:\u003c\/strong\u003e Not indicated for general weight loss; continue therapy \u003cstrong data-end=\"7571\" data-start=\"7532\"\u003eonly if VAT reduction is documented\u003c\/strong\u003e. FDA Prescribing Information\u003c\/p\u003e\n\u003chr data-end=\"7605\" data-start=\"7602\"\u003e\n\u003ch2 data-end=\"7630\" data-start=\"7607\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-end=\"8124\" data-start=\"7632\"\u003e\n\u003cli data-end=\"7749\" data-start=\"7632\"\u003e\n\u003cp data-end=\"7749\" data-start=\"7634\"\u003e\u003cstrong data-end=\"7660\" data-start=\"7634\"\u003eMetabolic phenotyping:\u003c\/strong\u003e Trials in \u003cstrong data-end=\"7689\" data-start=\"7671\"\u003eHIV-NAFLD\/MASH\u003c\/strong\u003e and \u003cstrong data-end=\"7716\" data-start=\"7694\"\u003esarcopenic obesity\u003c\/strong\u003e with imaging\/biopsy endpoints.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7912\" data-start=\"7750\"\u003e\n\u003cp data-end=\"7912\" data-start=\"7752\"\u003e\u003cstrong data-end=\"7776\" data-start=\"7752\"\u003eCombination therapy:\u003c\/strong\u003e Pairing with \u003cstrong data-end=\"7812\" data-start=\"7790\"\u003eGLP-1\/GIP agonists\u003c\/strong\u003e or \u003cstrong data-end=\"7836\" data-start=\"7816\"\u003eSGLT2 inhibitors\u003c\/strong\u003e to amplify hepatic and cardiometabolic outcomes while managing glycaemia.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8001\" data-start=\"7913\"\u003e\n\u003cp data-end=\"8001\" data-start=\"7915\"\u003e\u003cstrong data-end=\"7936\" data-start=\"7915\"\u003ePrecision dosing:\u003c\/strong\u003e \u003cstrong data-end=\"7967\" data-start=\"7937\"\u003eIGF-1 SDS-guided titration\u003c\/strong\u003e to balance efficacy and safety.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8124\" data-start=\"8002\"\u003e\n\u003cp data-end=\"8124\" data-start=\"8004\"\u003e\u003cstrong data-end=\"8028\" data-start=\"8004\"\u003eFormulation science:\u003c\/strong\u003e Long-acting depot or alternative delivery (e.g., transdermal, intranasal) to improve adherence.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"8129\" data-start=\"8126\"\u003e\n\u003ch3 data-end=\"8154\" data-start=\"8131\"\u003eSelected References\u003c\/h3\u003e\n\u003cp data-end=\"9060\" data-start=\"8156\"\u003eFalutz J. et al. Randomized trials of tesamorelin in HIV lipodystrophy—VAT reduction and metabolic effects. \u003cem data-end=\"8297\" data-start=\"8264\"\u003eNew England Journal of Medicine\u003c\/em\u003e; \u003cem data-end=\"8305\" data-start=\"8299\"\u003eAIDS\u003c\/em\u003e.\u003cbr data-end=\"8309\" data-start=\"8306\"\u003eStanley T.L. et al. Tesamorelin for HIV-associated NAFLD—reduced liver fat and fibrosis-progression risk. \u003cem data-end=\"8427\" data-start=\"8415\"\u003eLancet HIV\u003c\/em\u003e; \u003cem data-end=\"8456\" data-start=\"8429\"\u003eHepatology Communications\u003c\/em\u003e.\u003cbr data-end=\"8460\" data-start=\"8457\"\u003eEngelson E.S. et al. Body-image and QoL outcomes with tesamorelin. \u003cem data-end=\"8541\" data-start=\"8527\"\u003eHIV Medicine\u003c\/em\u003e; \u003cem data-end=\"8554\" data-start=\"8543\"\u003eAIDS Care\u003c\/em\u003e.\u003cbr data-end=\"8558\" data-start=\"8555\"\u003eJohnen H. et al. Adipokines, triglycerides, and inflammatory markers in VAT responders. \u003cem data-end=\"8694\" data-start=\"8646\"\u003eJournal of Clinical Endocrinology \u0026amp; Metabolism\u003c\/em\u003e.\u003cbr data-end=\"8698\" data-start=\"8695\"\u003eBaker L.D. et al. GHRH analog (tesamorelin) improves cognition in older adults with\/without MCI. \u003cem data-end=\"8818\" data-start=\"8795\"\u003eArchives of Neurology\u003c\/em\u003e; \u003cem data-end=\"8836\" data-start=\"8820\"\u003eJAMA Neurology\u003c\/em\u003e.\u003cbr data-end=\"8840\" data-start=\"8837\"\u003eGrunfeld C. et al. Glycaemic safety and IGF-1 monitoring across tesamorelin RCTs. \u003cem data-end=\"8937\" data-start=\"8922\"\u003eDiabetes Care\u003c\/em\u003e; \u003cem data-end=\"8945\" data-start=\"8939\"\u003eAIDS\u003c\/em\u003e.\u003cbr data-end=\"8949\" data-start=\"8946\"\u003eTheratechnologies. \u003cstrong data-end=\"9009\" data-start=\"8968\"\u003eEGRIFTA SV\/WR Prescribing Information\u003c\/strong\u003e—indication, dosing, contraindications, monitoring.\u003c\/p\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684855378258,"sku":null,"price":60.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/tesamorelin_10mg.png?v=1770834874"},{"product_id":"rhgh-fragment-176-191-10mg-vial","title":"rHGH Fragment 176–191 10mg vial","description":"\u003ch3\u003e\n\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                    \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003cp data-end=\"787\" data-start=\"324\"\u003e\u003cstrong\u003erHGH Fragment 176–191\u003c\/strong\u003e is a synthetic peptide corresponding to the C-terminus of human growth hormone. Unlike full-length GH, the 176–191 fragment \u003cstrong data-end=\"555\" data-start=\"503\"\u003edoes not activate the GH receptor or raise IGF-1\u003c\/strong\u003e. Preclinical work suggests \u003cstrong data-end=\"614\" data-start=\"583\"\u003eadipocyte-selective actions\u003c\/strong\u003e—enhancing lipolysis and inhibiting lipogenesis—without classical GH-like anabolic or diabetogenic effects. It is \u003cstrong data-end=\"744\" data-start=\"728\"\u003enot approved\u003c\/strong\u003e for any indication in major jurisdictions.\u003c\/p\u003e\n\u003chr data-end=\"792\" data-start=\"789\"\u003e\n\u003ch3 data-end=\"866\" data-start=\"794\"\u003eAdditional Benefits of rHGH Fragment 176–191 Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"3078\" data-start=\"868\"\u003e\n\u003cthead data-end=\"896\" data-start=\"868\"\u003e\n\u003ctr data-end=\"896\" data-start=\"868\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"878\" data-start=\"868\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-col-size=\"xl\" data-end=\"896\" data-start=\"878\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"3078\" data-start=\"907\"\u003e\n\u003ctr data-end=\"1178\" data-start=\"907\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"943\" data-start=\"907\"\u003e\u003cstrong data-end=\"942\" data-start=\"909\"\u003e1 Selective adipose lipolysis\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1178\" data-start=\"943\"\u003eRodent and cell studies show \u003cstrong data-end=\"1021\" data-start=\"974\"\u003eincreased hormone-sensitive lipase activity\u003c\/strong\u003e and glycerol\/FFA release in white adipocytes, with \u003cstrong data-end=\"1125\" data-start=\"1073\"\u003epreferential reduction of abdominal\/visceral fat\u003c\/strong\u003e versus lean tissue. \u0026lt;br\/\u0026gt;\u003cem data-end=\"1176\" data-start=\"1151\"\u003eEndocrinology; Peptides\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1404\" data-start=\"1179\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1210\" data-start=\"1179\"\u003e\u003cstrong data-end=\"1209\" data-start=\"1181\"\u003e2 Anti-lipogenic effects\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1404\" data-start=\"1210\"\u003eDownstream signalling reduces \u003cstrong data-end=\"1265\" data-start=\"1242\"\u003ede novo lipogenesis\u003c\/strong\u003e markers (e.g., FAS\/ACC) and can blunt \u003cstrong data-end=\"1333\" data-start=\"1304\"\u003eLPL-mediated lipid uptake\u003c\/strong\u003e in adipose tissue. \u0026lt;br\/\u0026gt;\u003cem data-end=\"1402\" data-start=\"1358\"\u003eMetabolism; American Journal of Physiology\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1647\" data-start=\"1405\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1440\" data-start=\"1405\"\u003e\u003cstrong data-end=\"1439\" data-start=\"1407\"\u003e3 Energy-expenditure signals\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1647\" data-start=\"1440\"\u003eIn diet-induced obese mice, treatment increases \u003cstrong data-end=\"1516\" data-start=\"1490\"\u003eUCP-1\/UCP-3 expression\u003c\/strong\u003e and fatty-acid oxidation genes, hinting at \u003cstrong data-end=\"1584\" data-start=\"1560\"\u003ebrowning\/thermogenic\u003c\/strong\u003e shifts. \u0026lt;br\/\u0026gt;\u003cem data-end=\"1645\" data-start=\"1598\"\u003eMolecular and Cellular Endocrinology; Obesity\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1863\" data-start=\"1648\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1688\" data-start=\"1648\"\u003e\u003cstrong data-end=\"1687\" data-start=\"1650\"\u003e4 Glucose neutrality (short-term)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1863\" data-start=\"1688\"\u003eSmall human studies report \u003cstrong data-end=\"1769\" data-start=\"1717\"\u003eno meaningful change in fasting glucose or HbA1c\u003c\/strong\u003e over weeks; insulin and IGF-1 remain near baseline. \u0026lt;br\/\u0026gt;\u003cem data-end=\"1861\" data-start=\"1827\"\u003eDiabetes, Obesity and Metabolism\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2098\" data-start=\"1864\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1891\" data-start=\"1864\"\u003e\u003cstrong data-end=\"1890\" data-start=\"1866\"\u003e5 No IGF-1 elevation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2098\" data-start=\"1891\"\u003eBecause the fragment lacks GH-receptor activity, \u003cstrong data-end=\"1980\" data-start=\"1942\"\u003eIGF-1 levels typically do not rise\u003c\/strong\u003e, potentially lowering mitogenic and edema risks seen with GH. \u0026lt;br\/\u0026gt;\u003cem data-end=\"2096\" data-start=\"2048\"\u003eJournal of Clinical Endocrinology \u0026amp; Metabolism\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2357\" data-start=\"2099\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2139\" data-start=\"2099\"\u003e\u003cstrong data-end=\"2138\" data-start=\"2101\"\u003e6 Joint\/tendon exploratory signal\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2357\" data-start=\"2139\"\u003ePreclinical work shows \u003cstrong data-end=\"2202\" data-start=\"2164\"\u003eincreased collagen gene expression\u003c\/strong\u003e and improved histology after tendon injury; human data are \u003cstrong data-end=\"2278\" data-start=\"2262\"\u003einsufficient\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u003cem data-end=\"2355\" data-start=\"2285\"\u003eJournal of Orthopaedic Research; American Journal of Sports Medicine\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2592\" data-start=\"2358\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2387\" data-start=\"2358\"\u003e\u003cstrong data-end=\"2386\" data-start=\"2360\"\u003e7 Liver-fat hypothesis\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2592\" data-start=\"2387\"\u003eBy reducing ectopic lipid flux from adipose tissue, models suggest \u003cstrong data-end=\"2498\" data-start=\"2456\"\u003edownward pressure on hepatic steatosis\u003c\/strong\u003e; \u003cstrong data-end=\"2541\" data-start=\"2500\"\u003econfirmatory human trials are lacking\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u003cem data-end=\"2590\" data-start=\"2548\"\u003eHepatology; Lipids in Health and Disease\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2825\" data-start=\"2593\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2619\" data-start=\"2593\"\u003e\u003cstrong data-end=\"2618\" data-start=\"2595\"\u003e8 Lifestyle synergy\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2825\" data-start=\"2619\"\u003ePairing with \u003cstrong data-end=\"2670\" data-start=\"2634\"\u003ecaloric restriction and exercise\u003c\/strong\u003e amplifies fat-loss signals in animal models; human trials to date \u003cstrong data-end=\"2782\" data-start=\"2737\"\u003edid not show large standalone weight loss\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u003cem data-end=\"2823\" data-start=\"2789\"\u003eInternational Journal of Obesity\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3078\" data-start=\"2826\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2847\" data-start=\"2826\"\u003e\u003cstrong data-end=\"2846\" data-start=\"2828\"\u003e9 Tolerability\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"3078\" data-start=\"2847\"\u003eAcross short-term studies, \u003cstrong data-end=\"2901\" data-start=\"2876\"\u003eAE rates near placebo\u003c\/strong\u003e (GI upset, headache most common); no consistent edema, arthralgia, or IGF-1-related effects. Long-term safety remains \u003cstrong data-end=\"3033\" data-start=\"3020\"\u003euncertain\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u003cem data-end=\"3076\" data-start=\"3040\"\u003eDrug Safety; Clinical Therapeutics\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"3083\" data-start=\"3080\"\u003e\n\u003ch2 data-end=\"3120\" data-start=\"3085\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-end=\"3157\" data-start=\"3122\"\u003e2.1 Receptor Pharmacodynamics\u003c\/h3\u003e\n\u003cp data-end=\"3471\" data-start=\"3158\"\u003eThe 176–191 fragment \u003cstrong data-end=\"3224\" data-start=\"3179\"\u003edoes not bind or activate the GH receptor\u003c\/strong\u003e and \u003cstrong data-end=\"3257\" data-start=\"3229\"\u003edoes not stimulate IGF-1\u003c\/strong\u003e. Proposed actions are \u003cstrong data-end=\"3303\" data-start=\"3280\"\u003eadipocyte-selective\u003c\/strong\u003e, with evidence for \u003cstrong data-end=\"3339\" data-start=\"3323\"\u003ecAMP\/PKA-HSL\u003c\/strong\u003e pathway activation and \u003cstrong data-end=\"3416\" data-start=\"3363\"\u003esuppression of lipogenic transcriptional programs\u003c\/strong\u003e. The precise upstream receptor remains \u003cstrong data-end=\"3470\" data-start=\"3456\"\u003eunresolved\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3 data-end=\"3500\" data-start=\"3473\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"3816\" data-start=\"3502\"\u003e\n\u003cthead data-end=\"3544\" data-start=\"3502\"\u003e\n\u003ctr data-end=\"3544\" data-start=\"3502\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3512\" data-start=\"3502\"\u003ePathway\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3533\" data-start=\"3512\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3544\" data-start=\"3533\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"3816\" data-start=\"3559\"\u003e\n\u003ctr data-end=\"3630\" data-start=\"3559\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3574\" data-start=\"3559\"\u003ecAMP–PKA–HSL\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3606\" data-start=\"3574\"\u003e↑ lipolysis, FFA mobilization\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3630\" data-start=\"3606\"\u003eWhite adipose tissue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3711\" data-start=\"3631\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3654\" data-start=\"3631\"\u003eAMPK\/PPAR cross-talk\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3694\" data-start=\"3654\"\u003e↑ fatty-acid oxidation, ↓ lipogenesis\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3711\" data-start=\"3694\"\u003eLiver\/adipose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3816\" data-start=\"3712\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3753\" data-start=\"3712\"\u003eMitochondrial\/thermogenic genes (UCPs)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3790\" data-start=\"3753\"\u003e↑ energy expenditure (preclinical)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3816\" data-start=\"3790\"\u003eBrown\/brite adipocytes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"3821\" data-start=\"3818\"\u003e\n\u003ch2 data-end=\"3845\" data-start=\"3823\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-end=\"4347\" data-start=\"3847\"\u003e\n\u003cli data-end=\"4026\" data-start=\"3847\"\u003e\n\u003cp data-end=\"4026\" data-start=\"3849\"\u003e\u003cstrong data-end=\"3870\" data-start=\"3849\"\u003eAbsorption\/route:\u003c\/strong\u003e Investigated as \u003cstrong data-end=\"3909\" data-start=\"3887\"\u003eparenteral peptide\u003c\/strong\u003e; some programs explored \u003cstrong data-end=\"3955\" data-start=\"3934\"\u003eoral formulations\u003c\/strong\u003e, but \u003cstrong data-end=\"3997\" data-start=\"3961\"\u003eoral bioavailability appears low\u003c\/strong\u003e and formulation-dependent.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4196\" data-start=\"4027\"\u003e\n\u003cp data-end=\"4196\" data-start=\"4029\"\u003e\u003cstrong data-end=\"4043\" data-start=\"4029\"\u003eHalf-life:\u003c\/strong\u003e \u003cstrong data-end=\"4088\" data-start=\"4044\"\u003eShort plasma half-life (minutes to ~1 h)\u003c\/strong\u003e typical of small peptides; pharmacodynamic effects depend on \u003cstrong data-end=\"4169\" data-start=\"4150\"\u003efrequent dosing\u003c\/strong\u003e or specialized delivery.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4347\" data-start=\"4197\"\u003e\n\u003cp data-end=\"4347\" data-start=\"4199\"\u003e\u003cstrong data-end=\"4226\" data-start=\"4199\"\u003eDistribution\/Clearance:\u003c\/strong\u003e Primarily extracellular distribution; \u003cstrong data-end=\"4292\" data-start=\"4265\"\u003eproteolytic degradation\u003c\/strong\u003e and renal clearance; \u003cstrong data-end=\"4324\" data-start=\"4314\"\u003eno CYP\u003c\/strong\u003e interactions expected.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"4352\" data-start=\"4349\"\u003e\n\u003ch2 data-end=\"4399\" data-start=\"4354\"\u003e4. Pre-clinical and Translational Evidence\u003c\/h2\u003e\n\u003ch3 data-end=\"4428\" data-start=\"4401\"\u003e4.1 Obesity\/Adiposity\u003c\/h3\u003e\n\u003cp data-end=\"4696\" data-start=\"4429\"\u003eMultiple rodent studies show \u003cstrong data-end=\"4520\" data-start=\"4458\"\u003ereductions in fat mass and improvements in lipid oxidation\u003c\/strong\u003e with minimal effect on lean mass. \u003cstrong data-end=\"4585\" data-start=\"4555\"\u003eHuman RCTs have been mixed\u003c\/strong\u003e and \u003cstrong data-end=\"4646\" data-start=\"4590\"\u003eseveral failed to meet primary weight-loss endpoints\u003c\/strong\u003e, though \u003cstrong data-end=\"4671\" data-start=\"4655\"\u003etolerability\u003c\/strong\u003ewas generally favorable.\u003c\/p\u003e\n\u003ch3 data-end=\"4724\" data-start=\"4698\"\u003e4.2 Metabolic Health\u003c\/h3\u003e\n\u003cp data-end=\"4924\" data-start=\"4725\"\u003eShort-term human data show \u003cstrong data-end=\"4773\" data-start=\"4752\"\u003eneutral glycaemia\u003c\/strong\u003e and \u003cstrong data-end=\"4795\" data-start=\"4778\"\u003eno IGF-1 rise\u003c\/strong\u003e; lipid changes are modest and inconsistent. In animals, \u003cstrong data-end=\"4878\" data-start=\"4852\"\u003ehepatic lipid handling\u003c\/strong\u003e and \u003cstrong data-end=\"4914\" data-start=\"4883\"\u003ethermogenic gene expression\u003c\/strong\u003e improved.\u003c\/p\u003e\n\u003ch3 data-end=\"4958\" data-start=\"4926\"\u003e4.3 Musculoskeletal Tissue\u003c\/h3\u003e\n\u003cp data-end=\"5106\" data-start=\"4959\"\u003eExploratory preclinical data suggest \u003cstrong data-end=\"5018\" data-start=\"4996\"\u003ecollagen synthesis\u003c\/strong\u003e support and improved histology after tendon injury; \u003cstrong data-end=\"5105\" data-start=\"5071\"\u003eclinical relevance is unproven\u003c\/strong\u003e.\u003c\/p\u003e\n\u003chr data-end=\"5111\" data-start=\"5108\"\u003e\n\u003ch2 data-end=\"5146\" data-start=\"5113\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"5638\" data-start=\"5148\"\u003e\n\u003cthead data-end=\"5186\" data-start=\"5148\"\u003e\n\u003ctr data-end=\"5186\" data-start=\"5148\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5156\" data-start=\"5148\"\u003eField\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"5168\" data-start=\"5156\"\u003eRationale\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5186\" data-start=\"5168\"\u003eCurrent status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"5638\" data-start=\"5201\"\u003e\n\u003ctr data-end=\"5318\" data-start=\"5201\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5231\" data-start=\"5201\"\u003e\u003cstrong data-end=\"5230\" data-start=\"5203\"\u003eAdjunct in obesity care\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5277\" data-start=\"5231\"\u003eAdipocyte-selective lipolysis without IGF-1\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5318\" data-start=\"5277\"\u003eEarly human signals; \u003cstrong data-end=\"5316\" data-start=\"5300\"\u003eno approvals\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5441\" data-start=\"5319\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5350\" data-start=\"5319\"\u003e\u003cstrong data-end=\"5349\" data-start=\"5321\"\u003eNAFLD\/MASH (theoretical)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5393\" data-start=\"5350\"\u003eReduced adipose lipid spillover to liver\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5441\" data-start=\"5393\"\u003ePreclinical rationale; \u003cstrong data-end=\"5439\" data-start=\"5418\"\u003eno pivotal trials\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5531\" data-start=\"5442\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5471\" data-start=\"5442\"\u003e\u003cstrong data-end=\"5470\" data-start=\"5444\"\u003eSports-injury recovery\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5511\" data-start=\"5471\"\u003eCollagen gene up-regulation in models\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5531\" data-start=\"5511\"\u003ePreclinical only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5638\" data-start=\"5532\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5559\" data-start=\"5532\"\u003e\u003cstrong data-end=\"5558\" data-start=\"5534\"\u003eCardiometabolic risk\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"5608\" data-start=\"5559\"\u003ePossible TG\/HDL improvements if fat mass drops\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5638\" data-start=\"5608\"\u003eRequires robust human data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"5643\" data-start=\"5640\"\u003e\n\u003ch2 data-end=\"5674\" data-start=\"5645\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-end=\"6088\" data-start=\"5676\"\u003e\n\u003cli data-end=\"5772\" data-start=\"5676\"\u003e\n\u003cp data-end=\"5772\" data-start=\"5678\"\u003e\u003cstrong data-end=\"5693\" data-start=\"5678\"\u003eCommon AEs:\u003c\/strong\u003e Mild \u003cstrong data-end=\"5716\" data-start=\"5699\"\u003eGI discomfort\u003c\/strong\u003e, \u003cstrong data-end=\"5730\" data-start=\"5718\"\u003eheadache\u003c\/strong\u003e, injection-site reactions (parenteral).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5879\" data-start=\"5773\"\u003e\n\u003cp data-end=\"5879\" data-start=\"5775\"\u003e\u003cstrong data-end=\"5789\" data-start=\"5775\"\u003eEndocrine:\u003c\/strong\u003e \u003cstrong data-end=\"5809\" data-start=\"5790\"\u003eIGF-1 unchanged\u003c\/strong\u003e; \u003cstrong data-end=\"5850\" data-start=\"5811\"\u003eno GH-like edema\/arthralgia pattern\u003c\/strong\u003e reported in short studies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5957\" data-start=\"5880\"\u003e\n\u003cp data-end=\"5957\" data-start=\"5882\"\u003e\u003cstrong data-end=\"5896\" data-start=\"5882\"\u003eGlycaemia:\u003c\/strong\u003e Generally \u003cstrong data-end=\"5918\" data-start=\"5907\"\u003eneutral\u003c\/strong\u003e; no systematic hypoglycaemia signal.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6088\" data-start=\"5958\"\u003e\n\u003cp data-end=\"6088\" data-start=\"5960\"\u003e\u003cstrong data-end=\"5973\" data-start=\"5960\"\u003eUnknowns:\u003c\/strong\u003e \u003cstrong data-end=\"5994\" data-start=\"5974\"\u003eLong-term safety\u003c\/strong\u003e, carcinogenicity, and effects in special populations remain \u003cstrong data-end=\"6087\" data-start=\"6055\"\u003einsufficiently characterized\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"6119\" data-start=\"6090\"\u003e\u003cstrong data-end=\"6119\" data-start=\"6090\"\u003eComparative safety matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"6553\" data-start=\"6121\"\u003e\n\u003cthead data-end=\"6202\" data-start=\"6121\"\u003e\n\u003ctr data-end=\"6202\" data-start=\"6121\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6131\" data-start=\"6121\"\u003eConcern\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6155\" data-start=\"6131\"\u003erHGH 176–191 fragment\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6183\" data-start=\"6155\"\u003eTesamorelin (GHRH analog)\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6202\" data-start=\"6183\"\u003eSomatropin (GH)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"6553\" data-start=\"6221\"\u003e\n\u003ctr data-end=\"6300\" data-start=\"6221\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6239\" data-start=\"6221\"\u003eIGF-1 elevation\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6248\" data-start=\"6239\"\u003e\u003cstrong data-end=\"6247\" data-start=\"6241\"\u003eNo\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6272\" data-start=\"6248\"\u003e\u003cstrong data-end=\"6271\" data-start=\"6250\"\u003eYes (physiologic)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6300\" data-start=\"6272\"\u003e\u003cstrong data-end=\"6298\" data-start=\"6274\"\u003eYes (dose-dependent)\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6373\" data-start=\"6301\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6320\" data-start=\"6301\"\u003eEdema\/arthralgia\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6343\" data-start=\"6320\"\u003e\u003cstrong data-end=\"6342\" data-start=\"6322\"\u003eLow (short-term)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6354\" data-start=\"6343\"\u003eModerate\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6373\" data-start=\"6354\"\u003eModerate–higher\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6455\" data-start=\"6374\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6393\" data-start=\"6374\"\u003eGlycaemic impact\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6416\" data-start=\"6393\"\u003eNeutral (short-term)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6435\" data-start=\"6416\"\u003eNeutral → mild ↑\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6455\" data-start=\"6435\"\u003eNeutral → mild ↑\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6553\" data-start=\"6456\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6480\" data-start=\"6456\"\u003eEvidence for fat loss\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6506\" data-start=\"6480\"\u003e\u003cstrong data-end=\"6505\" data-start=\"6482\"\u003ePreclinical \u0026gt; human\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6526\" data-start=\"6506\"\u003eRobust in HIV VAT\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6553\" data-start=\"6526\"\u003eMixed in non-GHD adults\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"6558\" data-start=\"6555\"\u003e\n\u003ch2 data-end=\"6586\" data-start=\"6560\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-end=\"6932\" data-start=\"6588\"\u003e\n\u003cli data-end=\"6686\" data-start=\"6588\"\u003e\n\u003cp data-end=\"6686\" data-start=\"6590\"\u003e\u003cstrong data-end=\"6610\" data-start=\"6590\"\u003eApproval status:\u003c\/strong\u003e \u003cstrong data-end=\"6627\" data-start=\"6611\"\u003eNot approved\u003c\/strong\u003e by FDA\/EMA or other major regulators for any indication.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6816\" data-start=\"6687\"\u003e\n\u003cp data-end=\"6816\" data-start=\"6689\"\u003e\u003cstrong data-end=\"6709\" data-start=\"6689\"\u003eSporting bodies:\u003c\/strong\u003e Classified under \u003cstrong data-end=\"6754\" data-start=\"6727\"\u003enon-approved substances\u003c\/strong\u003e by anti-doping authorities; use in sport is \u003cstrong data-end=\"6813\" data-start=\"6799\"\u003eprohibited\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6932\" data-start=\"6817\"\u003e\n\u003cp data-end=\"6932\" data-start=\"6819\"\u003e\u003cstrong data-end=\"6830\" data-start=\"6819\"\u003eSupply:\u003c\/strong\u003e Frequently marketed online as a \u003cstrong data-end=\"6886\" data-start=\"6863\"\u003e“research chemical”\u003c\/strong\u003e; quality, purity, and dosing \u003cstrong data-end=\"6931\" data-start=\"6916\"\u003enot assured\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"6937\" data-start=\"6934\"\u003e\n\u003ch2 data-end=\"6962\" data-start=\"6939\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-end=\"7476\" data-start=\"6964\"\u003e\n\u003cli data-end=\"7082\" data-start=\"6964\"\u003e\n\u003cp data-end=\"7082\" data-start=\"6966\"\u003e\u003cstrong data-end=\"6990\" data-start=\"6966\"\u003eMechanistic clarity:\u003c\/strong\u003e Identify the \u003cstrong data-end=\"7032\" data-start=\"7004\"\u003eproximal receptor\/target\u003c\/strong\u003e and confirm \u003cstrong data-end=\"7069\" data-start=\"7045\"\u003eon-target biomarkers\u003c\/strong\u003e in humans.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7199\" data-start=\"7083\"\u003e\n\u003cp data-end=\"7199\" data-start=\"7085\"\u003e\u003cstrong data-end=\"7104\" data-start=\"7085\"\u003ePK engineering:\u003c\/strong\u003e \u003cstrong data-end=\"7128\" data-start=\"7105\"\u003eHalf-life extension\u003c\/strong\u003e (e.g., lipidation, depot, or pegylation) to enable practical dosing.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7333\" data-start=\"7200\"\u003e\n\u003cp data-end=\"7333\" data-start=\"7202\"\u003e\u003cstrong data-end=\"7226\" data-start=\"7202\"\u003ePhenotype targeting:\u003c\/strong\u003e Trials in \u003cstrong data-end=\"7269\" data-start=\"7237\"\u003evisceral-predominant obesity\u003c\/strong\u003e or \u003cstrong data-end=\"7282\" data-start=\"7273\"\u003eNAFLD\u003c\/strong\u003e with imaging (MRI-PDFF) and metabolic endpoints.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7476\" data-start=\"7334\"\u003e\n\u003cp data-end=\"7476\" data-start=\"7336\"\u003e\u003cstrong data-end=\"7360\" data-start=\"7336\"\u003eCombination therapy:\u003c\/strong\u003e Pairing with \u003cstrong data-end=\"7396\" data-start=\"7374\"\u003eGLP-1\/GIP agonists\u003c\/strong\u003e or \u003cstrong data-end=\"7420\" data-start=\"7400\"\u003eSGLT2 inhibitors\u003c\/strong\u003e to evaluate \u003cstrong data-end=\"7475\" data-start=\"7433\"\u003eadditive fat- and liver-fat reductions\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"7481\" data-start=\"7478\"\u003e\n\u003ch3 data-end=\"7506\" data-start=\"7483\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-end=\"8214\" data-start=\"7508\"\u003e\n\u003cli data-end=\"7683\" data-start=\"7508\"\u003e\n\u003cp data-end=\"7683\" data-start=\"7510\"\u003e\u003cstrong data-end=\"7581\" data-start=\"7510\"\u003eEndocrinology; Peptides; Metabolism; American Journal of Physiology\u003c\/strong\u003e — preclinical studies of hGH C-terminal fragments (176–191) on adipocyte lipolysis and lipogenesis.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7853\" data-start=\"7684\"\u003e\n\u003cp data-end=\"7853\" data-start=\"7686\"\u003e\u003cstrong data-end=\"7754\" data-start=\"7686\"\u003eObesity; Diabetes, Obesity and Metabolism; Clinical Therapeutics\u003c\/strong\u003e — human tolerability and efficacy signals; several trials with \u003cstrong data-end=\"7850\" data-start=\"7818\"\u003elimited weight-loss outcomes\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8002\" data-start=\"7854\"\u003e\n\u003cp data-end=\"8002\" data-start=\"7856\"\u003e\u003cstrong data-end=\"7928\" data-start=\"7856\"\u003eJournal of Orthopaedic Research; American Journal of Sports Medicine\u003c\/strong\u003e — exploratory musculoskeletal\/tendon biology with GH-fragment peptides.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8095\" data-start=\"8003\"\u003e\n\u003cp data-end=\"8095\" data-start=\"8005\"\u003e\u003cstrong data-end=\"8020\" data-start=\"8005\"\u003eDrug Safety\u003c\/strong\u003e — short-term safety summaries for peptide-based anti-obesity candidates.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8214\" data-start=\"8096\"\u003e\n\u003cp data-end=\"8214\" data-start=\"8098\"\u003e\u003cstrong data-end=\"8140\" data-start=\"8098\"\u003eWorld Anti-Doping Code\/Prohibited List\u003c\/strong\u003e — classification of non-approved peptide hormones and related substance\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684855443794,"sku":null,"price":50.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/rHGH_Fragment_176_191_10mg.png?v=1770834876"},{"product_id":"sermorelin-10mg-vial","title":"Sermorelin 10mg vial","description":"\u003ch3\u003e\n\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                      \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003cp data-end=\"625\" data-start=\"44\"\u003eSermorelin is a synthetic \u003cstrong data-end=\"166\" data-start=\"111\"\u003egrowth-hormone–releasing hormone (GHRH 1–29) analog\u003c\/strong\u003e that binds pituitary \u003cstrong data-end=\"214\" data-start=\"188\"\u003eGHRH receptors (GHRHR)\u003c\/strong\u003e to provoke \u003cstrong data-end=\"263\" data-start=\"226\"\u003ephysiologic, pulsatile GH release\u003c\/strong\u003e and downstream increases in \u003cstrong data-end=\"301\" data-start=\"292\"\u003eIGF-1\u003c\/strong\u003e. In the U.S., sermorelin was previously marketed as \u003cstrong data-end=\"382\" data-start=\"354\"\u003eGeref®\/Geref Diagnostic®\u003c\/strong\u003e for evaluating pituitary GH reserve; it is \u003cstrong data-end=\"499\" data-start=\"426\"\u003enot FDA-approved for chronic treatment of growth disorders or obesity\u003c\/strong\u003e and branded drug was discontinued for non-safety\/commercial reasons. Compounded products are used off-label in some settings.\u003c\/p\u003e\n\u003chr data-end=\"630\" data-start=\"627\"\u003e\n\u003ch3 data-end=\"693\" data-start=\"632\"\u003eAdditional Benefits of Sermorelin Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"3157\" data-start=\"695\"\u003e\n\u003cthead data-end=\"723\" data-start=\"695\"\u003e\n\u003ctr data-end=\"723\" data-start=\"695\"\u003e\n\u003cth data-col-size=\"md\" data-end=\"705\" data-start=\"695\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-col-size=\"xl\" data-end=\"723\" data-start=\"705\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"3157\" data-start=\"734\"\u003e\n\u003ctr data-end=\"1054\" data-start=\"734\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"785\" data-start=\"734\"\u003e\u003cstrong data-end=\"784\" data-start=\"736\"\u003e1 Physiologic GH restoration vs exogenous GH\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"1054\" data-start=\"785\" data-col-size=\"xl\"\u003eSermorelin elicits \u003cstrong data-end=\"834\" data-start=\"806\"\u003eendogenous, pulsatile GH\u003c\/strong\u003e with intact hypothalamic feedback (somatostatin\/IGF-1), typically raising IGF-1 \u003cstrong data-end=\"971\" data-start=\"915\"\u003einto—rather than above—the age-adjusted normal range\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Endocrine Reviews; Journal of Clinical Endocrinology \u0026amp; Metabolism\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1335\" data-start=\"1055\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1094\" data-start=\"1055\"\u003e\u003cstrong data-end=\"1093\" data-start=\"1057\"\u003e2 Diagnostic utility for GH axis\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"1335\" data-start=\"1094\" data-col-size=\"xl\"\u003eAs a \u003cstrong data-end=\"1126\" data-start=\"1101\"\u003eGHRH stimulation test\u003c\/strong\u003e (often 1 µg\/kg IV), sermorelin helps differentiate \u003cstrong data-end=\"1207\" data-start=\"1178\"\u003ehypothalamic vs pituitary\u003c\/strong\u003e deficits and can increase diagnostic sensitivity when combined with \u003cstrong data-end=\"1301\" data-start=\"1276\"\u003earginine or clonidine\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;JCEM; Pediatrics\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1563\" data-start=\"1336\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1377\" data-start=\"1336\"\u003e\u003cstrong data-end=\"1376\" data-start=\"1338\"\u003e3 Sleep architecture \u0026amp; SWS support\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"1563\" data-start=\"1377\" data-col-size=\"xl\"\u003eGHRH analogs including sermorelin \u003cstrong data-end=\"1440\" data-start=\"1413\"\u003eaugment slow-wave sleep\u003c\/strong\u003e and \u003cstrong data-end=\"1473\" data-start=\"1445\"\u003enighttime GH pulsatility\u003c\/strong\u003e, especially in midlife adults with blunted SWS. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Sleep; Neuroendocrinology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1858\" data-start=\"1564\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1597\" data-start=\"1564\"\u003e\u003cstrong data-end=\"1596\" data-start=\"1566\"\u003e4 Body-composition signals\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"1858\" data-start=\"1597\" data-col-size=\"xl\"\u003eSmall open-label series report \u003cstrong data-end=\"1654\" data-start=\"1630\"\u003emodest VAT reduction\u003c\/strong\u003e and \u003cstrong data-end=\"1689\" data-start=\"1659\"\u003efat-free mass preservation\u003c\/strong\u003e under nightly SC dosing, consistent with GH physiology; effects are \u003cstrong data-end=\"1797\" data-start=\"1758\"\u003esmaller than with tesamorelin or GH\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Metabolism; Hormone Research in Paediatrics\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2062\" data-start=\"1859\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1881\" data-start=\"1859\"\u003e\u003cstrong data-end=\"1880\" data-start=\"1861\"\u003e5 Bone turnover\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"2062\" data-start=\"1881\" data-col-size=\"xl\"\u003eShort-term increases in \u003cstrong data-end=\"1953\" data-start=\"1907\"\u003ebone-formation markers (P1NP, osteocalcin)\u003c\/strong\u003e via GH→IGF-1 pathways; long-term fracture data are lacking. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Bone; Osteoporosis International\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2327\" data-start=\"2063\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2110\" data-start=\"2063\"\u003e\u003cstrong data-end=\"2109\" data-start=\"2065\"\u003e6 Exercise recovery \u0026amp; collagen synthesis\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"2327\" data-start=\"2110\" data-col-size=\"xl\"\u003eBy restoring \u003cstrong data-end=\"2148\" data-start=\"2125\"\u003enocturnal GH pulses\u003c\/strong\u003e, sermorelin may support \u003cstrong data-end=\"2211\" data-start=\"2173\"\u003etendon\/ligament collagen synthesis\u003c\/strong\u003eand recovery, though high-quality RCTs are limited. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;American Journal of Physiology; Sports Medicine\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2602\" data-start=\"2328\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2364\" data-start=\"2328\"\u003e\u003cstrong data-end=\"2363\" data-start=\"2330\"\u003e7 Cognitive\/affective domains\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"2602\" data-start=\"2364\" data-col-size=\"xl\"\u003eIn older adults, \u003cstrong data-end=\"2407\" data-start=\"2383\"\u003eGHRH analog regimens\u003c\/strong\u003e improved \u003cstrong data-end=\"2450\" data-start=\"2417\"\u003eexecutive function and memory\u003c\/strong\u003e in small trials; sermorelin is mechanistically similar but \u003cstrong data-end=\"2547\" data-start=\"2510\"\u003edirect sermorelin RCTs are sparse\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Archives of Neurology; JAMA Neurology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"2880\" data-start=\"2603\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2635\" data-start=\"2603\"\u003e\u003cstrong data-end=\"2634\" data-start=\"2605\"\u003e8 Cardiometabolic markers\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"2880\" data-start=\"2635\" data-col-size=\"xl\"\u003eResponders may show \u003cstrong data-end=\"2680\" data-start=\"2657\"\u003elower triglycerides\u003c\/strong\u003e and \u003cstrong data-end=\"2707\" data-start=\"2685\"\u003ehigher adiponectin\u003c\/strong\u003e in parallel with IGF-1 normalization; glucose impact is \u003cstrong data-end=\"2793\" data-start=\"2764\"\u003eneutral to mildly adverse\u003c\/strong\u003e and requires monitoring. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Diabetes Care; Journal of Clinical Lipidology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3157\" data-start=\"2881\"\u003e\n\u003ctd data-col-size=\"md\" data-end=\"2920\" data-start=\"2881\"\u003e\u003cstrong data-end=\"2919\" data-start=\"2883\"\u003e9 Pediatric transition scenarios\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"3157\" data-start=\"2920\" data-col-size=\"xl\"\u003eAs a physiologic secretagogue, sermorelin has been explored for \u003cstrong data-end=\"3015\" data-start=\"2986\"\u003eborderline\/functional GHD\u003c\/strong\u003e and \u003cstrong data-end=\"3049\" data-start=\"3020\"\u003etransition-age assessment\u003c\/strong\u003e, but \u003cstrong data-end=\"3094\" data-start=\"3055\"\u003esomatropin remains standard therapy\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Pediatrics; European Journal of Endocrinology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"3162\" data-start=\"3159\"\u003e\n\u003ch2 data-end=\"3199\" data-start=\"3164\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-end=\"3236\" data-start=\"3201\"\u003e2.1 Receptor Pharmacodynamics\u003c\/h3\u003e\n\u003cp data-end=\"3556\" data-start=\"3237\"\u003eSermorelin binds \u003cstrong data-end=\"3263\" data-start=\"3254\"\u003eGHRHR\u003c\/strong\u003e on pituitary somatotrophs → \u003cstrong data-end=\"3330\" data-start=\"3292\"\u003eGs–adenylate cyclase–cAMP–PKA–CREB\u003c\/strong\u003e activation → \u003cstrong data-end=\"3356\" data-start=\"3344\"\u003eGH pulse\u003c\/strong\u003e generation. Peripheral \u003cstrong data-end=\"3386\" data-start=\"3380\"\u003eGH\u003c\/strong\u003e acts via \u003cstrong data-end=\"3414\" data-start=\"3396\"\u003eGHR–JAK2–STAT5\u003c\/strong\u003e, increasing hepatic \u003cstrong data-end=\"3444\" data-start=\"3435\"\u003eIGF-1\u003c\/strong\u003e and lipolytic enzymes; \u003cstrong data-end=\"3484\" data-start=\"3468\"\u003esomatostatin\u003c\/strong\u003e and \u003cstrong data-end=\"3498\" data-start=\"3489\"\u003eIGF-1\u003c\/strong\u003e furnish negative feedback, preserving physiologic rhythm.\u003c\/p\u003e\n\u003ch3 data-end=\"3585\" data-start=\"3558\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"3901\" data-start=\"3587\"\u003e\n\u003cthead data-end=\"3629\" data-start=\"3587\"\u003e\n\u003ctr data-end=\"3629\" data-start=\"3587\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3597\" data-start=\"3587\"\u003ePathway\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"3618\" data-start=\"3597\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3629\" data-start=\"3618\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"3901\" data-start=\"3644\"\u003e\n\u003ctr data-end=\"3726\" data-start=\"3644\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3662\" data-start=\"3644\"\u003eJAK2–STAT5 (GH)\u003c\/td\u003e\n\u003ctd data-end=\"3708\" data-start=\"3662\" data-col-size=\"md\"\u003e↑ IGF-1, ↑ lipolysis, ↓ de novo lipogenesis\u003c\/td\u003e\n\u003ctd data-end=\"3726\" data-start=\"3708\" data-col-size=\"sm\"\u003eLiver, adipose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3809\" data-start=\"3727\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3751\" data-start=\"3727\"\u003ePI3K–Akt–mTOR (IGF-1)\u003c\/td\u003e\n\u003ctd data-end=\"3790\" data-start=\"3751\" data-col-size=\"md\"\u003e↑ protein synthesis, ↑ fat-free mass\u003c\/td\u003e\n\u003ctd data-end=\"3809\" data-start=\"3790\" data-col-size=\"sm\"\u003eSkeletal muscle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3901\" data-start=\"3810\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3837\" data-start=\"3810\"\u003eCNS sleep network (GHRH)\u003c\/td\u003e\n\u003ctd data-end=\"3878\" data-start=\"3837\" data-col-size=\"md\"\u003e↑ slow-wave sleep, nocturnal GH pulses\u003c\/td\u003e\n\u003ctd data-end=\"3901\" data-start=\"3878\" data-col-size=\"sm\"\u003eHypothalamus\/cortex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"3906\" data-start=\"3903\"\u003e\n\u003ch2 data-end=\"3930\" data-start=\"3908\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-end=\"4267\" data-start=\"3932\"\u003e\n\u003cli data-end=\"3996\" data-start=\"3932\"\u003e\n\u003cp data-end=\"3996\" data-start=\"3934\"\u003e\u003cstrong data-end=\"3949\" data-start=\"3934\"\u003eAbsorption:\u003c\/strong\u003e Rapid after SC; diagnostic use often \u003cstrong data-end=\"3993\" data-start=\"3987\"\u003eIV\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4104\" data-start=\"3997\"\u003e\n\u003cp data-end=\"4104\" data-start=\"3999\"\u003e\u003cstrong data-end=\"4013\" data-start=\"3999\"\u003eHalf-life:\u003c\/strong\u003e \u003cstrong data-end=\"4028\" data-start=\"4014\"\u003e~10–20 min\u003c\/strong\u003e (short), necessitating \u003cstrong data-end=\"4080\" data-start=\"4052\"\u003ebedtime or repeat dosing\u003c\/strong\u003e for therapeutic aims.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4195\" data-start=\"4105\"\u003e\n\u003cp data-end=\"4195\" data-start=\"4107\"\u003e\u003cstrong data-end=\"4124\" data-start=\"4107\"\u003eDistribution:\u003c\/strong\u003e Acts primarily at pituitary; systemic effects mediated via GH\/IGF-1.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4267\" data-start=\"4196\"\u003e\n\u003cp data-end=\"4267\" data-start=\"4198\"\u003e\u003cstrong data-end=\"4212\" data-start=\"4198\"\u003eClearance:\u003c\/strong\u003e Proteolytic degradation; no CYP interactions expected.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"4272\" data-start=\"4269\"\u003e\n\u003ch2 data-end=\"4319\" data-start=\"4274\"\u003e4. Pre-clinical and Translational Evidence\u003c\/h2\u003e\n\u003ch3 data-end=\"4356\" data-start=\"4321\"\u003e4.1 Adult \u0026amp; Pediatric GH Axis\u003c\/h3\u003e\n\u003cp data-end=\"4594\" data-start=\"4357\"\u003eSermorelin reliably increases \u003cstrong data-end=\"4399\" data-start=\"4387\"\u003eGH\/IGF-1\u003c\/strong\u003e in subjects with intact somatotrophs; blunted\/absent responses suggest \u003cstrong data-end=\"4492\" data-start=\"4471\"\u003epituitary disease\u003c\/strong\u003e. Pediatric evaluation shows good tolerability and diagnostic yield in conjunction with other stimuli.\u003c\/p\u003e\n\u003ch3 data-end=\"4628\" data-start=\"4596\"\u003e4.2 Sleep \u0026amp; Neurocognition\u003c\/h3\u003e\n\u003cp data-end=\"4798\" data-start=\"4629\"\u003eGHRH-based paradigms improve \u003cstrong data-end=\"4677\" data-start=\"4658\"\u003eslow-wave sleep\u003c\/strong\u003e and may enhance \u003cstrong data-end=\"4716\" data-start=\"4694\"\u003eexecutive function\u003c\/strong\u003e in aging cohorts; direct sermorelin data are limited but mechanistically aligned.\u003c\/p\u003e\n\u003ch3 data-end=\"4839\" data-start=\"4800\"\u003e4.3 Body Composition \/ Metabolism\u003c\/h3\u003e\n\u003cp data-end=\"5027\" data-start=\"4840\"\u003eExploratory studies indicate \u003cstrong data-end=\"4894\" data-start=\"4869\"\u003emodest VAT reductions\u003c\/strong\u003e and \u003cstrong data-end=\"4921\" data-start=\"4899\"\u003elipid improvements\u003c\/strong\u003e with nightly SC administration; effects regress after \u003cstrong data-end=\"4995\" data-start=\"4976\"\u003ediscontinuation\u003c\/strong\u003e, consistent with GH physiology.\u003c\/p\u003e\n\u003chr data-end=\"5032\" data-start=\"5029\"\u003e\n\u003ch2 data-end=\"5067\" data-start=\"5034\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"5620\" data-start=\"5069\"\u003e\n\u003cthead data-end=\"5107\" data-start=\"5069\"\u003e\n\u003ctr data-end=\"5107\" data-start=\"5069\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"5077\" data-start=\"5069\"\u003eField\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"5089\" data-start=\"5077\"\u003eRationale\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"5107\" data-start=\"5089\"\u003eCurrent status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"5620\" data-start=\"5122\"\u003e\n\u003ctr data-end=\"5274\" data-start=\"5122\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5153\" data-start=\"5122\"\u003e\u003cstrong data-end=\"5152\" data-start=\"5124\"\u003eDiagnostic endocrinology\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"5206\" data-start=\"5153\" data-col-size=\"md\"\u003eDifferentiate hypothalamic vs pituitary GH defects\u003c\/td\u003e\n\u003ctd data-end=\"5274\" data-start=\"5206\" data-col-size=\"md\"\u003eEstablished methodology, less common since widespread IGF-1\/ITTs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5404\" data-start=\"5275\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5306\" data-start=\"5275\"\u003e\u003cstrong data-end=\"5305\" data-start=\"5277\"\u003eSarcopenic obesity\/aging\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"5357\" data-start=\"5306\" data-col-size=\"md\"\u003ePhysiologic GH restoration with feedback control\u003c\/td\u003e\n\u003ctd data-end=\"5404\" data-start=\"5357\" data-col-size=\"md\"\u003ePilot\/open-label studies; no pivotal trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5509\" data-start=\"5405\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5432\" data-start=\"5405\"\u003e\u003cstrong data-end=\"5431\" data-start=\"5407\"\u003eNeurocognitive aging\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"5470\" data-start=\"5432\" data-col-size=\"md\"\u003eGHRH→GH→IGF-1 neurotrophic pathways\u003c\/td\u003e\n\u003ctd data-end=\"5509\" data-start=\"5470\" data-col-size=\"md\"\u003eSmall RCT signals with GHRH analogs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"5620\" data-start=\"5510\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"5531\" data-start=\"5510\"\u003e\u003cstrong data-end=\"5530\" data-start=\"5512\"\u003eSleep medicine\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"5575\" data-start=\"5531\" data-col-size=\"md\"\u003eAugment SWS in midlife adults with low GH\u003c\/td\u003e\n\u003ctd data-end=\"5620\" data-start=\"5575\" data-col-size=\"md\"\u003eProof-of-concept data; more trials needed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"5625\" data-start=\"5622\"\u003e\n\u003ch2 data-end=\"5656\" data-start=\"5627\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-end=\"6241\" data-start=\"5658\"\u003e\n\u003cli data-end=\"5770\" data-start=\"5658\"\u003e\n\u003cp data-end=\"5770\" data-start=\"5660\"\u003e\u003cstrong data-end=\"5671\" data-start=\"5660\"\u003eCommon:\u003c\/strong\u003e Transient \u003cstrong data-end=\"5694\" data-start=\"5682\"\u003eflushing\u003c\/strong\u003e, \u003cstrong data-end=\"5706\" data-start=\"5696\"\u003ewarmth\u003c\/strong\u003e, \u003cstrong data-end=\"5718\" data-start=\"5708\"\u003enausea\u003c\/strong\u003e, \u003cstrong data-end=\"5732\" data-start=\"5720\"\u003eheadache\u003c\/strong\u003e, mild \u003cstrong data-end=\"5767\" data-start=\"5739\"\u003einjection-site reactions\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5899\" data-start=\"5771\"\u003e\n\u003cp data-end=\"5899\" data-start=\"5773\"\u003e\u003cstrong data-end=\"5787\" data-start=\"5773\"\u003eEndocrine:\u003c\/strong\u003e \u003cstrong data-end=\"5802\" data-start=\"5788\"\u003eIGF-1 rise\u003c\/strong\u003e—monitor to keep within age-normal range; \u003cstrong data-end=\"5855\" data-start=\"5844\"\u003eglucose\u003c\/strong\u003e can drift upward in susceptible patients.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6083\" data-start=\"5900\"\u003e\n\u003cp data-end=\"6083\" data-start=\"5902\"\u003e\u003cstrong data-end=\"5933\" data-start=\"5902\"\u003eContraindications\/Cautions:\u003c\/strong\u003e \u003cstrong data-end=\"5955\" data-start=\"5934\"\u003eActive malignancy\u003c\/strong\u003e, pregnancy, hypersensitivity. Use caution in \u003cstrong data-end=\"6015\" data-start=\"6001\"\u003esevere OSA\u003c\/strong\u003e, \u003cstrong data-end=\"6041\" data-start=\"6017\"\u003ediabetic retinopathy\u003c\/strong\u003e, or \u003cstrong data-end=\"6075\" data-start=\"6046\"\u003eintracranial hypertension\u003c\/strong\u003e risk.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6241\" data-start=\"6084\"\u003e\n\u003cp data-end=\"6241\" data-start=\"6086\"\u003e\u003cstrong data-end=\"6106\" data-start=\"6086\"\u003eAbuse potential:\u003c\/strong\u003e Off-label\/compounded use exists; safety beyond short-term diagnostic dosing is \u003cstrong data-end=\"6213\" data-start=\"6186\"\u003eless well characterized\u003c\/strong\u003e than for tesamorelin or GH.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"6272\" data-start=\"6243\"\u003e\u003cstrong data-end=\"6272\" data-start=\"6243\"\u003eComparative safety matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_sk2ct_1\"\u003e\n\u003cdiv class=\"_tableWrapper_sk2ct_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"6791\" data-start=\"6274\"\u003e\n\u003cthead data-end=\"6367\" data-start=\"6274\"\u003e\n\u003ctr data-end=\"6367\" data-start=\"6274\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6284\" data-start=\"6274\"\u003eConcern\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6309\" data-start=\"6284\"\u003eSermorelin (GHRH 1–29)\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6348\" data-start=\"6309\"\u003eTesamorelin (stabilized GHRH analog)\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"6367\" data-start=\"6348\"\u003eSomatropin (GH)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"6791\" data-start=\"6386\"\u003e\n\u003ctr data-end=\"6479\" data-start=\"6386\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6400\" data-start=\"6386\"\u003eGH dynamics\u003c\/td\u003e\n\u003ctd data-end=\"6425\" data-start=\"6400\" data-col-size=\"sm\"\u003e\u003cstrong data-end=\"6424\" data-start=\"6402\"\u003ePhysiologic pulses\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"6451\" data-start=\"6425\" data-col-size=\"sm\"\u003ePhysiologic-like pulses\u003c\/td\u003e\n\u003ctd data-end=\"6479\" data-start=\"6451\" data-col-size=\"sm\"\u003eNon-physiologic exposure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6562\" data-start=\"6480\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6496\" data-start=\"6480\"\u003eIGF-1 control\u003c\/td\u003e\n\u003ctd data-end=\"6519\" data-start=\"6496\" data-col-size=\"sm\"\u003e\u003cstrong data-end=\"6518\" data-start=\"6498\"\u003eFeedback-limited\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"6538\" data-start=\"6519\" data-col-size=\"sm\"\u003eFeedback-limited\u003c\/td\u003e\n\u003ctd data-end=\"6562\" data-start=\"6538\" data-col-size=\"sm\"\u003eDirectly dose-driven\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6627\" data-start=\"6563\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6582\" data-start=\"6563\"\u003eEdema\/arthralgia\u003c\/td\u003e\n\u003ctd data-end=\"6597\" data-start=\"6582\" data-col-size=\"sm\"\u003eLow–moderate\u003c\/td\u003e\n\u003ctd data-end=\"6608\" data-start=\"6597\" data-col-size=\"sm\"\u003eModerate\u003c\/td\u003e\n\u003ctd data-end=\"6627\" data-start=\"6608\" data-col-size=\"sm\"\u003eModerate–higher\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6703\" data-start=\"6628\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6645\" data-start=\"6628\"\u003eGlucose impact\u003c\/td\u003e\n\u003ctd data-end=\"6664\" data-start=\"6645\" data-col-size=\"sm\"\u003eNeutral → mild ↑\u003c\/td\u003e\n\u003ctd data-end=\"6683\" data-start=\"6664\" data-col-size=\"sm\"\u003eNeutral → mild ↑\u003c\/td\u003e\n\u003ctd data-end=\"6703\" data-start=\"6683\" data-col-size=\"sm\"\u003eNeutral → mild ↑\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6791\" data-start=\"6704\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"6728\" data-start=\"6704\"\u003eEvidence base for VAT\u003c\/td\u003e\n\u003ctd data-end=\"6750\" data-start=\"6728\" data-col-size=\"sm\"\u003eLimited\/exploratory\u003c\/td\u003e\n\u003ctd data-end=\"6764\" data-start=\"6750\" data-col-size=\"sm\"\u003eRobust RCTs\u003c\/td\u003e\n\u003ctd data-end=\"6791\" data-start=\"6764\" data-col-size=\"sm\"\u003eMixed in non-GHD adults\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"6796\" data-start=\"6793\"\u003e\n\u003ch2 data-end=\"6824\" data-start=\"6798\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-end=\"7277\" data-start=\"6826\"\u003e\n\u003cli data-end=\"6978\" data-start=\"6826\"\u003e\n\u003cp data-end=\"6978\" data-start=\"6828\"\u003e\u003cstrong data-end=\"6844\" data-start=\"6828\"\u003eU.S. status:\u003c\/strong\u003e Prior approval \u003cstrong data-end=\"6889\" data-start=\"6860\"\u003efor diagnostic evaluation\u003c\/strong\u003e of pituitary GH reserve (Geref\/Geref Diagnostic); \u003cstrong data-end=\"6975\" data-start=\"6940\"\u003ecommercial product discontinued\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7068\" data-start=\"6979\"\u003e\n\u003cp data-end=\"7068\" data-start=\"6981\"\u003e\u003cstrong data-end=\"7005\" data-start=\"6981\"\u003eTreatment approvals:\u003c\/strong\u003e \u003cstrong data-end=\"7014\" data-start=\"7006\"\u003eNone\u003c\/strong\u003e for chronic therapy of GHD, obesity, or anti-aging.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7277\" data-start=\"7069\"\u003e\n\u003cp data-end=\"7277\" data-start=\"7071\"\u003e\u003cstrong data-end=\"7084\" data-start=\"7071\"\u003eGuidance:\u003c\/strong\u003e Professional societies recommend \u003cstrong data-end=\"7132\" data-start=\"7118\"\u003esomatropin\u003c\/strong\u003e for confirmed GHD; \u003cstrong data-end=\"7167\" data-start=\"7152\"\u003etesamorelin\u003c\/strong\u003e for \u003cstrong data-end=\"7204\" data-start=\"7172\"\u003eHIV-associated lipodystrophy\u003c\/strong\u003e. Compounded sermorelin products lack FDA evaluation for safety\/efficacy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"7282\" data-start=\"7279\"\u003e\n\u003ch2 data-end=\"7307\" data-start=\"7284\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-end=\"7757\" data-start=\"7309\"\u003e\n\u003cli data-end=\"7423\" data-start=\"7309\"\u003e\n\u003cp data-end=\"7423\" data-start=\"7311\"\u003e\u003cstrong data-end=\"7339\" data-start=\"7311\"\u003eLong-acting GHRH analogs\u003c\/strong\u003e or \u003cstrong data-end=\"7363\" data-start=\"7343\"\u003edelivery systems\u003c\/strong\u003e (e.g., depot\/intranasal) to overcome the short half-life.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7528\" data-start=\"7424\"\u003e\n\u003cp data-end=\"7528\" data-start=\"7426\"\u003e\u003cstrong data-end=\"7449\" data-start=\"7426\"\u003eHead-to-head trials\u003c\/strong\u003e versus GH or tesamorelin in \u003cstrong data-end=\"7500\" data-start=\"7478\"\u003esarcopenic obesity\u003c\/strong\u003e and \u003cstrong data-end=\"7514\" data-start=\"7505\"\u003eNAFLD\u003c\/strong\u003e phenotypes.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7665\" data-start=\"7529\"\u003e\n\u003cp data-end=\"7665\" data-start=\"7531\"\u003e\u003cstrong data-end=\"7558\" data-start=\"7531\"\u003eBiomarker-guided dosing\u003c\/strong\u003e using \u003cstrong data-end=\"7578\" data-start=\"7565\"\u003eIGF-1 SDS\u003c\/strong\u003e and \u003cstrong data-end=\"7606\" data-start=\"7583\"\u003esleep metrics (SWS)\u003c\/strong\u003e to personalize benefit while minimizing glycaemic drift.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"7757\" data-start=\"7666\"\u003e\n\u003cp data-end=\"7757\" data-start=\"7668\"\u003e\u003cstrong data-end=\"7694\" data-start=\"7668\"\u003eNeurocognitive studies\u003c\/strong\u003e in aging\/MCI cohorts to test class effects on memory networks.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"7762\" data-start=\"7759\"\u003e\n\u003ch3 data-end=\"7787\" data-start=\"7764\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-end=\"8809\" data-start=\"7789\"\u003e\n\u003cli data-end=\"7903\" data-start=\"7789\"\u003e\n\u003cp data-end=\"7903\" data-start=\"7791\"\u003eThorner MO, Merriam GR, et al. \u003cstrong data-end=\"7880\" data-start=\"7822\"\u003ePhysiology and pharmacology of GHRH and secretagogues.\u003c\/strong\u003e \u003cem data-end=\"7900\" data-start=\"7881\"\u003eEndocrine Reviews\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8028\" data-start=\"7904\"\u003e\n\u003cp data-end=\"8028\" data-start=\"7906\"\u003eGeref®\/\u003cstrong data-end=\"7934\" data-start=\"7913\"\u003eGeref Diagnostic®\u003c\/strong\u003e U.S. Prescribing Information (archival): \u003cstrong data-end=\"8025\" data-start=\"7976\"\u003eSermorelin acetate for GH stimulation testing\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8140\" data-start=\"8029\"\u003e\n\u003cp data-end=\"8140\" data-start=\"8031\"\u003eHo KY, et al. \u003cstrong data-end=\"8130\" data-start=\"8045\"\u003eGH pulse generation by GHRH in adults; feedback regulation by somatostatin\/IGF-1.\u003c\/strong\u003e \u003cem data-end=\"8137\" data-start=\"8131\"\u003eJCEM\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8255\" data-start=\"8141\"\u003e\n\u003cp data-end=\"8255\" data-start=\"8143\"\u003eVan Cauter E, Born J. \u003cstrong data-end=\"8222\" data-start=\"8165\"\u003eGHRH, slow-wave sleep, and GH secretion across aging.\u003c\/strong\u003e \u003cem data-end=\"8230\" data-start=\"8223\"\u003eSleep\u003c\/em\u003e; \u003cem data-end=\"8252\" data-start=\"8232\"\u003eNeuroendocrinology\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8374\" data-start=\"8256\"\u003e\n\u003cp data-end=\"8374\" data-start=\"8258\"\u003eBaker LD, et al. \u003cstrong data-end=\"8342\" data-start=\"8275\"\u003eGHRH analog improves cognition in healthy older adults and MCI.\u003c\/strong\u003e \u003cem data-end=\"8356\" data-start=\"8343\"\u003eArch Neurol\u003c\/em\u003e; \u003cem data-end=\"8371\" data-start=\"8358\"\u003eJAMA Neurol\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8472\" data-start=\"8375\"\u003e\n\u003cp data-end=\"8472\" data-start=\"8377\"\u003eRudman D, et al. \u003cstrong data-end=\"8456\" data-start=\"8394\"\u003eBody-composition responses to GH-axis modulation in aging.\u003c\/strong\u003e \u003cem data-end=\"8469\" data-start=\"8457\"\u003eMetabolism\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8582\" data-start=\"8473\"\u003e\n\u003cp data-end=\"8582\" data-start=\"8475\"\u003eGiustina A, et al. \u003cstrong data-end=\"8543\" data-start=\"8494\"\u003eGuidelines for adult GHD diagnosis\/treatment.\u003c\/strong\u003e \u003cem data-end=\"8579\" data-start=\"8544\"\u003eEuropean Journal of Endocrinology\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8716\" data-start=\"8583\"\u003e\n\u003cp data-end=\"8716\" data-start=\"8585\"\u003eEngelson ES, Stanley TL, et al. \u003cstrong data-end=\"8672\" data-start=\"8617\"\u003eVAT, lipids, adipokines under GH-axis manipulation.\u003c\/strong\u003e \u003cem data-end=\"8679\" data-start=\"8673\"\u003eJCEM\u003c\/em\u003e; \u003cem data-end=\"8713\" data-start=\"8681\"\u003eJournal of Clinical Lipidology\u003c\/em\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"8809\" data-start=\"8717\"\u003e\n\u003cp data-end=\"8809\" data-start=\"8719\"\u003ePediatric Endocrine Society statements on \u003cstrong data-end=\"8784\" data-start=\"8761\"\u003estimulation testing\u003c\/strong\u003e and \u003cstrong data-end=\"8808\" data-start=\"8789\"\u003etransition care\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684855509330,"sku":null,"price":60.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/Sermorelin_10mg.png?v=1770834876"},{"product_id":"aod9604-5mg-vial","title":"AOD9604 5mg vial","description":"\u003cp data-start=\"318\" data-end=\"800\" class=\"\"\u003e\u003cstrong data-start=\"318\" data-end=\"329\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                            \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"318\" data-end=\"800\" class=\"\"\u003e\u003cstrong data-start=\"318\" data-end=\"329\"\u003eAOD9604\u003c\/strong\u003e is a synthetic peptide fragment derived from the C-terminal region (amino acids 177–191) of human growth hormone (hGH), with an additional N-terminal tyrosine residue. Originally developed for obesity management, AOD9604 aims to replicate the lipolytic (fat-reducing) effects of hGH without its associated anabolic (growth-promoting) actions. Despite initial promise, its clinical development has faced challenges, and it remains unapproved by major regulatory agencies.\u003c\/p\u003e\n\u003chr data-start=\"802\" data-end=\"805\" class=\"\"\u003e\n\u003ch2 data-start=\"807\" data-end=\"836\" class=\"\"\u003e\u003cstrong data-start=\"810\" data-end=\"836\"\u003e2. Mechanism of Action\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp data-start=\"838\" data-end=\"994\" class=\"\"\u003eAOD9604 is designed to stimulate lipolysis and inhibit lipogenesis, thereby promoting fat breakdown and preventing fat accumulation. Its mechanisms include:\u003c\/p\u003e\n\u003cul data-start=\"996\" data-end=\"1683\"\u003e\n\u003cli data-start=\"996\" data-end=\"1402\" class=\"\"\u003e\n\u003cp data-start=\"998\" data-end=\"1402\" class=\"\"\u003e\u003cstrong data-start=\"998\" data-end=\"1039\"\u003eActivation of β3-Adrenergic Receptors\u003c\/strong\u003e: AOD9604 appears to enhance lipolysis by upregulating β3-adrenergic receptors in adipose tissue. Studies in obese mice have shown that AOD9604 increases β3-AR expression, leading to enhanced fat metabolism. However, its lipolytic effects are diminished in β3-AR knockout mice, suggesting a critical role for these receptors .\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1404\" data-end=\"1683\" class=\"\"\u003e\n\u003cp data-start=\"1406\" data-end=\"1683\" class=\"\"\u003e\u003cstrong data-start=\"1406\" data-end=\"1456\"\u003eIndependence from IGF-1 and Glucose Metabolism\u003c\/strong\u003e: Unlike full-length hGH, AOD9604 does not significantly affect insulin-like growth factor 1 (IGF-1) levels or glucose metabolism, reducing the risk of hyperglycemia and insulin resistance .\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"1685\" data-end=\"1688\" class=\"\"\u003e\n\u003ch2 data-start=\"1690\" data-end=\"1717\" class=\"\"\u003e\u003cstrong data-start=\"1693\" data-end=\"1717\"\u003e3. Clinical Efficacy\u003c\/strong\u003e\u003c\/h2\u003e\n\u003ch3 data-start=\"1719\" data-end=\"1751\" class=\"\"\u003e\u003cstrong data-start=\"1723\" data-end=\"1751\"\u003e3.1. Preclinical Studies\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp data-start=\"1753\" data-end=\"1796\" class=\"\"\u003eIn animal models, AOD9604 has demonstrated:\u003c\/p\u003e\n\u003cul data-start=\"1798\" data-end=\"2303\"\u003e\n\u003cli data-start=\"1798\" data-end=\"2078\" class=\"\"\u003e\n\u003cp data-start=\"1800\" data-end=\"2078\" class=\"\"\u003e\u003cstrong data-start=\"1800\" data-end=\"1820\"\u003eWeight Reduction\u003c\/strong\u003e: Obese Zucker rats treated with AOD9604 showed a significant reduction in body weight gain compared to controls. The peptide enhanced lipolytic activity in adipose tissues without adverse effects on insulin sensitivity .\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2080\" data-end=\"2303\" class=\"\"\u003e\n\u003cp data-start=\"2082\" data-end=\"2303\" class=\"\"\u003e\u003cstrong data-start=\"2082\" data-end=\"2109\"\u003eEnhanced Fat Metabolism\u003c\/strong\u003e: Chronic administration in obese mice led to increased expression of β3-AR and improved lipid metabolism, supporting its potential as a fat-reducing agent .\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"2305\" data-end=\"2339\" class=\"\"\u003e\u003cstrong data-start=\"2309\" data-end=\"2339\"\u003e3.2. Human Clinical Trials\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul data-start=\"2341\" data-end=\"2885\"\u003e\n\u003cli data-start=\"2341\" data-end=\"2638\" class=\"\"\u003e\n\u003cp data-start=\"2343\" data-end=\"2638\" class=\"\"\u003e\u003cstrong data-start=\"2343\" data-end=\"2360\"\u003e12-Week Trial\u003c\/strong\u003e: In a randomized, placebo-controlled trial, subjects receiving 1 mg\/day of AOD9604 experienced an average weight loss of 2.6 kg, compared to 0.8 kg in the placebo group. The treatment was well-tolerated with no significant adverse effects .\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2640\" data-end=\"2885\" class=\"\"\u003e\n\u003cp data-start=\"2642\" data-end=\"2885\" class=\"\"\u003e\u003cstrong data-start=\"2642\" data-end=\"2659\"\u003e24-Week Trial\u003c\/strong\u003e: A subsequent larger study involving 536 subjects did not demonstrate significant weight loss compared to placebo, leading to the discontinuation of its development for obesity treatment .\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"2887\" data-end=\"2890\" class=\"\"\u003e\n\u003ch2 data-start=\"2892\" data-end=\"2925\" class=\"\"\u003e\u003cstrong data-start=\"2895\" data-end=\"2925\"\u003e4. Safety and Tolerability\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp data-start=\"2927\" data-end=\"3002\" class=\"\"\u003eAOD9604 has been generally well-tolerated in both animal and human studies:\u003c\/p\u003e\n\u003cul data-start=\"3004\" data-end=\"3486\"\u003e\n\u003cli data-start=\"3004\" data-end=\"3284\" class=\"\"\u003e\n\u003cp data-start=\"3006\" data-end=\"3284\" class=\"\"\u003e\u003cstrong data-start=\"3006\" data-end=\"3037\"\u003eNon-Genotoxic and Non-Toxic\u003c\/strong\u003e: Comprehensive toxicological assessments, including Ames tests and chromosomal aberration assays, revealed no genotoxic or toxic effects. Chronic administration in rats and monkeys showed no adverse outcomes .\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3286\" data-end=\"3486\" class=\"\"\u003e\n\u003cp data-start=\"3288\" data-end=\"3486\" class=\"\"\u003e\u003cstrong data-start=\"3288\" data-end=\"3312\"\u003eMinimal Side Effects\u003c\/strong\u003e: Clinical trials reported minimal side effects, with no significant impact on IGF-1 levels, glucose metabolism, or insulin sensitivity .\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"3488\" data-end=\"3491\" class=\"\"\u003e\n\u003ch2 data-start=\"3493\" data-end=\"3535\" class=\"\"\u003e\u003cstrong data-start=\"3496\" data-end=\"3535\"\u003e5. Additional Therapeutic Potential\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp data-start=\"3537\" data-end=\"3606\" class=\"\"\u003eBeyond weight management, AOD9604 has shown potential in other areas:\u003c\/p\u003e\n\u003cul data-start=\"3608\" data-end=\"4261\"\u003e\n\u003cli data-start=\"3608\" data-end=\"3957\" class=\"\"\u003e\n\u003cp data-start=\"3610\" data-end=\"3957\" class=\"\"\u003e\u003cstrong data-start=\"3610\" data-end=\"3636\"\u003eCartilage Regeneration\u003c\/strong\u003e: In a study involving osteoarthritic rabbits, intra-articular injections of AOD9604, alone or combined with hyaluronic acid, led to improved cartilage morphology and reduced histopathological damage. This suggests potential applications in joint repair and osteoarthritis treatment .\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3959\" data-end=\"4261\" class=\"\"\u003e\n\u003cp data-start=\"3961\" data-end=\"4261\" class=\"\"\u003e\u003cstrong data-start=\"3961\" data-end=\"3986\"\u003eCellular Regeneration\u003c\/strong\u003e: In vitro studies indicate that AOD9604 may promote the differentiation of mesenchymal stem cells into bone and muscle cells, as well as enhance proteoglycan and collagen production in chondrocytes, supporting tissue repair processes .\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4263\" data-end=\"4266\" class=\"\"\u003e\n\u003ch2 data-start=\"4268\" data-end=\"4312\" class=\"\"\u003e\u003cstrong data-start=\"4271\" data-end=\"4312\"\u003e6. Regulatory Status and Availability\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cul data-start=\"4314\" data-end=\"4844\"\u003e\n\u003cli data-start=\"4314\" data-end=\"4573\" class=\"\"\u003e\n\u003cp data-start=\"4316\" data-end=\"4573\" class=\"\"\u003e\u003cstrong data-start=\"4316\" data-end=\"4339\"\u003eRegulatory Approval\u003c\/strong\u003e: AOD9604 is not approved by the U.S. Food and Drug Administration (FDA) or other major regulatory bodies for any therapeutic use. Its development for obesity treatment was discontinued due to insufficient efficacy in clinical trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4575\" data-end=\"4844\" class=\"\"\u003e\n\u003cp data-start=\"4577\" data-end=\"4844\" class=\"\"\u003e\u003cstrong data-start=\"4577\" data-end=\"4592\"\u003eCurrent Use\u003c\/strong\u003e: Despite the lack of approval, AOD9604 is available through some compounding pharmacies and wellness clinics, often marketed for weight loss and anti-aging purposes. However, its use in these contexts is off-label and lacks robust clinical validation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4846\" data-end=\"4849\" class=\"\"\u003e\n\u003ch2 data-start=\"4851\" data-end=\"4871\" class=\"\"\u003e\u003cstrong data-start=\"4854\" data-end=\"4871\"\u003e7. Conclusion\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp data-start=\"4873\" data-end=\"5471\" class=\"\"\u003eAOD9604 is a synthetic peptide that mimics the fat-reducing effects of hGH without its growth-promoting actions. While preclinical studies and early clinical trials showed promise in weight management and tissue regeneration, subsequent larger trials failed to demonstrate significant efficacy, leading to the cessation of its development for obesity treatment. Its safety profile appears favorable, but the lack of regulatory approval and comprehensive clinical data limits its therapeutic application. Further research is needed to fully elucidate its potential benefits and mechanisms of action.\u003c\/p\u003e\n\u003chr data-start=\"5473\" data-end=\"5476\" class=\"\"\u003e\n\u003cp data-start=\"5478\" data-end=\"5493\" class=\"\"\u003e\u003cstrong data-start=\"5478\" data-end=\"5493\"\u003eReferences:\u003c\/strong\u003e\u003c\/p\u003e\n\u003col data-start=\"5495\" data-end=\"6609\"\u003e\n\u003cli data-start=\"5495\" data-end=\"5749\" class=\"\"\u003e\n\u003cp data-start=\"5498\" data-end=\"5749\" class=\"\"\u003eHeffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. \u003cem data-start=\"5672\" data-end=\"5687\"\u003eEndocrinology\u003c\/em\u003e. 2001;142(12):5182-9.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5751\" data-end=\"5922\" class=\"\"\u003e\n\u003cp data-start=\"5754\" data-end=\"5922\" class=\"\"\u003eNg FM, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. \u003cem data-start=\"5853\" data-end=\"5863\"\u003eHorm Res\u003c\/em\u003e. 2000;53(6):274-8.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5924\" data-end=\"6076\" class=\"\"\u003e\n\u003cp data-start=\"5927\" data-end=\"6076\" class=\"\"\u003eObesity Pharmacotherapy: Current Perspectives and Future Directions. \u003cem data-start=\"5996\" data-end=\"6024\"\u003eFrontiers in Endocrinology\u003c\/em\u003e. 2013;4:73.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6078\" data-end=\"6247\" class=\"\"\u003e\n\u003cp data-start=\"6081\" data-end=\"6247\" class=\"\"\u003eSafety and Tolerability of the Hexadecapeptide AOD9604 in Humans. \u003cem data-start=\"6147\" data-end=\"6188\"\u003eJournal of Endocrinology and Metabolism\u003c\/em\u003e. 2013;3(1-2):7-15.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6249\" data-end=\"6470\" class=\"\"\u003e\n\u003cp data-start=\"6252\" data-end=\"6470\" class=\"\"\u003eEffect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in a Rabbit Model of Osteoarthritis. \u003cem data-start=\"6368\" data-end=\"6409\"\u003eAnnals of Clinical \u0026amp; Laboratory Science\u003c\/em\u003e. 2015;45(4):426-432.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6472\" data-end=\"6609\" class=\"\"\u003e\n\u003cp data-start=\"6475\" data-end=\"6609\" class=\"\"\u003eAOD 9604 Peptide: Research in Lipolysis, Cell Regeneration, and Cancer. \u003cem data-start=\"6547\" data-end=\"6562\"\u003eCore Peptides\u003c\/em\u003e. 2024\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684860064082,"sku":null,"price":30.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/AOD9604_5MG.png?v=1770834904"},{"product_id":"igf1-des-1mg-vial","title":"IGF1-Des 2mg vial","description":"\u003cp data-start=\"481\" data-end=\"953\" class=\"\"\u003e\u003cstrong data-start=\"481\" data-end=\"494\"\u003e\u003cstrong data-end=\"392\" data-start=\"377\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                           \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cspan\u003eF\u003c\/span\u003eOR HUMAN CONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"481\" data-end=\"953\" class=\"\"\u003e\u003cstrong data-start=\"481\" data-end=\"494\"\u003eIGF-1 DES\u003c\/strong\u003e, also known as \u003cstrong data-start=\"510\" data-end=\"528\"\u003eIGF-1 DES(1-3)\u003c\/strong\u003e, is a truncated variant of the naturally occurring peptide hormone \u003cstrong data-start=\"596\" data-end=\"636\"\u003eInsulin-like Growth Factor 1 (IGF-1)\u003c\/strong\u003e. IGF-1 is a critical growth factor that mediates the effects of growth hormone (GH) in tissues, especially muscle, bone, and cartilage. The DES(1-3) form is characterized by the removal of the first three amino acids at the N-terminal, making IGF-1 DES shorter, more potent, and faster-acting than full-length IGF-1.\u003c\/p\u003e\n\u003chr data-start=\"955\" data-end=\"958\" class=\"\"\u003e\n\u003ch2 data-start=\"960\" data-end=\"997\" class=\"\"\u003eChemical and Biological Properties\u003c\/h2\u003e\n\u003cul data-start=\"999\" data-end=\"1415\"\u003e\n\u003cli data-start=\"999\" data-end=\"1030\" class=\"\"\u003e\n\u003cp data-start=\"1001\" data-end=\"1030\" class=\"\"\u003e\u003cstrong data-start=\"1001\" data-end=\"1015\"\u003eFull Name:\u003c\/strong\u003e IGF-1 DES(1-3)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1031\" data-end=\"1135\" class=\"\"\u003e\n\u003cp data-start=\"1033\" data-end=\"1135\" class=\"\"\u003e\u003cstrong data-start=\"1033\" data-end=\"1047\"\u003eStructure:\u003c\/strong\u003e Shortened variant of IGF-1 with the removal of amino acids 1–3 from the N-terminal end.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1136\" data-end=\"1272\" class=\"\"\u003e\n\u003cp data-start=\"1138\" data-end=\"1272\" class=\"\"\u003e\u003cstrong data-start=\"1138\" data-end=\"1165\"\u003eMolecular Modification:\u003c\/strong\u003e Shorter structure increases potency, affinity for IGF-1 receptors, and resistance to IGF-binding proteins.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1273\" data-end=\"1415\" class=\"\"\u003e\n\u003cp data-start=\"1275\" data-end=\"1415\" class=\"\"\u003e\u003cstrong data-start=\"1275\" data-end=\"1301\"\u003eAdministration Routes:\u003c\/strong\u003e Primarily administered via subcutaneous or intramuscular injection due to peptide bioavailability considerations.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"1417\" data-end=\"1420\" class=\"\"\u003e\n\u003ch2 data-start=\"1422\" data-end=\"1444\" class=\"\"\u003eMechanism of Action\u003c\/h2\u003e\n\u003cp data-start=\"1446\" data-end=\"1575\" class=\"\"\u003eIGF-1 DES exhibits enhanced biological activity and rapid action due to key structural differences compared to full-length IGF-1:\u003c\/p\u003e\n\u003ch3 data-start=\"1577\" data-end=\"1623\" class=\"\"\u003e1. Increased Receptor Affinity and Potency\u003c\/h3\u003e\n\u003cul data-start=\"1624\" data-end=\"1755\"\u003e\n\u003cli data-start=\"1624\" data-end=\"1755\" class=\"\"\u003e\n\u003cp data-start=\"1626\" data-end=\"1755\" class=\"\"\u003eGreater affinity and potency at IGF-1 receptors, significantly amplifying its anabolic, anti-catabolic, and regenerative effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"1757\" data-end=\"1807\" class=\"\"\u003e2. Resistance to IGF-Binding Proteins (IGFBPs)\u003c\/h3\u003e\n\u003cul data-start=\"1808\" data-end=\"1943\"\u003e\n\u003cli data-start=\"1808\" data-end=\"1943\" class=\"\"\u003e\n\u003cp data-start=\"1810\" data-end=\"1943\" class=\"\"\u003eReduced binding affinity to IGFBPs, allowing free circulation and immediate bioactivity, leading to rapid cellular uptake and action.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"1945\" data-end=\"1981\" class=\"\"\u003e3. Anabolic and Myogenic Effects\u003c\/h3\u003e\n\u003cul data-start=\"1982\" data-end=\"2144\"\u003e\n\u003cli data-start=\"1982\" data-end=\"2062\" class=\"\"\u003e\n\u003cp data-start=\"1984\" data-end=\"2062\" class=\"\"\u003ePromotes muscle cell proliferation (hyperplasia), differentiation, and growth.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2063\" data-end=\"2144\" class=\"\"\u003e\n\u003cp data-start=\"2065\" data-end=\"2144\" class=\"\"\u003eEnhances satellite cell activation, critical for muscle repair and hypertrophy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"2146\" data-end=\"2178\" class=\"\"\u003e4. Anti-Catabolic Properties\u003c\/h3\u003e\n\u003cul data-start=\"2179\" data-end=\"2283\"\u003e\n\u003cli data-start=\"2179\" data-end=\"2283\" class=\"\"\u003e\n\u003cp data-start=\"2181\" data-end=\"2283\" class=\"\"\u003eProtects muscle tissue from breakdown, especially in conditions of stress, injury, or caloric deficit.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"2285\" data-end=\"2288\" class=\"\"\u003e\n\u003ch2 data-start=\"2290\" data-end=\"2344\" class=\"\"\u003ePotential Therapeutic and Experimental Applications\u003c\/h2\u003e\n\u003cp data-start=\"2346\" data-end=\"2438\" class=\"\"\u003eIGF-1 DES has demonstrated promising results in preclinical research and experimental usage:\u003c\/p\u003e\n\u003ch3 data-start=\"2440\" data-end=\"2490\" class=\"\"\u003e1. Muscle Hypertrophy and Athletic Performance\u003c\/h3\u003e\n\u003cul data-start=\"2491\" data-end=\"2635\"\u003e\n\u003cli data-start=\"2491\" data-end=\"2635\" class=\"\"\u003e\n\u003cp data-start=\"2493\" data-end=\"2635\" class=\"\"\u003eRapid and pronounced muscle growth, improved recovery, and enhanced muscular strength, popular among bodybuilders and athletes experimentally.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"2637\" data-end=\"2669\" class=\"\"\u003e2. Muscle-Wasting Conditions\u003c\/h3\u003e\n\u003cul data-start=\"2670\" data-end=\"2783\"\u003e\n\u003cli data-start=\"2670\" data-end=\"2783\" class=\"\"\u003e\n\u003cp data-start=\"2672\" data-end=\"2783\" class=\"\"\u003ePotential therapeutic use in treating muscle atrophy related to chronic illness, aging (sarcopenia), or injury.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"2785\" data-end=\"2831\" class=\"\"\u003e3. Injury Rehabilitation and Tissue Repair\u003c\/h3\u003e\n\u003cul data-start=\"2832\" data-end=\"2957\"\u003e\n\u003cli data-start=\"2832\" data-end=\"2957\" class=\"\"\u003e\n\u003cp data-start=\"2834\" data-end=\"2957\" class=\"\"\u003eAccelerates healing of muscle, tendon, ligament injuries, and facilitates rapid rehabilitation following trauma or surgery.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"2959\" data-end=\"2995\" class=\"\"\u003e4. Bone Density and Joint Health\u003c\/h3\u003e\n\u003cul data-start=\"2996\" data-end=\"3118\"\u003e\n\u003cli data-start=\"2996\" data-end=\"3118\" class=\"\"\u003e\n\u003cp data-start=\"2998\" data-end=\"3118\" class=\"\"\u003eImproves bone mineral density and may assist in joint healing, potentially beneficial in osteoporosis or joint injuries.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"3120\" data-end=\"3158\" class=\"\"\u003e5. Metabolic Health (Experimental)\u003c\/h3\u003e\n\u003cul data-start=\"3159\" data-end=\"3298\"\u003e\n\u003cli data-start=\"3159\" data-end=\"3298\" class=\"\"\u003e\n\u003cp data-start=\"3161\" data-end=\"3298\" class=\"\"\u003eMay positively impact insulin sensitivity, lipid metabolism, and overall metabolic function, though less explored than traditional IGF-1.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"3300\" data-end=\"3303\" class=\"\"\u003e\n\u003ch2 data-start=\"3305\" data-end=\"3356\" class=\"\"\u003eDosage and Administration (Experimental Context)\u003c\/h2\u003e\n\u003cp data-start=\"3358\" data-end=\"3549\" class=\"\"\u003eNo standardized clinical dosage guidelines currently exist due to the experimental nature of IGF-1 DES. Typical experimental protocols based on anecdotal reports and limited research include:\u003c\/p\u003e\n\u003cul data-start=\"3551\" data-end=\"3932\"\u003e\n\u003cli data-start=\"3551\" data-end=\"3641\" class=\"\"\u003e\n\u003cp data-start=\"3553\" data-end=\"3641\" class=\"\"\u003e\u003cstrong data-start=\"3553\" data-end=\"3570\"\u003eDosage Range:\u003c\/strong\u003e 20–50 mcg per administration (common experimental dosage: ~25–50 mcg).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3642\" data-end=\"3771\" class=\"\"\u003e\n\u003cp data-start=\"3644\" data-end=\"3771\" class=\"\"\u003e\u003cstrong data-start=\"3644\" data-end=\"3654\"\u003eRoute:\u003c\/strong\u003e Usually intramuscular or subcutaneous injection, immediately before or after exercise to maximize localized effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3772\" data-end=\"3864\" class=\"\"\u003e\n\u003cp data-start=\"3774\" data-end=\"3864\" class=\"\"\u003e\u003cstrong data-start=\"3774\" data-end=\"3788\"\u003eFrequency:\u003c\/strong\u003e Typically dosed 1–2 times per day during training days or recovery periods.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3865\" data-end=\"3932\" class=\"\"\u003e\n\u003cp data-start=\"3867\" data-end=\"3932\" class=\"\"\u003e\u003cstrong data-start=\"3867\" data-end=\"3884\"\u003eCycle Length:\u003c\/strong\u003e Commonly 4–6 weeks of use, followed by a break.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"3934\" data-end=\"4044\" class=\"\"\u003e\u003cstrong data-start=\"3934\" data-end=\"3943\"\u003eNote:\u003c\/strong\u003e Above dosages and practices are anecdotal and experimental; rigorous clinical validation is lacking.\u003c\/p\u003e\n\u003chr data-start=\"4046\" data-end=\"4049\" class=\"\"\u003e\n\u003ch2 data-start=\"4051\" data-end=\"4085\" class=\"\"\u003eSafety Profile and Side Effects\u003c\/h2\u003e\n\u003cp data-start=\"4087\" data-end=\"4235\" class=\"\"\u003eWhile IGF-1 DES appears generally well-tolerated in limited experimental contexts, full safety profiles remain unclear due to minimal human studies:\u003c\/p\u003e\n\u003ch3 data-start=\"4237\" data-end=\"4286\" class=\"\"\u003eCommon Side Effects (Mild and Rarely Severe):\u003c\/h3\u003e\n\u003cul data-start=\"4287\" data-end=\"4502\"\u003e\n\u003cli data-start=\"4287\" data-end=\"4343\" class=\"\"\u003e\n\u003cp data-start=\"4289\" data-end=\"4343\" class=\"\"\u003eInjection site redness, irritation, or minor swelling.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4344\" data-end=\"4426\" class=\"\"\u003e\n\u003cp data-start=\"4346\" data-end=\"4426\" class=\"\"\u003eMild headaches or temporary hypoglycemia (due to insulin-like properties; rare).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4427\" data-end=\"4502\" class=\"\"\u003e\n\u003cp data-start=\"4429\" data-end=\"4502\" class=\"\"\u003ePossible water retention or transient joint discomfort at higher dosages.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"4504\" data-end=\"4534\" class=\"\"\u003ePotential Long-term Risks:\u003c\/h3\u003e\n\u003cul data-start=\"4535\" data-end=\"4725\"\u003e\n\u003cli data-start=\"4535\" data-end=\"4649\" class=\"\"\u003e\n\u003cp data-start=\"4537\" data-end=\"4649\" class=\"\"\u003eTheoretical concerns include IGF-1-mediated proliferation of existing tumor cells or altered glucose metabolism.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4650\" data-end=\"4725\" class=\"\"\u003e\n\u003cp data-start=\"4652\" data-end=\"4725\" class=\"\"\u003eLong-term human studies and chronic safety data remain limited or absent.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4727\" data-end=\"4730\" class=\"\"\u003e\n\u003ch2 data-start=\"4732\" data-end=\"4768\" class=\"\"\u003eContraindications and Precautions\u003c\/h2\u003e\n\u003cul data-start=\"4770\" data-end=\"5234\"\u003e\n\u003cli data-start=\"4770\" data-end=\"4947\" class=\"\"\u003e\n\u003cp data-start=\"4772\" data-end=\"4795\" class=\"\"\u003e\u003cstrong data-start=\"4772\" data-end=\"4794\"\u003eContraindications:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"4798\" data-end=\"4947\"\u003e\n\u003cli data-start=\"4798\" data-end=\"4890\" class=\"\"\u003e\n\u003cp data-start=\"4800\" data-end=\"4890\" class=\"\"\u003eActive cancer or pre-existing tumors (due to theoretical risks of promoting tumor growth).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4893\" data-end=\"4947\" class=\"\"\u003e\n\u003cp data-start=\"4895\" data-end=\"4947\" class=\"\"\u003ePregnancy or breastfeeding (unknown safety profile).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4949\" data-end=\"5088\" class=\"\"\u003e\n\u003cp data-start=\"4951\" data-end=\"4974\" class=\"\"\u003e\u003cstrong data-start=\"4951\" data-end=\"4973\"\u003eDrug Interactions:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"4977\" data-end=\"5088\"\u003e\n\u003cli data-start=\"4977\" data-end=\"5088\" class=\"\"\u003e\n\u003cp data-start=\"4979\" data-end=\"5088\" class=\"\"\u003ePotential interactions with insulin or oral hypoglycemic medications (due to insulin-like metabolic effects).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5090\" data-end=\"5234\" class=\"\"\u003e\n\u003cp data-start=\"5092\" data-end=\"5109\" class=\"\"\u003e\u003cstrong data-start=\"5092\" data-end=\"5108\"\u003ePrecautions:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"5112\" data-end=\"5234\"\u003e\n\u003cli data-start=\"5112\" data-end=\"5234\" class=\"\"\u003e\n\u003cp data-start=\"5114\" data-end=\"5234\" class=\"\"\u003eIndividuals with diabetes or impaired glucose tolerance should consult healthcare professionals before experimental use.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"5236\" data-end=\"5239\" class=\"\"\u003e\n\u003ch2 data-start=\"5241\" data-end=\"5271\" class=\"\"\u003eLegal and Regulatory Status\u003c\/h2\u003e\n\u003cul data-start=\"5273\" data-end=\"5599\"\u003e\n\u003cli data-start=\"5273\" data-end=\"5386\" class=\"\"\u003e\n\u003cp data-start=\"5275\" data-end=\"5386\" class=\"\"\u003eIGF-1 DES is \u003cstrong data-start=\"5288\" data-end=\"5304\"\u003enot approved\u003c\/strong\u003e by major regulatory agencies (FDA, EMA, Health Canada) for therapeutic human use.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5387\" data-end=\"5466\" class=\"\"\u003e\n\u003cp data-start=\"5389\" data-end=\"5466\" class=\"\"\u003eTypically marketed as a research peptide labeled \"not for human consumption.\"\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5467\" data-end=\"5599\" class=\"\"\u003e\n\u003cp data-start=\"5469\" data-end=\"5599\" class=\"\"\u003eExplicitly banned by WADA (World Anti-Doping Agency) for competitive athletes due to significant performance-enhancing properties.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"5601\" data-end=\"5604\" class=\"\"\u003e\n\u003ch2 data-start=\"5606\" data-end=\"5645\" class=\"\"\u003eCurrent Research Status and Evidence\u003c\/h2\u003e\n\u003cul data-start=\"5647\" data-end=\"6262\"\u003e\n\u003cli data-start=\"5647\" data-end=\"5817\" class=\"\"\u003e\n\u003cp data-start=\"5649\" data-end=\"5675\" class=\"\"\u003e\u003cstrong data-start=\"5649\" data-end=\"5674\"\u003ePreclinical Research:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"5678\" data-end=\"5817\"\u003e\n\u003cli data-start=\"5678\" data-end=\"5817\" class=\"\"\u003e\n\u003cp data-start=\"5680\" data-end=\"5817\" class=\"\"\u003eExtensive animal studies confirm enhanced potency, muscle-building, tissue regeneration, and recovery effects compared to standard IGF-1.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5819\" data-end=\"6074\" class=\"\"\u003e\n\u003cp data-start=\"5821\" data-end=\"5848\" class=\"\"\u003e\u003cstrong data-start=\"5821\" data-end=\"5847\"\u003eHuman Clinical Trials:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"5851\" data-end=\"6074\"\u003e\n\u003cli data-start=\"5851\" data-end=\"5935\" class=\"\"\u003e\n\u003cp data-start=\"5853\" data-end=\"5935\" class=\"\"\u003eExtremely limited; primarily anecdotal evidence from unregulated experimental use.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5938\" data-end=\"6074\" class=\"\"\u003e\n\u003cp data-start=\"5940\" data-end=\"6074\" class=\"\"\u003eHuman research focusing explicitly on IGF-1 DES remains sparse, and standardized clinical studies are necessary for robust validation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6076\" data-end=\"6262\" class=\"\"\u003e\n\u003cp data-start=\"6078\" data-end=\"6114\" class=\"\"\u003e\u003cstrong data-start=\"6078\" data-end=\"6113\"\u003eLimitations and Research Needs:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"6117\" data-end=\"6262\"\u003e\n\u003cli data-start=\"6117\" data-end=\"6161\" class=\"\"\u003e\n\u003cp data-start=\"6119\" data-end=\"6161\" class=\"\"\u003eLack of controlled human clinical studies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6164\" data-end=\"6262\" class=\"\"\u003e\n\u003cp data-start=\"6166\" data-end=\"6262\" class=\"\"\u003eNeed for established optimal dosing, administration protocols, and long-term safety assessments.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"6264\" data-end=\"6267\" class=\"\"\u003e\n\u003ch2 data-start=\"6269\" data-end=\"6311\" class=\"\"\u003eSummary of Potential Benefits and Risks\u003c\/h2\u003e\n\u003cdiv class=\"group pointer-events-none relative flex justify-center *:pointer-events-auto\"\u003e\n\u003cspan class=\"pointer-events-none absolute start-full top-4 z-10 hidden h-full w-fit ps-2 md:block\" data-state=\"closed\"\u003e\u003cbutton class=\"hover:bg-token-main-surface-secondary text-token-text-secondary pointer-events-auto rounded-lg px-1 py-1 opacity-0 transition-opacity duration-200 group-focus-within:opacity-100 group-hover:opacity-100\"\u003e\u003csvg width=\"24\" height=\"24\" viewbox=\"0 0 24 24\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"icon-md-heavy\"\u003e\u003cpath fill-rule=\"evenodd\" clip-rule=\"evenodd\" d=\"M7 5C7 3.34315 8.34315 2 10 2H19C20.6569 2 22 3.34315 22 5V14C22 15.6569 20.6569 17 19 17H17V19C17 20.6569 15.6569 22 14 22H5C3.34315 22 2 20.6569 2 19V10C2 8.34315 3.34315 7 5 7H7V5ZM9 7H14C15.6569 7 17 8.34315 17 10V15H19C19.5523 15 20 14.5523 20 14V5C20 4.44772 19.5523 4 19 4H10C9.44772 4 9 4.44772 9 5V7ZM5 9C4.44772 9 4 9.44772 4 10V19C4 19.5523 4.44772 20 5 20H14C14.5523 20 15 19.5523 15 19V10C15 9.44772 14.5523 9 14 9H5Z\" fill=\"currentColor\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\u003c\/button\u003e\u003c\/span\u003e\n\u003cdiv class=\"tableContainer horzScrollShadows relative\"\u003e\n\u003ctable class=\"min-w-full\" data-start=\"6313\" data-end=\"6909\"\u003e\n\u003cthead data-start=\"6313\" data-end=\"6411\"\u003e\n\u003ctr data-start=\"6313\" data-end=\"6411\"\u003e\n\u003cth data-start=\"6313\" data-end=\"6356\"\u003e\u003cstrong data-start=\"6315\" data-end=\"6337\"\u003ePotential Benefits\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6356\" data-end=\"6411\"\u003e\u003cstrong data-start=\"6358\" data-end=\"6393\"\u003ePotential Risks and Limitations\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"6512\" data-end=\"6909\"\u003e\n\u003ctr data-start=\"6512\" data-end=\"6610\"\u003e\n\u003ctd class=\"max-w-[calc(var(--thread-content-max-width)*2\/3)]\" data-start=\"6512\" data-end=\"6555\"\u003eEnhanced muscle growth and regeneration\u003c\/td\u003e\n\u003ctd class=\"max-w-[calc(var(--thread-content-max-width)*2\/3)] min-w-[calc(var(--thread-content-max-width)\/3)]\" data-start=\"6555\" data-end=\"6610\"\u003eLimited human clinical safety and efficacy data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6611\" data-end=\"6709\"\u003e\n\u003ctd class=\"max-w-[calc(var(--thread-content-max-width)*2\/3)]\" data-start=\"6611\" data-end=\"6654\"\u003eAccelerated injury recovery\u003c\/td\u003e\n\u003ctd class=\"max-w-[calc(var(--thread-content-max-width)*2\/3)] min-w-[calc(var(--thread-content-max-width)\/3)]\" data-start=\"6654\" data-end=\"6709\"\u003ePossible tumor-promoting effects (theoretical risk)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6710\" data-end=\"6810\"\u003e\n\u003ctd class=\"max-w-[calc(var(--thread-content-max-width)*2\/3)]\" data-start=\"6710\" data-end=\"6753\"\u003eImproved bone density and joint health\u003c\/td\u003e\n\u003ctd class=\"max-w-[calc(var(--thread-content-max-width)*2\/3)] min-w-[calc(var(--thread-content-max-width)\/3)]\" data-start=\"6753\" data-end=\"6810\"\u003ePotential metabolic impacts (e.g., glucose regulation)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6811\" data-end=\"6909\"\u003e\n\u003ctd class=\"max-w-[calc(var(--thread-content-max-width)*2\/3)]\" data-start=\"6811\" data-end=\"6854\"\u003eAnti-catabolic and anabolic properties\u003c\/td\u003e\n\u003ctd class=\"max-w-[calc(var(--thread-content-max-width)*2\/3)]\" data-start=\"6854\" data-end=\"6909\"\u003eRegulatory uncertainty and restrictions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"6911\" data-end=\"6914\" class=\"\"\u003e\n\u003ch2 data-start=\"6916\" data-end=\"6955\" class=\"\"\u003eFuture Directions and Research Needs\u003c\/h2\u003e\n\u003cul data-start=\"6957\" data-end=\"7287\"\u003e\n\u003cli data-start=\"6957\" data-end=\"7050\" class=\"\"\u003e\n\u003cp data-start=\"6959\" data-end=\"7050\" class=\"\"\u003eRigorous human clinical trials to confirm therapeutic efficacy, optimal dosing, and safety.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7051\" data-end=\"7160\" class=\"\"\u003e\n\u003cp data-start=\"7053\" data-end=\"7160\" class=\"\"\u003eLong-term safety studies to address potential risks related to tumor growth, metabolism, and chronic usage.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7161\" data-end=\"7287\" class=\"\"\u003e\n\u003cp data-start=\"7163\" data-end=\"7287\" class=\"\"\u003eExploration of IGF-1 DES’s therapeutic potential in muscle-wasting conditions, injury recovery, and osteoporosis management.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"7289\" data-end=\"7292\" class=\"\"\u003e\n\u003ch2 data-start=\"7294\" data-end=\"7307\" class=\"\"\u003eConclusion\u003c\/h2\u003e\n\u003cp data-start=\"7309\" data-end=\"7807\" class=\"\"\u003eIGF-1 DES is a highly potent, truncated variant of IGF-1 characterized by enhanced bioactivity, resistance to binding proteins, and rapid anabolic and regenerative effects. Although experimental and anecdotal data strongly support its therapeutic promise, significant research gaps, regulatory limitations, and safety concerns remain. Rigorous clinical validation and regulatory approval will be essential before IGF-1 DES can be legitimately recommended for clinical or widespread therapeutic use.\u003c\/p\u003e\n\u003chr data-start=\"7809\" data-end=\"7812\" class=\"\"\u003e\n\u003ch2 data-start=\"7814\" data-end=\"7847\" class=\"\"\u003eReferences \u003c\/h2\u003e\n\u003cul data-start=\"7849\" data-end=\"8334\"\u003e\n\u003cli data-start=\"7849\" data-end=\"7991\" class=\"\"\u003e\n\u003cp data-start=\"7851\" data-end=\"7991\" class=\"\"\u003ePhilippou, A., \u0026amp; Barton, E. R. (2014). \"Optimizing IGF-I for skeletal muscle therapeutics.\" \u003cem data-start=\"7943\" data-end=\"7974\"\u003eGrowth Hormone \u0026amp; IGF Research\u003c\/em\u003e, 24(5), 157–163.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7992\" data-end=\"8217\" class=\"\"\u003e\n\u003cp data-start=\"7994\" data-end=\"8217\" class=\"\"\u003eShavlakadze, T., \u0026amp; Grounds, M. D. (2006). \"Therapeutic interventions for age-related muscle wasting: importance of innervation and exercise for preventing sarcopenia.\" \u003cem data-start=\"8162\" data-end=\"8199\"\u003eJournal of Experimental Gerontology\u003c\/em\u003e, 41(11), 965–981.\u003cbr\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"8341\" data-end=\"8618\" class=\"\"\u003e \u003c\/p\u003e\n\u003cp data-start=\"8341\" data-end=\"8618\" class=\"\"\u003e\u003cstrong data-start=\"8341\" data-end=\"8356\"\u003eDisclaimer:\u003c\/strong\u003e\u003cbr data-start=\"8356\" data-end=\"8359\"\u003eThis review is provided for educational purposes. IGF-1 DES is an experimental research peptide not approved by regulatory authorities for clinical therapeutic use. Always consult healthcare professionals before considering experimental compounds or peptides\u003c\/p\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":52684864520530,"sku":null,"price":90.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/igf_des.png?v=1770834935"},{"product_id":"bac-water-10ml-vial","title":"BAC water 10ml vial","description":"\u003cp data-start=\"105\" data-end=\"486\" class=\"\"\u003e\u003cstrong data-start=\"105\" data-end=\"150\"\u003e\u003cstrong data-start=\"400\" data-end=\"442\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                           \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN CONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"105\" data-end=\"486\" class=\"\"\u003e\u003cstrong data-start=\"105\" data-end=\"150\"\u003eBacteriostatic Water for Injection (BWFI)\u003c\/strong\u003e is a \u003cstrong data-start=\"156\" data-end=\"191\"\u003esterile, non-pyrogenic solution\u003c\/strong\u003e of water that contains \u003cstrong data-start=\"215\" data-end=\"248\"\u003e0.9% benzyl alcohol (9 mg\/mL)\u003c\/strong\u003e as a \u003cstrong data-start=\"254\" data-end=\"270\"\u003epreservative\u003c\/strong\u003e. It is used \u003cstrong data-start=\"283\" data-end=\"334\"\u003eto dilute or dissolve medications for injection\u003c\/strong\u003e and is distinct from sterile water in that it \u003cstrong data-start=\"381\" data-end=\"410\"\u003einhibits bacterial growth\u003c\/strong\u003e, allowing for \u003cstrong data-start=\"425\" data-end=\"461\"\u003emultiple uses from the same vial\u003c\/strong\u003e within a specified time.\u003c\/p\u003e\n\u003chr data-start=\"488\" data-end=\"491\" class=\"\"\u003e\n\u003ch3 data-start=\"493\" data-end=\"515\" class=\"\"\u003e\u003cstrong data-start=\"497\" data-end=\"515\"\u003eKey Components\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul data-start=\"516\" data-end=\"713\"\u003e\n\u003cli data-start=\"516\" data-end=\"608\" class=\"\"\u003e\n\u003cp data-start=\"518\" data-end=\"608\" class=\"\"\u003e\u003cstrong data-start=\"518\" data-end=\"548\"\u003eWater for Injection (WFI):\u003c\/strong\u003e Sterile, purified water that meets pharmacopeial standards.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"609\" data-end=\"713\" class=\"\"\u003e\n\u003cp data-start=\"611\" data-end=\"713\" class=\"\"\u003e\u003cstrong data-start=\"611\" data-end=\"637\"\u003eBenzyl Alcohol (0.9%):\u003c\/strong\u003e A bacteriostatic agent that prevents microbial contamination after opening.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"715\" data-end=\"718\" class=\"\"\u003e\n\u003ch3 data-start=\"720\" data-end=\"740\" class=\"\"\u003e\u003cstrong data-start=\"724\" data-end=\"740\"\u003ePrimary Uses\u003c\/strong\u003e\u003c\/h3\u003e\n\u003ch4 data-start=\"742\" data-end=\"776\" class=\"\"\u003e\u003cstrong data-start=\"747\" data-end=\"776\"\u003e1. Peptide Reconstitution\u003c\/strong\u003e\u003c\/h4\u003e\n\u003cul data-start=\"777\" data-end=\"965\"\u003e\n\u003cli data-start=\"777\" data-end=\"896\" class=\"\"\u003e\n\u003cp data-start=\"779\" data-end=\"896\" class=\"\"\u003eCommonly used to \u003cstrong data-start=\"796\" data-end=\"833\"\u003ereconstitute lyophilized peptides\u003c\/strong\u003e (e.g., BPC-157, GHK-Cu, PT-141) before subcutaneous injection.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"897\" data-end=\"965\" class=\"\"\u003e\n\u003cp data-start=\"899\" data-end=\"965\" class=\"\"\u003ePreserves peptide stability for \u003cstrong data-start=\"931\" data-end=\"948\"\u003eup to 28 days\u003c\/strong\u003e if refrigerated.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 data-start=\"967\" data-end=\"1001\" class=\"\"\u003e\u003cstrong data-start=\"972\" data-end=\"1001\"\u003e2. Injectable Medications\u003c\/strong\u003e\u003c\/h4\u003e\n\u003cul data-start=\"1002\" data-end=\"1106\"\u003e\n\u003cli data-start=\"1002\" data-end=\"1106\" class=\"\"\u003e\n\u003cp data-start=\"1004\" data-end=\"1106\" class=\"\"\u003eUsed to dilute drugs like \u003cstrong data-start=\"1030\" data-end=\"1105\"\u003ehormones (HGH, HCG), antibiotics, or other IV\/IM injectable medications\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4 data-start=\"1108\" data-end=\"1143\" class=\"\"\u003e\u003cstrong data-start=\"1113\" data-end=\"1143\"\u003e3. Multi-dose Applications\u003c\/strong\u003e\u003c\/h4\u003e\n\u003cul data-start=\"1144\" data-end=\"1347\"\u003e\n\u003cli data-start=\"1144\" data-end=\"1347\" class=\"\"\u003e\n\u003cp data-start=\"1146\" data-end=\"1347\" class=\"\"\u003eUnlike sterile water (single-use), bacteriostatic water allows for \u003cstrong data-start=\"1213\" data-end=\"1237\"\u003emultiple withdrawals\u003c\/strong\u003e from the same vial without contamination, making it \u003cstrong data-start=\"1290\" data-end=\"1308\"\u003ecost-effective\u003c\/strong\u003e and \u003cstrong data-start=\"1313\" data-end=\"1326\"\u003epractical\u003c\/strong\u003e for repeated dosing.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"1349\" data-end=\"1352\" class=\"\"\u003e\n\u003ch3 data-start=\"1354\" data-end=\"1393\" class=\"\"\u003e\u003cstrong data-start=\"1358\" data-end=\"1393\"\u003eHow to Use Bacteriostatic Water\u003c\/strong\u003e\u003c\/h3\u003e\n\u003ch4 data-start=\"1395\" data-end=\"1437\" class=\"\"\u003e\u003cstrong data-start=\"1400\" data-end=\"1437\"\u003eReconstituting Peptides (Example)\u003c\/strong\u003e\u003c\/h4\u003e\n\u003col data-start=\"1438\" data-end=\"1795\"\u003e\n\u003cli data-start=\"1438\" data-end=\"1526\" class=\"\"\u003e\n\u003cp data-start=\"1441\" data-end=\"1526\" class=\"\"\u003e\u003cstrong data-start=\"1441\" data-end=\"1463\"\u003ePrepare materials:\u003c\/strong\u003e Alcohol wipes, syringe, vial of peptide, bacteriostatic water.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1527\" data-end=\"1563\" class=\"\"\u003e\n\u003cp data-start=\"1530\" data-end=\"1563\" class=\"\"\u003e\u003cstrong data-start=\"1530\" data-end=\"1549\"\u003eClean vial tops\u003c\/strong\u003e with alcohol.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1564\" data-end=\"1643\" class=\"\"\u003e\n\u003cp data-start=\"1567\" data-end=\"1643\" class=\"\"\u003e\u003cstrong data-start=\"1567\" data-end=\"1590\"\u003eDraw desired amount\u003c\/strong\u003e of bacteriostatic water into a syringe (e.g., 1 mL).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1644\" data-end=\"1738\" class=\"\"\u003e\n\u003cp data-start=\"1647\" data-end=\"1738\" class=\"\"\u003e\u003cstrong data-start=\"1647\" data-end=\"1670\"\u003eInject water slowly\u003c\/strong\u003e into the peptide vial (against the side of the vial to avoid foam).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1739\" data-end=\"1795\" class=\"\"\u003e\n\u003cp data-start=\"1742\" data-end=\"1795\" class=\"\"\u003e\u003cstrong data-start=\"1742\" data-end=\"1758\"\u003eGently swirl\u003c\/strong\u003e until fully dissolved. Do not shake.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch4 data-start=\"1797\" data-end=\"1826\" class=\"\"\u003e\u003cstrong data-start=\"1802\" data-end=\"1826\"\u003eStorage Instructions\u003c\/strong\u003e\u003c\/h4\u003e\n\u003cul data-start=\"1827\" data-end=\"1985\"\u003e\n\u003cli data-start=\"1827\" data-end=\"1904\" class=\"\"\u003e\n\u003cp data-start=\"1829\" data-end=\"1904\" class=\"\"\u003eStore \u003cstrong data-start=\"1835\" data-end=\"1861\"\u003ereconstituted peptides\u003c\/strong\u003e in the \u003cstrong data-start=\"1869\" data-end=\"1903\"\u003erefrigerator (2–8°C \/ 36–46°F)\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1905\" data-end=\"1985\" class=\"\"\u003e\n\u003cp data-start=\"1907\" data-end=\"1985\" class=\"\"\u003eOnce opened, a vial of bacteriostatic water should be used within \u003cstrong data-start=\"1973\" data-end=\"1984\"\u003e28 days\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"1987\" data-end=\"1990\" class=\"\"\u003e\n\u003ch3 data-start=\"1992\" data-end=\"2010\" class=\"\"\u003e\u003cstrong data-start=\"1996\" data-end=\"2010\"\u003eAdvantages\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_16hzy_1\"\u003e\n\u003cdiv class=\"_tableWrapper_16hzy_14 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"2012\" data-end=\"2473\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"2012\" data-end=\"2085\"\u003e\n\u003ctr data-start=\"2012\" data-end=\"2085\"\u003e\n\u003cth data-start=\"2012\" data-end=\"2045\" data-col-size=\"sm\"\u003eFeature\u003c\/th\u003e\n\u003cth data-start=\"2045\" data-end=\"2068\" data-col-size=\"sm\"\u003eBacteriostatic Water\u003c\/th\u003e\n\u003cth data-start=\"2068\" data-end=\"2085\" data-col-size=\"sm\"\u003eSterile Water\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"2159\" data-end=\"2473\"\u003e\n\u003ctr data-start=\"2159\" data-end=\"2231\"\u003e\n\u003ctd data-start=\"2159\" data-end=\"2191\" data-col-size=\"sm\"\u003eContains Preservative\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"2191\" data-end=\"2214\"\u003eYes (benzyl alcohol)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"2214\" data-end=\"2231\"\u003eNo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2232\" data-end=\"2311\"\u003e\n\u003ctd data-start=\"2232\" data-end=\"2264\" data-col-size=\"sm\"\u003eMulti-use (within 28 days)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"2264\" data-end=\"2287\"\u003eYes\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"2287\" data-end=\"2311\"\u003eNo (single use only)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2312\" data-end=\"2386\"\u003e\n\u003ctd data-start=\"2312\" data-end=\"2344\" data-col-size=\"sm\"\u003eShelf Life After Opening\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"2344\" data-end=\"2367\"\u003e~28 days\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"2367\" data-end=\"2386\"\u003eUse immediately\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2387\" data-end=\"2473\"\u003e\n\u003ctd data-start=\"2387\" data-end=\"2419\" data-col-size=\"sm\"\u003eUse in Peptide Reconstitution\u003c\/td\u003e\n\u003ctd data-start=\"2419\" data-end=\"2442\" data-col-size=\"sm\"\u003eIdeal\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"2442\" data-end=\"2473\"\u003eAcceptable for one-time use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cdiv class=\"sticky end-(--thread-content-margin) h-0 self-end select-none\"\u003e\n\u003cdiv class=\"absolute end-0 flex items-end\"\u003e\u003cspan class=\"\" data-state=\"closed\"\u003e\u003cbutton class=\"bg-token-bg-primary hover:bg-token-bg-tertiary text-token-text-secondary my-1 rounded-sm p-1 transition-opacity group-[:not(:hover):not(:focus-within)]:pointer-events-none group-[:not(:hover):not(:focus-within)]:opacity-0\"\u003e\u003csvg width=\"24\" height=\"24\" viewbox=\"0 0 24 24\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"icon-md-heavy\"\u003e\u003cpath fill-rule=\"evenodd\" clip-rule=\"evenodd\" d=\"M7 5C7 3.34315 8.34315 2 10 2H19C20.6569 2 22 3.34315 22 5V14C22 15.6569 20.6569 17 19 17H17V19C17 20.6569 15.6569 22 14 22H5C3.34315 22 2 20.6569 2 19V10C2 8.34315 3.34315 7 5 7H7V5ZM9 7H14C15.6569 7 17 8.34315 17 10V15H19C19.5523 15 20 14.5523 20 14V5C20 4.44772 19.5523 4 19 4H10C9.44772 4 9 4.44772 9 5V7ZM5 9C4.44772 9 4 9.44772 4 10V19C4 19.5523 4.44772 20 5 20H14C14.5523 20 15 19.5523 15 19V10C15 9.44772 14.5523 9 14 9H5Z\" fill=\"currentColor\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\u003c\/button\u003e\u003c\/span\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"2475\" data-end=\"2478\" class=\"\"\u003e\n\u003ch3 data-start=\"2480\" data-end=\"2515\" class=\"\"\u003e\u003cstrong data-start=\"2484\" data-end=\"2515\"\u003eCautions and Considerations\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul data-start=\"2517\" data-end=\"2839\"\u003e\n\u003cli data-start=\"2517\" data-end=\"2617\" class=\"\"\u003e\n\u003cp data-start=\"2519\" data-end=\"2617\" class=\"\"\u003e\u003cstrong data-start=\"2519\" data-end=\"2547\"\u003eNot for use in neonates:\u003c\/strong\u003e Benzyl alcohol is associated with \u003cstrong data-start=\"2582\" data-end=\"2604\"\u003e“gasping syndrome”\u003c\/strong\u003e in newborns.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2618\" data-end=\"2742\" class=\"\"\u003e\n\u003cp data-start=\"2620\" data-end=\"2742\" class=\"\"\u003e\u003cstrong data-start=\"2620\" data-end=\"2655\"\u003eDo not use IV in large volumes:\u003c\/strong\u003e The benzyl alcohol content makes it unsuitable for large-volume intravenous infusions.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2743\" data-end=\"2839\" class=\"\"\u003e\n\u003cp data-start=\"2745\" data-end=\"2839\" class=\"\"\u003e\u003cstrong data-start=\"2745\" data-end=\"2771\"\u003eUse aseptic technique:\u003c\/strong\u003e Always wipe vials and use sterile equipment to avoid contamination.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"2841\" data-end=\"2844\" class=\"\"\u003e\n\u003ch3 data-start=\"2846\" data-end=\"2876\" class=\"\"\u003e\u003cstrong data-start=\"2850\" data-end=\"2876\"\u003eStorage and Shelf Life\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cul data-start=\"2877\" data-end=\"3075\"\u003e\n\u003cli data-start=\"2877\" data-end=\"2970\" class=\"\"\u003e\n\u003cp data-start=\"2879\" data-end=\"2970\" class=\"\"\u003e\u003cstrong data-start=\"2879\" data-end=\"2897\"\u003eUnopened Vial:\u003c\/strong\u003e Typically has a \u003cstrong data-start=\"2914\" data-end=\"2937\"\u003e2–3 year shelf life\u003c\/strong\u003e when stored at room temperature.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2971\" data-end=\"3075\" class=\"\"\u003e\n\u003cp data-start=\"2973\" data-end=\"3075\" class=\"\"\u003e\u003cstrong data-start=\"2973\" data-end=\"2991\"\u003eAfter Opening:\u003c\/strong\u003e Must be used within \u003cstrong data-start=\"3012\" data-end=\"3023\"\u003e28 days\u003c\/strong\u003e due to potential bacterial contamination over time.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":52684866453842,"sku":null,"price":10.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/bac_water.png?v=1770834947"},{"product_id":"ghrp-6-10mg-vial","title":"GHRP-6 10mg vial","description":"\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e\u003cstrong data-end=\"392\" data-start=\"377\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                           \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"text-decoration: underline; color: rgb(255, 42, 0);\"\u003eFOR HUMAN CONSUMPTION\u003cmeta charset=\"UTF-8\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"77\" data-end=\"708\"\u003eGHRP-6 is a hexapeptide \u003cstrong data-start=\"134\" data-end=\"185\"\u003eghrelin\/secretagogue receptor (GHSR-1a) agonist\u003c\/strong\u003e that triggers \u003cstrong data-start=\"200\" data-end=\"241\"\u003epulsatile growth-hormone (GH) release\u003c\/strong\u003e from pituitary somatotrophs via \u003cstrong data-start=\"274\" data-end=\"293\"\u003eGq\/PLC\/IP₃–Ca²⁺\u003c\/strong\u003e signalling. It \u003cstrong data-start=\"309\" data-end=\"333\"\u003esynergizes with GHRH\u003c\/strong\u003e (e.g., sermorelin\/CJC) and is partly \u003cstrong data-start=\"371\" data-end=\"402\"\u003eantagonized by somatostatin\u003c\/strong\u003e. Centrally, it activates \u003cstrong data-start=\"428\" data-end=\"440\"\u003eNPY\/AgRP\u003c\/strong\u003e circuits → \u003cstrong data-start=\"452\" data-end=\"475\"\u003eorexigenic appetite\u003c\/strong\u003e and GI effects. Downstream GH elevates \u003cstrong data-start=\"515\" data-end=\"524\"\u003eIGF-1\u003c\/strong\u003e, supporting anabolism, connective-tissue turnover, and recovery. GHRP-6 is \u003cstrong data-start=\"600\" data-end=\"624\"\u003enot FDA\/EMA-approved\u003c\/strong\u003e; it is a research peptide and \u003cstrong data-start=\"655\" data-end=\"677\"\u003eprohibited by WADA\u003c\/strong\u003e (S2: GH-releasing substances).\u003c\/p\u003e\n\u003chr data-start=\"710\" data-end=\"713\"\u003e\n\u003ch3 data-start=\"715\" data-end=\"772\"\u003eAdditional Benefits of GHRP-6 Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"774\" data-end=\"2957\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"774\" data-end=\"802\"\u003e\n\u003ctr data-start=\"774\" data-end=\"802\"\u003e\n\u003cth data-start=\"774\" data-end=\"784\" data-col-size=\"md\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-start=\"784\" data-end=\"802\" data-col-size=\"xl\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"813\" data-end=\"2957\"\u003e\n\u003ctr data-start=\"813\" data-end=\"1083\"\u003e\n\u003ctd data-start=\"813\" data-end=\"850\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"815\" data-end=\"849\"\u003e1 Robust GH pulse + IGF-1 rise\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"850\" data-end=\"1083\" data-col-size=\"xl\"\u003eReproducible \u003cstrong data-start=\"865\" data-end=\"893\"\u003edose-dependent GH surges\u003c\/strong\u003e with \u003cstrong data-start=\"899\" data-end=\"918\"\u003eIGF-1 increases\u003c\/strong\u003e over weeks; greater peaks when \u003cstrong data-start=\"950\" data-end=\"980\"\u003eco-dosed with GHRH analogs\u003c\/strong\u003e versus either alone. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Journal of Clinical Endocrinology \u0026amp; Metabolism; Endocrine Reviews\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1084\" data-end=\"1335\"\u003e\n\u003ctd data-start=\"1084\" data-end=\"1142\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1086\" data-end=\"1141\"\u003e2 Appetite restoration \u0026amp; weight in catabolic states\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1142\" data-end=\"1335\" data-col-size=\"xl\"\u003e\n\u003cstrong data-start=\"1144\" data-end=\"1172\"\u003eStrong orexigenic effect\u003c\/strong\u003e increases intake\/weight in \u003cstrong data-start=\"1200\" data-end=\"1228\"\u003ecachexia, COPD\/CHF rehab\u003c\/strong\u003e pilots; must balance with glycaemic control. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Clinical Nutrition; Supportive Care in Cancer\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1336\" data-end=\"1566\"\u003e\n\u003ctd data-start=\"1336\" data-end=\"1369\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1338\" data-end=\"1368\"\u003e3 Sleep \u0026amp; recovery signals\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1369\" data-end=\"1566\" data-col-size=\"xl\"\u003eBedtime dosing can \u003cstrong data-start=\"1390\" data-end=\"1423\"\u003eaugment slow-wave sleep (SWS)\u003c\/strong\u003e and nocturnal GH pulsatility, supporting \u003cstrong data-start=\"1465\" data-end=\"1477\"\u003erecovery\u003c\/strong\u003e; effects vary by age and baseline sleep. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Sleep; Psychoneuroendocrinology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1567\" data-end=\"1862\"\u003e\n\u003ctd data-start=\"1567\" data-end=\"1611\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1569\" data-end=\"1610\"\u003e4 Tendon\/ligament \u0026amp; collagen turnover\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1611\" data-end=\"1862\" data-col-size=\"xl\"\u003eGH\/IGF-1–mediated increases in \u003cstrong data-start=\"1644\" data-end=\"1673\"\u003etype-I collagen synthesis\u003c\/strong\u003e and \u003cstrong data-start=\"1678\" data-end=\"1699\"\u003etenocyte activity\u003c\/strong\u003e suggest utility in \u003cstrong data-start=\"1719\" data-end=\"1737\"\u003eoveruse\/repair\u003c\/strong\u003e contexts (preclinical → translational). \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;American Journal of Sports Medicine; Journal of Orthopaedic Research\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1863\" data-end=\"2072\"\u003e\n\u003ctd data-start=\"1863\" data-end=\"1894\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1865\" data-end=\"1893\"\u003e5 Bone-formation markers\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1894\" data-end=\"2072\" data-col-size=\"xl\"\u003eUp-shifts \u003cstrong data-start=\"1906\" data-end=\"1926\"\u003eP1NP\/osteocalcin\u003c\/strong\u003e and improves bone micro-anabolism in hyposecretory states; fracture outcomes untested. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Bone; Journal of Bone and Mineral Research\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2073\" data-end=\"2311\"\u003e\n\u003ctd data-start=\"2073\" data-end=\"2108\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2075\" data-end=\"2107\"\u003e6 Cardiometabolic \u0026amp; vascular\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2108\" data-end=\"2311\" data-col-size=\"xl\"\u003eGhrelin-pathway agonism shows \u003cstrong data-start=\"2140\" data-end=\"2171\"\u003eendothelial and LV function\u003c\/strong\u003e benefits and \u003cstrong data-start=\"2185\" data-end=\"2210\"\u003esympathetic dampening\u003c\/strong\u003e in models of HF\/ischemia; human data are early. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Circulation; Cardiovascular Research\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2312\" data-end=\"2508\"\u003e\n\u003ctd data-start=\"2312\" data-end=\"2355\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2314\" data-end=\"2354\"\u003e7 GI motility and mucosal protection\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2355\" data-end=\"2508\" data-col-size=\"xl\"\u003eImproves \u003cstrong data-start=\"2366\" data-end=\"2386\"\u003egastric emptying\u003c\/strong\u003e, supports \u003cstrong data-start=\"2397\" data-end=\"2421\"\u003eepithelial integrity\u003c\/strong\u003e, and reduces mucosal cytokines in injury models. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Gastroenterology; Gut\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2509\" data-end=\"2752\"\u003e\n\u003ctd data-start=\"2509\" data-end=\"2539\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2511\" data-end=\"2538\"\u003e8 Neuroendocrine \u0026amp; mood\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2539\" data-end=\"2752\" data-col-size=\"xl\"\u003eGhrelin signalling can \u003cstrong data-start=\"2564\" data-end=\"2584\"\u003ereduce anhedonia\u003c\/strong\u003e and support \u003cstrong data-start=\"2597\" data-end=\"2616\"\u003eneuroplasticity\u003c\/strong\u003e; limited pilot data with GHRP-class agents show \u003cstrong data-start=\"2665\" data-end=\"2681\"\u003efatigue\/mood\u003c\/strong\u003e improvements. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Molecular Psychiatry; Neuroendocrinology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2753\" data-end=\"2957\"\u003e\n\u003ctd data-start=\"2753\" data-end=\"2775\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2755\" data-end=\"2774\"\u003e9 Rehab synergy\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2775\" data-end=\"2957\" data-col-size=\"xl\"\u003e\n\u003cstrong data-start=\"2777\" data-end=\"2798\"\u003eAdditive benefits\u003c\/strong\u003e on lean mass\/strength when paired with \u003cstrong data-start=\"2838\" data-end=\"2873\"\u003eprogressive resistance training\u003c\/strong\u003e and adequate protein intake. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Sports Medicine; Journal of Physiology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"2959\" data-end=\"2962\"\u003e\n\u003ch2 data-start=\"2964\" data-end=\"2999\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-start=\"3001\" data-end=\"3036\"\u003e2.1 Receptor Pharmacodynamics\u003c\/h3\u003e\n\u003cul data-start=\"3037\" data-end=\"3441\"\u003e\n\u003cli data-start=\"3037\" data-end=\"3183\"\u003e\n\u003cp data-start=\"3039\" data-end=\"3183\"\u003e\u003cstrong data-start=\"3039\" data-end=\"3058\"\u003ePrimary target:\u003c\/strong\u003e \u003cstrong data-start=\"3059\" data-end=\"3070\"\u003eGHSR-1a\u003c\/strong\u003e (ghrelin receptor) on hypothalamic neurons and pituitary somatotrophs → \u003cstrong data-start=\"3143\" data-end=\"3164\"\u003eGq\/PLC → IP₃\/Ca²⁺\u003c\/strong\u003e → GH exocytosis.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3184\" data-end=\"3320\"\u003e\n\u003cp data-start=\"3186\" data-end=\"3320\"\u003e\u003cstrong data-start=\"3186\" data-end=\"3203\"\u003eAxis biology:\u003c\/strong\u003e \u003cstrong data-start=\"3204\" data-end=\"3228\"\u003eSynergizes with GHRH\u003c\/strong\u003e; \u003cstrong data-start=\"3230\" data-end=\"3257\"\u003eblunted by somatostatin\u003c\/strong\u003e; preserves \u003cstrong data-start=\"3269\" data-end=\"3296\"\u003ephysiologic pulsatility\u003c\/strong\u003e versus continuous GH.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3321\" data-end=\"3441\"\u003e\n\u003cp data-start=\"3323\" data-end=\"3441\"\u003e\u003cstrong data-start=\"3323\" data-end=\"3343\"\u003eCentral effects:\u003c\/strong\u003e Activates \u003cstrong data-start=\"3354\" data-end=\"3366\"\u003eNPY\/AgRP\u003c\/strong\u003e (orexigeny), modulates \u003cstrong data-start=\"3390\" data-end=\"3408\"\u003esleep circuits\u003c\/strong\u003e, and affects \u003cstrong data-start=\"3422\" data-end=\"3440\"\u003eautonomic tone\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"3443\" data-end=\"3470\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"3472\" data-end=\"3960\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"3472\" data-end=\"3514\"\u003e\n\u003ctr data-start=\"3472\" data-end=\"3514\"\u003e\n\u003cth data-start=\"3472\" data-end=\"3482\" data-col-size=\"sm\"\u003ePathway\u003c\/th\u003e\n\u003cth data-start=\"3482\" data-end=\"3503\" data-col-size=\"md\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-start=\"3503\" data-end=\"3514\" data-col-size=\"sm\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"3529\" data-end=\"3960\"\u003e\n\u003ctr data-start=\"3529\" data-end=\"3632\"\u003e\n\u003ctd data-start=\"3529\" data-end=\"3563\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3531\" data-end=\"3562\"\u003eGH → GHR–JAK2–STAT5 → IGF-1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3563\" data-end=\"3606\" data-col-size=\"md\"\u003e↑ Protein synthesis, recovery, lipolysis\u003c\/td\u003e\n\u003ctd data-start=\"3606\" data-end=\"3632\" data-col-size=\"sm\"\u003eMuscle, liver, adipose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3633\" data-end=\"3706\"\u003e\n\u003ctd data-start=\"3633\" data-end=\"3659\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3635\" data-end=\"3658\"\u003eNPY\/AgRP activation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3659\" data-end=\"3687\" data-col-size=\"md\"\u003e↑ Appetite, ↑ GI motility\u003c\/td\u003e\n\u003ctd data-start=\"3687\" data-end=\"3706\" data-col-size=\"sm\"\u003eHypothalamus\/GI\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3707\" data-end=\"3792\"\u003e\n\u003ctd data-start=\"3707\" data-end=\"3737\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3709\" data-end=\"3736\"\u003eCollagen \u0026amp; ECM turnover\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3737\" data-end=\"3767\" data-col-size=\"md\"\u003e↑ Type-I collagen synthesis\u003c\/td\u003e\n\u003ctd data-start=\"3767\" data-end=\"3792\" data-col-size=\"sm\"\u003eTendon\/ligament, skin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3793\" data-end=\"3861\"\u003e\n\u003ctd data-start=\"3793\" data-end=\"3816\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3795\" data-end=\"3815\"\u003eBone remodelling\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3816\" data-end=\"3849\" data-col-size=\"md\"\u003e↑ Formation markers (P1NP\/OCN)\u003c\/td\u003e\n\u003ctd data-start=\"3849\" data-end=\"3861\" data-col-size=\"sm\"\u003eSkeleton\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3862\" data-end=\"3960\"\u003e\n\u003ctd data-start=\"3862\" data-end=\"3891\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"3864\" data-end=\"3890\"\u003eEndothelial signalling\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"3891\" data-end=\"3942\" data-col-size=\"md\"\u003eImproved NO bioavailability, LV support (models)\u003c\/td\u003e\n\u003ctd data-start=\"3942\" data-end=\"3960\" data-col-size=\"sm\"\u003eCardiovascular\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"3962\" data-end=\"3965\"\u003e\n\u003ch2 data-start=\"3967\" data-end=\"3989\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-start=\"3991\" data-end=\"4433\"\u003e\n\u003cli data-start=\"3991\" data-end=\"4044\"\u003e\n\u003cp data-start=\"3993\" data-end=\"4044\"\u003e\u003cstrong data-start=\"3993\" data-end=\"4003\"\u003eRoute:\u003c\/strong\u003e \u003cstrong data-start=\"4004\" data-end=\"4010\"\u003eSC\u003c\/strong\u003e (research\/clinical physiology).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4045\" data-end=\"4134\"\u003e\n\u003cp data-start=\"4047\" data-end=\"4134\"\u003e\u003cstrong data-start=\"4047\" data-end=\"4062\"\u003eOnset\/peak:\u003c\/strong\u003e GH peaks \u003cstrong data-start=\"4072\" data-end=\"4086\"\u003e~20–45 min\u003c\/strong\u003e post-dose; returns to baseline by \u003cstrong data-start=\"4121\" data-end=\"4131\"\u003e~2–3 h\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4135\" data-end=\"4233\"\u003e\n\u003cp data-start=\"4137\" data-end=\"4233\"\u003e\u003cstrong data-start=\"4137\" data-end=\"4151\"\u003eHalf-life:\u003c\/strong\u003e \u003cstrong data-start=\"4152\" data-end=\"4174\"\u003eShort (≈15–30 min)\u003c\/strong\u003e for peptide; biological effects exceed plasma residence.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4234\" data-end=\"4433\"\u003e\n\u003cp data-start=\"4236\" data-end=\"4433\"\u003e\u003cstrong data-start=\"4236\" data-end=\"4258\"\u003eDosing in studies:\u003c\/strong\u003e ~\u003cstrong data-start=\"4260\" data-end=\"4273\"\u003e1–2 µg\/kg\u003c\/strong\u003e SC per pulse; common research use \u003cstrong data-start=\"4308\" data-end=\"4322\"\u003e100–200 µg\u003c\/strong\u003e 1–3×\/day. \u003cstrong data-start=\"4333\" data-end=\"4372\"\u003eCo-administration with GHRH analogs\u003c\/strong\u003e (e.g., \u003cstrong data-start=\"4380\" data-end=\"4410\"\u003eCJC-1295-no-DAC\/sermorelin\u003c\/strong\u003e) potentiates GH\/IGF-1.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4435\" data-end=\"4438\"\u003e\n\u003ch2 data-start=\"4440\" data-end=\"4485\"\u003e4. Pre-clinical and Translational Evidence\u003c\/h2\u003e\n\u003ch3 data-start=\"4487\" data-end=\"4523\"\u003e4.1 GH Axis \u0026amp; Body Composition\u003c\/h3\u003e\n\u003cp data-start=\"4524\" data-end=\"4695\"\u003eRepeated dosing elevates \u003cstrong data-start=\"4549\" data-end=\"4558\"\u003eIGF-1\u003c\/strong\u003e and \u003cstrong data-start=\"4563\" data-end=\"4580\"\u003efat-free mass\u003c\/strong\u003e signals; fat-mass effects depend on \u003cstrong data-start=\"4617\" data-end=\"4635\"\u003edietary intake\u003c\/strong\u003e (orexigeny can offset lipolysis without nutrition control).\u003c\/p\u003e\n\u003ch3 data-start=\"4697\" data-end=\"4729\"\u003e4.2 Musculoskeletal\/Repair\u003c\/h3\u003e\n\u003cp data-start=\"4730\" data-end=\"4916\"\u003eAnimal and human physiology show \u003cstrong data-start=\"4763\" data-end=\"4785\"\u003ecollagen synthesis\u003c\/strong\u003e up-regulation and improved \u003cstrong data-start=\"4813\" data-end=\"4830\"\u003etendon matrix\u003c\/strong\u003e organisation with GH\/IGF-1 signalling; targeted trials with GHRP-6 are still limited.\u003c\/p\u003e\n\u003ch3 data-start=\"4918\" data-end=\"4943\"\u003e4.3 Cardiometabolic\u003c\/h3\u003e\n\u003cp data-start=\"4944\" data-end=\"5111\"\u003eGhrelin-mimetic actions may \u003cstrong data-start=\"4972\" data-end=\"5004\"\u003eimprove endothelial function\u003c\/strong\u003e and \u003cstrong data-start=\"5009\" data-end=\"5027\"\u003eLV performance\u003c\/strong\u003e in HF\/ischemia models; confirmatory human data for GHRP-6 specifically are pending.\u003c\/p\u003e\n\u003cblockquote data-start=\"5113\" data-end=\"5312\"\u003e\n\u003cp data-start=\"5115\" data-end=\"5312\"\u003e\u003cstrong data-start=\"5115\" data-end=\"5141\"\u003eEvidence quality note:\u003c\/strong\u003e Strong \u003cstrong data-start=\"5149\" data-end=\"5163\"\u003ephysiology\u003c\/strong\u003e and \u003cstrong data-start=\"5168\" data-end=\"5183\"\u003eclass-level\u003c\/strong\u003e data for GH pulsatility and orexigeny; \u003cstrong data-start=\"5223\" data-end=\"5261\"\u003especific randomized human outcomes\u003c\/strong\u003e with GHRP-6 are limited. Extrapolate with caution.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-start=\"5314\" data-end=\"5317\"\u003e\n\u003ch2 data-start=\"5319\" data-end=\"5352\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"5354\" data-end=\"5950\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"5354\" data-end=\"5392\"\u003e\n\u003ctr data-start=\"5354\" data-end=\"5392\"\u003e\n\u003cth data-start=\"5354\" data-end=\"5362\" data-col-size=\"sm\"\u003eField\u003c\/th\u003e\n\u003cth data-start=\"5362\" data-end=\"5374\" data-col-size=\"md\"\u003eRationale\u003c\/th\u003e\n\u003cth data-start=\"5374\" data-end=\"5392\" data-col-size=\"sm\"\u003eCurrent status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"5407\" data-end=\"5950\"\u003e\n\u003ctr data-start=\"5407\" data-end=\"5490\"\u003e\n\u003ctd data-start=\"5407\" data-end=\"5432\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5409\" data-end=\"5431\"\u003eSarcopenia\/frailty\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5432\" data-end=\"5467\" data-col-size=\"md\"\u003eOral intake ↑ + GH\/IGF-1 support\u003c\/td\u003e\n\u003ctd data-start=\"5467\" data-end=\"5490\" data-col-size=\"sm\"\u003eEarly translational\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5491\" data-end=\"5575\"\u003e\n\u003ctd data-start=\"5491\" data-end=\"5512\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5493\" data-end=\"5511\"\u003eCachexia\/rehab\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5512\" data-end=\"5557\" data-col-size=\"md\"\u003eAppetite + anabolism for weight\/FFM regain\u003c\/td\u003e\n\u003ctd data-start=\"5557\" data-end=\"5575\" data-col-size=\"sm\"\u003ePilot concepts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5576\" data-end=\"5655\"\u003e\n\u003ctd data-start=\"5576\" data-end=\"5605\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5578\" data-end=\"5604\"\u003eTendon\/ligament repair\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5605\" data-end=\"5626\" data-col-size=\"md\"\u003eCollagen anabolism\u003c\/td\u003e\n\u003ctd data-start=\"5626\" data-end=\"5655\" data-col-size=\"sm\"\u003ePreclinical → feasibility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5656\" data-end=\"5721\"\u003e\n\u003ctd data-start=\"5656\" data-end=\"5684\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5658\" data-end=\"5683\"\u003eBone health (adjunct)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5684\" data-end=\"5706\" data-col-size=\"md\"\u003eFormation markers ↑\u003c\/td\u003e\n\u003ctd data-start=\"5706\" data-end=\"5721\" data-col-size=\"sm\"\u003eExploratory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5722\" data-end=\"5783\"\u003e\n\u003ctd data-start=\"5722\" data-end=\"5747\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5724\" data-end=\"5746\"\u003eSleep\/SWS deficits\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5747\" data-end=\"5769\" data-col-size=\"md\"\u003eNocturnal GH pulses\u003c\/td\u003e\n\u003ctd data-start=\"5769\" data-end=\"5783\" data-col-size=\"sm\"\u003ePoC needed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5784\" data-end=\"5868\"\u003e\n\u003ctd data-start=\"5784\" data-end=\"5802\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5786\" data-end=\"5801\"\u003eHF\/ischemia\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5802\" data-end=\"5830\" data-col-size=\"md\"\u003eEndothelial\/LV signalling\u003c\/td\u003e\n\u003ctd data-start=\"5830\" data-end=\"5868\" data-col-size=\"sm\"\u003ePreclinical\/early human physiology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5869\" data-end=\"5950\"\u003e\n\u003ctd data-start=\"5869\" data-end=\"5897\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5871\" data-end=\"5896\"\u003eGI motility\/mucositis\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5897\" data-end=\"5935\" data-col-size=\"md\"\u003ePro-motility, epithelial protection\u003c\/td\u003e\n\u003ctd data-start=\"5935\" data-end=\"5950\" data-col-size=\"sm\"\u003ePreclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"5952\" data-end=\"5955\"\u003e\n\u003ch2 data-start=\"5957\" data-end=\"5986\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-start=\"5988\" data-end=\"6935\"\u003e\n\u003cli data-start=\"5988\" data-end=\"6200\"\u003e\n\u003cp data-start=\"5990\" data-end=\"6200\"\u003e\u003cstrong data-start=\"5990\" data-end=\"6001\"\u003eCommon:\u003c\/strong\u003e \u003cstrong data-start=\"6002\" data-end=\"6019\"\u003eMarked hunger\u003c\/strong\u003e, \u003cstrong data-start=\"6021\" data-end=\"6040\"\u003eflushing\/warmth\u003c\/strong\u003e, \u003cstrong data-start=\"6042\" data-end=\"6071\"\u003etransient lightheadedness\u003c\/strong\u003e, \u003cstrong data-start=\"6073\" data-end=\"6093\"\u003eperipheral edema\u003c\/strong\u003e, \u003cstrong data-start=\"6095\" data-end=\"6130\"\u003ecarpal-tunnel-like paresthesias\u003c\/strong\u003e, \u003cstrong data-start=\"6132\" data-end=\"6144\"\u003eheadache\u003c\/strong\u003e, \u003cstrong data-start=\"6146\" data-end=\"6175\"\u003einjection-site irritation\u003c\/strong\u003e, \u003cstrong data-start=\"6177\" data-end=\"6197\"\u003ereflux\/heartburn\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6201\" data-end=\"6321\"\u003e\n\u003cp data-start=\"6203\" data-end=\"6321\"\u003e\u003cstrong data-start=\"6203\" data-end=\"6217\"\u003eEndocrine:\u003c\/strong\u003e \u003cstrong data-start=\"6218\" data-end=\"6244\"\u003eProlactin and cortisol\u003c\/strong\u003e can rise \u003cstrong data-start=\"6254\" data-end=\"6265\"\u003eacutely\u003c\/strong\u003e; \u003cstrong data-start=\"6267\" data-end=\"6286\"\u003eIGF-1 elevation\u003c\/strong\u003e depends on frequency\/co-therapy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6322\" data-end=\"6456\"\u003e\n\u003cp data-start=\"6324\" data-end=\"6456\"\u003e\u003cstrong data-start=\"6324\" data-end=\"6338\"\u003eMetabolic:\u003c\/strong\u003e Ghrelin-like signalling may \u003cstrong data-start=\"6367\" data-end=\"6400\"\u003eraise fasting glucose\/insulin\u003c\/strong\u003e; manage diet and monitor in \u003cstrong data-start=\"6429\" data-end=\"6453\"\u003eprediabetes\/diabetes\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6457\" data-end=\"6537\"\u003e\n\u003cp data-start=\"6459\" data-end=\"6537\"\u003e\u003cstrong data-start=\"6459\" data-end=\"6472\"\u003eCV\/Renal:\u003c\/strong\u003e Sodium\/water retention → \u003cstrong data-start=\"6498\" data-end=\"6510\"\u003eBP drift\u003c\/strong\u003e in susceptible patients.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6538\" data-end=\"6613\"\u003e\n\u003cp data-start=\"6540\" data-end=\"6613\"\u003e\u003cstrong data-start=\"6540\" data-end=\"6555\"\u003eNeuropsych:\u003c\/strong\u003e Vivid dreams\/insomnia in a minority (timing dependent).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6614\" data-end=\"6756\"\u003e\n\u003cp data-start=\"6616\" data-end=\"6756\"\u003e\u003cstrong data-start=\"6616\" data-end=\"6646\"\u003eContraindications\/Caution:\u003c\/strong\u003e \u003cstrong data-start=\"6647\" data-end=\"6668\"\u003eActive malignancy\u003c\/strong\u003e, \u003cstrong data-start=\"6670\" data-end=\"6699\"\u003eproliferative retinopathy\u003c\/strong\u003e, \u003cstrong data-start=\"6701\" data-end=\"6726\"\u003euncontrolled diabetes\u003c\/strong\u003e, \u003cstrong data-start=\"6728\" data-end=\"6742\"\u003esevere OSA\u003c\/strong\u003e, pregnancy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6757\" data-end=\"6935\"\u003e\n\u003cp data-start=\"6759\" data-end=\"6935\"\u003e\u003cstrong data-start=\"6759\" data-end=\"6781\"\u003eDrug interactions:\u003c\/strong\u003e Additive effects with \u003cstrong data-start=\"6804\" data-end=\"6830\"\u003eother GH secretagogues\u003c\/strong\u003e; theoretical interactions with \u003cstrong data-start=\"6862\" data-end=\"6884\"\u003edopamine\/prolactin\u003c\/strong\u003e modulators and \u003cstrong data-start=\"6900\" data-end=\"6921\"\u003eacid-suppressants\u003c\/strong\u003e (for reflux).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"6937\" data-end=\"6966\"\u003e\u003cstrong data-start=\"6937\" data-end=\"6966\"\u003eComparative safety matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"6968\" data-end=\"7594\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"6968\" data-end=\"7054\"\u003e\n\u003ctr data-start=\"6968\" data-end=\"7054\"\u003e\n\u003cth data-start=\"6968\" data-end=\"6978\" data-col-size=\"sm\"\u003eFeature\u003c\/th\u003e\n\u003cth data-start=\"6978\" data-end=\"6991\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6980\" data-end=\"6990\"\u003eGHRP-6\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6991\" data-end=\"7004\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6993\" data-end=\"7003\"\u003eGHRP-2\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"7004\" data-end=\"7020\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7006\" data-end=\"7019\"\u003eHexarelin\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"7020\" data-end=\"7054\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7022\" data-end=\"7052\"\u003eMK-677 (oral GHSR agonist)\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"7077\" data-end=\"7594\"\u003e\n\u003ctr data-start=\"7077\" data-end=\"7148\"\u003e\n\u003ctd data-start=\"7077\" data-end=\"7094\" data-col-size=\"sm\"\u003eAppetite drive\u003c\/td\u003e\n\u003ctd data-start=\"7094\" data-end=\"7105\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7096\" data-end=\"7104\"\u003eHigh\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7105\" data-end=\"7116\" data-col-size=\"sm\"\u003eModerate\u003c\/td\u003e\n\u003ctd data-start=\"7116\" data-end=\"7131\" data-col-size=\"sm\"\u003eLow–moderate\u003c\/td\u003e\n\u003ctd data-start=\"7131\" data-end=\"7148\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7133\" data-end=\"7146\"\u003eVery high\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7149\" data-end=\"7285\"\u003e\n\u003ctd data-start=\"7149\" data-end=\"7177\" data-col-size=\"sm\"\u003eGH\/IGF-1 rise (per pulse)\u003c\/td\u003e\n\u003ctd data-start=\"7177\" data-end=\"7201\" data-col-size=\"sm\"\u003eHigh; \u003cstrong data-start=\"7185\" data-end=\"7200\"\u003e↑ with GHRH\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd data-start=\"7201\" data-end=\"7233\" data-col-size=\"sm\"\u003eHigh; slightly less orexigeny\u003c\/td\u003e\n\u003ctd data-start=\"7233\" data-end=\"7264\" data-col-size=\"sm\"\u003eHigh; stronger \u003cstrong data-start=\"7250\" data-end=\"7263\"\u003ePRL\/Cort↑\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd data-start=\"7264\" data-end=\"7285\" data-col-size=\"sm\"\u003eSustained daily ↑\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7286\" data-end=\"7357\"\u003e\n\u003ctd data-start=\"7286\" data-end=\"7303\" data-col-size=\"sm\"\u003eEdema\/CTS-like\u003c\/td\u003e\n\u003ctd data-start=\"7303\" data-end=\"7314\" data-col-size=\"sm\"\u003eModerate\u003c\/td\u003e\n\u003ctd data-start=\"7314\" data-end=\"7325\" data-col-size=\"sm\"\u003eModerate\u003c\/td\u003e\n\u003ctd data-start=\"7325\" data-end=\"7336\" data-col-size=\"sm\"\u003eModerate\u003c\/td\u003e\n\u003ctd data-start=\"7336\" data-end=\"7357\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7338\" data-end=\"7355\"\u003eModerate–high\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7358\" data-end=\"7429\"\u003e\n\u003ctd data-start=\"7358\" data-end=\"7379\" data-col-size=\"sm\"\u003eProlactin\/Cortisol\u003c\/td\u003e\n\u003ctd data-start=\"7379\" data-end=\"7395\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7381\" data-end=\"7394\"\u003e↑ (acute)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7395\" data-end=\"7410\" data-col-size=\"sm\"\u003e↑ (moderate)\u003c\/td\u003e\n\u003ctd data-start=\"7410\" data-end=\"7419\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7412\" data-end=\"7418\"\u003e↑↑\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7419\" data-end=\"7429\" data-col-size=\"sm\"\u003eMild ↑\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7430\" data-end=\"7517\"\u003e\n\u003ctd data-start=\"7430\" data-end=\"7441\" data-col-size=\"sm\"\u003eRoute\/PK\u003c\/td\u003e\n\u003ctd data-start=\"7441\" data-end=\"7465\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7443\" data-end=\"7464\"\u003eSC; t½ ~15–30 min\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7465\" data-end=\"7480\" data-col-size=\"sm\"\u003eSC; short t½\u003c\/td\u003e\n\u003ctd data-start=\"7480\" data-end=\"7495\" data-col-size=\"sm\"\u003eSC; short t½\u003c\/td\u003e\n\u003ctd data-start=\"7495\" data-end=\"7517\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7497\" data-end=\"7515\"\u003eOral; t½ 4–6 h\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7518\" data-end=\"7594\"\u003e\n\u003ctd data-start=\"7518\" data-end=\"7532\" data-col-size=\"sm\"\u003eGI symptoms\u003c\/td\u003e\n\u003ctd data-start=\"7532\" data-end=\"7558\" data-col-size=\"sm\"\u003eReflux\/GERD more common\u003c\/td\u003e\n\u003ctd data-start=\"7558\" data-end=\"7568\" data-col-size=\"sm\"\u003eSimilar\u003c\/td\u003e\n\u003ctd data-start=\"7568\" data-end=\"7578\" data-col-size=\"sm\"\u003eSimilar\u003c\/td\u003e\n\u003ctd data-start=\"7578\" data-end=\"7594\" data-col-size=\"sm\"\u003eNausea, GERD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"7596\" data-end=\"7599\"\u003e\n\u003ch2 data-start=\"7601\" data-end=\"7627\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-start=\"7629\" data-end=\"7844\"\u003e\n\u003cli data-start=\"7629\" data-end=\"7672\"\u003e\n\u003cp data-start=\"7631\" data-end=\"7672\"\u003e\u003cstrong data-start=\"7631\" data-end=\"7645\"\u003eApprovals:\u003c\/strong\u003e None for any indication.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7673\" data-end=\"7738\"\u003e\n\u003cp data-start=\"7675\" data-end=\"7738\"\u003e\u003cstrong data-start=\"7675\" data-end=\"7685\"\u003eSport:\u003c\/strong\u003e \u003cstrong data-start=\"7686\" data-end=\"7705\"\u003eWADA-prohibited\u003c\/strong\u003e (S2, GH-releasing substances).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7739\" data-end=\"7844\"\u003e\n\u003cp data-start=\"7741\" data-end=\"7844\"\u003e\u003cstrong data-start=\"7741\" data-end=\"7760\"\u003eSupply quality:\u003c\/strong\u003e Research-chemical products vary; ensure \u003cstrong data-start=\"7801\" data-end=\"7814\"\u003eGMP-grade\u003c\/strong\u003e material in any formal study.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"7846\" data-end=\"7849\"\u003e\n\u003ch2 data-start=\"7851\" data-end=\"7874\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-start=\"7876\" data-end=\"8670\"\u003e\n\u003cli data-start=\"7876\" data-end=\"7991\"\u003e\n\u003cp data-start=\"7878\" data-end=\"7991\"\u003e\u003cstrong data-start=\"7878\" data-end=\"7901\"\u003eChronopharmacology:\u003c\/strong\u003e Optimize \u003cstrong data-start=\"7911\" data-end=\"7938\"\u003ebedtime vs pre-training\u003c\/strong\u003e pulses for SWS and recovery while managing reflux.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7992\" data-end=\"8200\"\u003e\n\u003cp data-start=\"7994\" data-end=\"8200\"\u003e\u003cstrong data-start=\"7994\" data-end=\"8018\"\u003eCombination therapy:\u003c\/strong\u003e Pair \u003cstrong data-start=\"8024\" data-end=\"8049\"\u003eGHRP-6 + GHRH analogs\u003c\/strong\u003e to lower dose burden and enhance \u003cstrong data-start=\"8083\" data-end=\"8110\"\u003ephysiologic pulsatility\u003c\/strong\u003e; consider \u003cstrong data-start=\"8121\" data-end=\"8134\"\u003eGLP-1\/GIP\u003c\/strong\u003e co-therapy to temper orexigeny in weight-sensitive populations.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8201\" data-end=\"8415\"\u003e\n\u003cp data-start=\"8203\" data-end=\"8415\"\u003e\u003cstrong data-start=\"8203\" data-end=\"8233\"\u003eIndication-focused trials:\u003c\/strong\u003e \u003cstrong data-start=\"8234\" data-end=\"8254\"\u003eSarcopenia\/rehab\u003c\/strong\u003e (DXA, stair-climb power), \u003cstrong data-start=\"8281\" data-end=\"8299\"\u003etendon healing\u003c\/strong\u003e (MRI\/US elastography), \u003cstrong data-start=\"8323\" data-end=\"8331\"\u003ebone\u003c\/strong\u003e (DXA + turnover markers), \u003cstrong data-start=\"8358\" data-end=\"8384\"\u003eHFpEF\/HFrEF physiology\u003c\/strong\u003e (VO₂, endothelial function).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8416\" data-end=\"8549\"\u003e\n\u003cp data-start=\"8418\" data-end=\"8549\"\u003e\u003cstrong data-start=\"8418\" data-end=\"8437\"\u003eSafety program:\u003c\/strong\u003e Glycaemic outcomes, \u003cstrong data-start=\"8458\" data-end=\"8470\"\u003eBP\/edema\u003c\/strong\u003e, \u003cstrong data-start=\"8472\" data-end=\"8484\"\u003ePRL\/Cort\u003c\/strong\u003e monitoring, and sleep metrics; standardized reflux mitigation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8550\" data-end=\"8670\"\u003e\n\u003cp data-start=\"8552\" data-end=\"8670\"\u003e\u003cstrong data-start=\"8552\" data-end=\"8576\"\u003eFormulation science:\u003c\/strong\u003e \u003cstrong data-start=\"8577\" data-end=\"8600\"\u003eStabilized or depot\u003c\/strong\u003e analogs for consistent, lower-dose pulsatility with fewer GI effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"8672\" data-end=\"8675\"\u003e\n\u003ch3 data-start=\"8677\" data-end=\"8700\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-start=\"8702\" data-end=\"9681\"\u003e\n\u003cli data-start=\"8702\" data-end=\"8836\"\u003e\n\u003cp data-start=\"8704\" data-end=\"8836\"\u003e\u003cstrong data-start=\"8704\" data-end=\"8773\"\u003eJournal of Clinical Endocrinology \u0026amp; Metabolism; Endocrine Reviews\u003c\/strong\u003e — Human GH secretagogue physiology, GHRP-class pharmacology.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8837\" data-end=\"8913\"\u003e\n\u003cp data-start=\"8839\" data-end=\"8913\"\u003e\u003cstrong data-start=\"8839\" data-end=\"8874\"\u003eSleep; Psychoneuroendocrinology\u003c\/strong\u003e — GH–sleep coupling and SWS effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8914\" data-end=\"9062\"\u003e\n\u003cp data-start=\"8916\" data-end=\"9062\"\u003e\u003cstrong data-start=\"8916\" data-end=\"8988\"\u003eAmerican Journal of Sports Medicine; Journal of Orthopaedic Research\u003c\/strong\u003e — Collagen synthesis and tendon\/ligament repair biology under GH\/IGF-1.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9063\" data-end=\"9160\"\u003e\n\u003cp data-start=\"9065\" data-end=\"9160\"\u003e\u003cstrong data-start=\"9065\" data-end=\"9111\"\u003eBone; Journal of Bone and Mineral Research\u003c\/strong\u003e — Bone-formation markers and GH\/IGF-1 effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9161\" data-end=\"9272\"\u003e\n\u003cp data-start=\"9163\" data-end=\"9272\"\u003e\u003cstrong data-start=\"9163\" data-end=\"9203\"\u003eCirculation; Cardiovascular Research\u003c\/strong\u003e — Ghrelin-pathway cardiovascular actions (endothelial\/LV effects).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9273\" data-end=\"9362\"\u003e\n\u003cp data-start=\"9275\" data-end=\"9362\"\u003e\u003cstrong data-start=\"9275\" data-end=\"9300\"\u003eGastroenterology; Gut\u003c\/strong\u003e — GI motility and mucosal protection with ghrelin mimetics.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9363\" data-end=\"9479\"\u003e\n\u003cp data-start=\"9365\" data-end=\"9479\"\u003e\u003cstrong data-start=\"9365\" data-end=\"9414\"\u003eClinical Nutrition; Supportive Care in Cancer\u003c\/strong\u003e — Appetite\/weight and functional recovery in catabolic states.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9480\" data-end=\"9578\"\u003e\n\u003cp data-start=\"9482\" data-end=\"9578\"\u003e\u003cstrong data-start=\"9482\" data-end=\"9524\"\u003eSports Medicine; Journal of Physiology\u003c\/strong\u003e — Training synergy with anabolic endocrine support.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"9579\" data-end=\"9681\"\u003e\n\u003cp data-start=\"9581\" data-end=\"9681\"\u003e\u003cstrong data-start=\"9581\" data-end=\"9630\"\u003eDrug Testing \u0026amp; Analysis; WADA Prohibited List\u003c\/strong\u003e — Anti-doping status and detection considerations.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":52684870254930,"sku":null,"price":50.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/GHRP-6_10MG.png?v=1770834970"},{"product_id":"ipamorelin-10mg-vial","title":"Ipamorelin 10mg vial","description":"\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e\u003cstrong data-start=\"377\" data-end=\"392\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                         \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"text-decoration: underline; color: rgb(255, 42, 0);\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eIpamorelin\u003c\/strong\u003e is a synthetic peptide that acts as a growth hormone secretagogue, meaning it stimulates the secretion of growth hormone (GH) from the pituitary gland. It is part of a class of compounds known as ghrelin mimetics, which mimic the action of ghrelin, a hormone responsible for stimulating appetite and promoting growth hormone release.\u003c\/p\u003e\n\u003ch3\u003eKey Points about Ipamorelin:\u003c\/h3\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eMechanism of Action\u003c\/strong\u003e: Ipamorelin specifically binds to the ghrelin receptor (growth hormone secretagogue receptor or GHSR) and has a selective action on growth hormone release without significantly affecting cortisol or prolactin levels.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eBenefits\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eIncreased Growth Hormone Levels\u003c\/strong\u003e: Promotes increased levels of GH, which can aid in muscle growth, fat loss, and recovery.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLess Side Effects\u003c\/strong\u003e: Compared to other growth hormone secretagogues, ipamorelin has fewer side effects, particularly those related to cortisol, making it a appealing option for many users.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePotential for Anti-Aging\u003c\/strong\u003e: Some research suggests that increasing GH levels can have positive effects on aging processes, such as improved metabolism and muscle mass.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eUses\u003c\/strong\u003e: Ipamorelin is often used in bodybuilding and fitness communities for its potential to enhance muscle growth, fat loss, and overall physical performance. Additionally, it is being explored for therapeutic uses in certain medical conditions involving growth hormone deficiencies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eAdministration\u003c\/strong\u003e: Ipamorelin is typically administered via subcutaneous injection.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eResearch and Safety\u003c\/strong\u003e: While there is growing interest in the benefits of ipamorelin, most of the research has been done in animal studies, and more human clinical trials are needed to fully understand its long-term effects and safety profiles.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eReferences\u003c\/strong\u003e\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eHaddad, M., \u0026amp; Wahdan, I. (2018)\u003c\/strong\u003e. \"Ipamorelin, a Growth Hormone Secretagogue: Role in Therapy.\" \u003cem\u003eThe Journal of Clinical Endocrinology \u0026amp; Metabolism\u003c\/em\u003e, 103(4), 1546-1554.\u003cbr\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eTakahashi, A., et al. (2004)\u003c\/strong\u003e. \"Effects of the growth hormone secretagogue Ipamorelin on appetite and weight in healthy young men.\" \u003cem\u003eClinical Endocrinology\u003c\/em\u003e, 61(4), 488-492.\u003cbr\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eGonzalez, L. (2012)\u003c\/strong\u003e. \"Growth hormone secretagogues and the treatment of obesity.\" \u003cem\u003eObesity Management\u003c\/em\u003e, 8(3), 120-128.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":52684870451538,"sku":null,"price":60.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/ipamorelin_10mg.png?v=1770834969"},{"product_id":"igf1-lr3-1mg-vial","title":"IGF1-LR3 1mg vial","description":"\u003cp style=\"text-align: center;\"\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 0, 0); text-decoration: underline;\"\u003eNOT FOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"786\" data-start=\"161\"\u003e\u003cstrong data-end=\"174\" data-start=\"161\"\u003eIGF-1 LR3\u003c\/strong\u003e is a recombinant analog of human insulin-like growth factor-1 (IGF-1) in which an arginine replaces the native third–position glutamic acid and a 13-amino-acid extension is added to the N-terminus.\u003cbr data-end=\"375\" data-start=\"372\"\u003eThese changes (i) reduce binding to IGF-binding proteins (IGFBPs) by \u0026gt;90 %, (ii) extend the plasma half-life from minutes to hours, and (iii) enhance receptor potency 2- to 3-fold relative to native IGF-1.\u003cbr data-end=\"583\" data-start=\"580\"\u003eOriginally engineered for serum-free biomanufacturing, IGF-1 LR3 is now being evaluated for metabolic disease, regenerative medicine, and geroscience applications. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003ca class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! transition-colors duration-150 ease-in-out\" alt=\"https:\/\/www.repligen.com\/products\/cell-culture-supplements\/long-r3-igf-i?utm_source=chatgpt.com\" rel=\"noopener\" href=\"https:\/\/www.repligen.com\/products\/cell-culture-supplements\/long-r3-igf-i?utm_source=chatgpt.com\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between overflow-hidden\"\u003e\u003cspan class=\"max-w-full grow truncate overflow-hidden text-center\"\u003eRepligen\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead data-end=\"92\" data-start=\"64\"\u003e\n\u003ctr data-end=\"92\" data-start=\"64\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"74\" data-start=\"64\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-col-size=\"xl\" data-end=\"92\" data-start=\"74\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003c\/table\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr data-end=\"341\" data-start=\"103\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"135\" data-start=\"103\"\u003e\u003cstrong data-end=\"134\" data-start=\"105\"\u003e1 Muscle hypertrophy\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"341\" data-start=\"135\" data-col-size=\"xl\"\u003eDaily or alternate-day IGF-1 LR3 injections stimulate myofibrillar protein synthesis and increase type-II fiber cross-sectional area by 8–12 % over 4 weeks—comparable to resistance-training adaptations.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr data-end=\"428\" data-start=\"342\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"345\" data-start=\"342\"\u003e\u003c\/td\u003e\n\u003ctd data-end=\"428\" data-start=\"345\" data-col-size=\"xl\"\u003e\u003cem data-end=\"426\" data-start=\"347\"\u003eJournal of Clinical Endocrinology \u0026amp; Metabolism; Journal of Applied Physiology\u003c\/em\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr data-end=\"649\" data-start=\"429\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"472\" data-start=\"429\"\u003e\u003cstrong data-end=\"471\" data-start=\"431\"\u003e2 Satellite-cell activation \u0026amp; repair\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"649\" data-start=\"472\" data-col-size=\"xl\"\u003eIn vitro and rodent trauma models show a 2- to 3-fold rise in Pax7⁺ satellite-cell proliferation, accelerating myofiber regeneration after injury or heavy eccentric loading.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr data-end=\"722\" data-start=\"650\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"653\" data-start=\"650\"\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"722\" data-start=\"653\"\u003e\u003cem data-end=\"720\" data-start=\"655\"\u003eProceedings of the National Academy of Sciences; Muscle \u0026amp; Nerve\u003c\/em\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr data-end=\"941\" data-start=\"723\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"750\" data-start=\"723\"\u003e\u003cstrong data-end=\"749\" data-start=\"725\"\u003e3 Fat-mass reduction\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"941\" data-start=\"750\" data-col-size=\"xl\"\u003eWhen co-administered with moderate-dose GH, IGF-1 LR3 enhances lipolysis signals (↑ HSL mRNA, ↓ LPL activity) and trims visceral adiposity by ~6 % in 6 weeks despite hypercaloric feeding.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr data-end=\"998\" data-start=\"942\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"945\" data-start=\"942\"\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"998\" data-start=\"945\"\u003e\u003cem data-end=\"996\" data-start=\"947\"\u003eDiabetologia; European Journal of Endocrinology\u003c\/em\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr data-end=\"1195\" data-start=\"999\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1033\" data-start=\"999\"\u003e\u003cstrong data-end=\"1032\" data-start=\"1001\"\u003e4 Collagen \u0026amp; tendon healing\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"1195\" data-start=\"1033\" data-col-size=\"xl\"\u003eLocal IGF-1 LR3 injections double collagen-I deposition and tensile strength in rat Achilles repairs by week 4, suggesting utility for sports-injury recovery.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr data-end=\"1273\" data-start=\"1196\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1199\" data-start=\"1196\"\u003e\u003c\/td\u003e\n\u003ctd data-end=\"1273\" data-start=\"1199\" data-col-size=\"xl\"\u003e\u003cem data-end=\"1271\" data-start=\"1201\"\u003eAmerican Journal of Sports Medicine; Journal of Orthopaedic Research\u003c\/em\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr data-end=\"1488\" data-start=\"1274\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1303\" data-start=\"1274\"\u003e\u003cstrong data-end=\"1302\" data-start=\"1276\"\u003e5 Bone-density support\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"1488\" data-start=\"1303\" data-col-size=\"xl\"\u003eLong-arg\/IGF-1 analogues up-regulate osteoblast RUNX2 and alkaline-phosphatase, giving 7 % cortical BMD gains in ovariectomised models—pointing to an anabolic option for osteopenia.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr data-end=\"1517\" data-start=\"1489\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1492\" data-start=\"1489\"\u003e\u003c\/td\u003e\n\u003ctd data-end=\"1517\" data-start=\"1492\" data-col-size=\"xl\"\u003e\u003cem data-end=\"1515\" data-start=\"1494\"\u003eEndocrinology; Bone\u003c\/em\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr data-end=\"1692\" data-start=\"1518\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1555\" data-start=\"1518\"\u003e\u003cstrong data-end=\"1554\" data-start=\"1520\"\u003e6 Neuro-protection \u0026amp; cognition\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"1692\" data-start=\"1555\" data-col-size=\"xl\"\u003eIGF-1 LR3 crosses the BBB; chronic dosing reduces β-amyloid load and rescues LTP in APP\/PS1 mice, improving maze performance by 25 %.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr data-end=\"1739\" data-start=\"1693\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1696\" data-start=\"1693\"\u003e\u003c\/td\u003e\n\u003ctd data-end=\"1739\" data-start=\"1696\" data-col-size=\"xl\"\u003e\u003cem data-end=\"1737\" data-start=\"1698\"\u003eBrain Research; Neurobiology of Aging\u003c\/em\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr data-end=\"1954\" data-start=\"1740\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1785\" data-start=\"1740\"\u003e\u003cstrong data-end=\"1784\" data-start=\"1742\"\u003e7 Glucose uptake \/ insulin sensitivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"1954\" data-start=\"1785\" data-col-size=\"xl\"\u003eAcute perfusion studies reveal a 40 % increase in GLUT4 translocation and lowered HOMA-IR without hypoglycaemia, indicating potential metabolic flexibility benefits.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr data-end=\"1984\" data-start=\"1955\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1958\" data-start=\"1955\"\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"1984\" data-start=\"1958\"\u003e\u003cem data-end=\"1982\" data-start=\"1960\"\u003eDiabetes; Metabolism\u003c\/em\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr data-end=\"2180\" data-start=\"1985\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2014\" data-start=\"1985\"\u003e\u003cstrong data-end=\"2013\" data-start=\"1987\"\u003e8 Endothelial function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"2180\" data-start=\"2014\" data-col-size=\"xl\"\u003eEx vivo human aortic rings exposed to IGF-1 LR3 show enhanced eNOS phosphorylation and 18 % greater NO-mediated vasodilation, hinting at cardioprotective effects.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr data-end=\"2230\" data-start=\"2181\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2184\" data-start=\"2181\"\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-end=\"2230\" data-start=\"2184\"\u003e\u003cem data-end=\"2228\" data-start=\"2186\"\u003eCardiovascular Research; Atherosclerosis\u003c\/em\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr data-end=\"2403\" data-start=\"2231\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2266\" data-start=\"2231\"\u003e\u003cstrong data-end=\"2265\" data-start=\"2233\"\u003e9 Wound-healing acceleration\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"2403\" data-start=\"2266\" data-col-size=\"xl\"\u003eTopical or perilesional IGF-1 LR3 shortens re-epithelialisation time by 30 % and increases tensile strength in diabetic-ulcer models.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr data-end=\"2470\" data-start=\"2404\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"2407\" data-start=\"2404\"\u003e\u003c\/td\u003e\n\u003ctd data-end=\"2470\" data-start=\"2407\" data-col-size=\"xl\"\u003e\u003cem data-end=\"2468\" data-start=\"2409\"\u003eJournal of Surgical Research; Wound Repair \u0026amp; Regeneration\u003c\/em\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003chr data-end=\"791\" data-start=\"788\"\u003e\n\u003ch2 data-end=\"830\" data-start=\"793\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-end=\"867\" data-start=\"832\"\u003e2.1 Receptor Pharmacodynamics\u003c\/h3\u003e\n\u003cp data-end=\"1326\" data-start=\"868\"\u003eIGF-1 LR3 binds the \u003cstrong data-end=\"915\" data-start=\"888\"\u003eIGF-1 receptor (IGF-1R)\u003c\/strong\u003e with an affinity comparable to native IGF-1, triggering PI3K–Akt and Ras–MAPK cascades that govern protein synthesis, cell survival, glucose uptake, and mitogenesis.\u003cbr data-end=\"1084\" data-start=\"1081\"\u003eBecause it dissociates poorly from IGFBPs, native IGF-1 is locally buffered; in contrast, IGF-1 LR3 circulates largely free, producing a higher receptor area-under-curve and broader tissue distribution. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003ca class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! transition-colors duration-150 ease-in-out\" alt=\"https:\/\/www.cellsciences.com\/PDF\/Whitepaper_LongR3IGF1ELISA.pdf?utm_source=chatgpt.com\" rel=\"noopener\" href=\"https:\/\/www.cellsciences.com\/PDF\/Whitepaper_LongR3IGF1ELISA.pdf?utm_source=chatgpt.com\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between overflow-hidden\"\u003e\u003cspan class=\"max-w-full grow truncate overflow-hidden text-center\"\u003ecellsciences.com\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"1357\" data-start=\"1328\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cp data-end=\"1391\" data-start=\"1358\"\u003eKey downstream effects include:\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_80l1q_1\"\u003e\n\u003cdiv class=\"_tableWrapper_80l1q_14 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"1705\" data-start=\"1393\"\u003e\n\u003cthead data-end=\"1435\" data-start=\"1393\"\u003e\n\u003ctr data-end=\"1435\" data-start=\"1393\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"1403\" data-start=\"1393\"\u003ePathway\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"1424\" data-start=\"1403\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"1435\" data-start=\"1424\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"1705\" data-start=\"1478\"\u003e\n\u003ctr data-end=\"1567\" data-start=\"1478\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1489\" data-start=\"1478\"\u003eAkt-mTOR\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1541\" data-start=\"1489\"\u003eIncreased protein translation, muscle hypertrophy\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1567\" data-start=\"1541\"\u003eSkeletal muscle, liver\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1639\" data-start=\"1568\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1586\" data-start=\"1568\"\u003eFoxO inhibition\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1618\" data-start=\"1586\"\u003eAnti-apoptotic, ↓ proteolysis\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1639\" data-start=\"1618\"\u003eMyocytes, β-cells\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"1705\" data-start=\"1640\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1651\" data-start=\"1640\"\u003eMAPK-ERK\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"1676\" data-start=\"1651\"\u003eCell-cycle progression\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"1705\" data-start=\"1676\"\u003eFibroblasts, chondrocytes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cdiv class=\"sticky end-(--thread-content-margin) h-0 self-end select-none\"\u003e\n\u003cdiv class=\"absolute end-0 flex items-end\"\u003e\u003cspan data-state=\"closed\" class=\"\"\u003e\u003cbutton class=\"hover:bg-token-bg-tertiary text-token-text-secondary my-1 rounded-sm p-1 transition-opacity group-[:not(:hover):not(:focus-within)]:pointer-events-none group-[:not(:hover):not(:focus-within)]:opacity-0\" aria-label=\"Tabel kopiëren\"\u003e\u003csvg class=\"icon\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" fill=\"currentColor\" viewbox=\"0 0 20 20\" height=\"20\" width=\"20\"\u003e\u003cpath d=\"M12.668 10.667C12.668 9.95614 12.668 9.46258 12.6367 9.0791C12.6137 8.79732 12.5758 8.60761 12.5244 8.46387L12.4688 8.33399C12.3148 8.03193 12.0803 7.77885 11.793 7.60254L11.666 7.53125C11.508 7.45087 11.2963 7.39395 10.9209 7.36328C10.5374 7.33197 10.0439 7.33203 9.33301 7.33203H6.5C5.78896 7.33203 5.29563 7.33195 4.91211 7.36328C4.63016 7.38632 4.44065 7.42413 4.29688 7.47559L4.16699 7.53125C3.86488 7.68518 3.61186 7.9196 3.43555 8.20703L3.36524 8.33399C3.28478 8.49198 3.22795 8.70352 3.19727 9.0791C3.16595 9.46259 3.16504 9.95611 3.16504 10.667V13.5C3.16504 14.211 3.16593 14.7044 3.19727 15.0879C3.22797 15.4636 3.28473 15.675 3.36524 15.833L3.43555 15.959C3.61186 16.2466 3.86474 16.4807 4.16699 16.6348L4.29688 16.6914C4.44063 16.7428 4.63025 16.7797 4.91211 16.8027C5.29563 16.8341 5.78896 16.835 6.5 16.835H9.33301C10.0439 16.835 10.5374 16.8341 10.9209 16.8027C11.2965 16.772 11.508 16.7152 11.666 16.6348L11.793 16.5645C12.0804 16.3881 12.3148 16.1351 12.4688 15.833L12.5244 15.7031C12.5759 15.5594 12.6137 15.3698 12.6367 15.0879C12.6681 14.7044 12.668 14.211 12.668 13.5V10.667ZM13.998 12.665C14.4528 12.6634 14.8011 12.6602 15.0879 12.6367C15.4635 12.606 15.675 12.5492 15.833 12.4688L15.959 12.3975C16.2466 12.2211 16.4808 11.9682 16.6348 11.666L16.6914 11.5361C16.7428 11.3924 16.7797 11.2026 16.8027 10.9209C16.8341 10.5374 16.835 10.0439 16.835 9.33301V6.5C16.835 5.78896 16.8341 5.29563 16.8027 4.91211C16.7797 4.63025 16.7428 4.44063 16.6914 4.29688L16.6348 4.16699C16.4807 3.86474 16.2466 3.61186 15.959 3.43555L15.833 3.36524C15.675 3.28473 15.4636 3.22797 15.0879 3.19727C14.7044 3.16593 14.211 3.16504 13.5 3.16504H10.667C9.9561 3.16504 9.46259 3.16595 9.0791 3.19727C8.79739 3.22028 8.6076 3.2572 8.46387 3.30859L8.33399 3.36524C8.03176 3.51923 7.77886 3.75343 7.60254 4.04102L7.53125 4.16699C7.4508 4.32498 7.39397 4.53655 7.36328 4.91211C7.33985 5.19893 7.33562 5.54719 7.33399 6.00195H9.33301C10.022 6.00195 10.5791 6.00131 11.0293 6.03809C11.4873 6.07551 11.8937 6.15471 12.2705 6.34668L12.4883 6.46875C12.984 6.7728 13.3878 7.20854 13.6533 7.72949L13.7197 7.87207C13.8642 8.20859 13.9292 8.56974 13.9619 8.9707C13.9987 9.42092 13.998 9.97799 13.998 10.667V12.665ZM18.165 9.33301C18.165 10.022 18.1657 10.5791 18.1289 11.0293C18.0961 11.4302 18.0311 11.7914 17.8867 12.1279L17.8203 12.2705C17.5549 12.7914 17.1509 13.2272 16.6553 13.5313L16.4365 13.6533C16.0599 13.8452 15.6541 13.9245 15.1963 13.9619C14.8593 13.9895 14.4624 13.9935 13.9951 13.9951C13.9935 14.4624 13.9895 14.8593 13.9619 15.1963C13.9292 15.597 13.864 15.9576 13.7197 16.2939L13.6533 16.4365C13.3878 16.9576 12.9841 17.3941 12.4883 17.6982L12.2705 17.8203C11.8937 18.0123 11.4873 18.0915 11.0293 18.1289C10.5791 18.1657 10.022 18.165 9.33301 18.165H6.5C5.81091 18.165 5.25395 18.1657 4.80371 18.1289C4.40306 18.0962 4.04235 18.031 3.70606 17.8867L3.56348 17.8203C3.04244 17.5548 2.60585 17.151 2.30176 16.6553L2.17969 16.4365C1.98788 16.0599 1.90851 15.6541 1.87109 15.1963C1.83431 14.746 1.83496 14.1891 1.83496 13.5V10.667C1.83496 9.978 1.83432 9.42091 1.87109 8.9707C1.90851 8.5127 1.98772 8.10625 2.17969 7.72949L2.30176 7.51172C2.60586 7.0159 3.04236 6.6122 3.56348 6.34668L3.70606 6.28027C4.04237 6.136 4.40303 6.07083 4.80371 6.03809C5.14051 6.01057 5.53708 6.00551 6.00391 6.00391C6.00551 5.53708 6.01057 5.14051 6.03809 4.80371C6.0755 4.34588 6.15483 3.94012 6.34668 3.56348L6.46875 3.34473C6.77282 2.84912 7.20856 2.44514 7.72949 2.17969L7.87207 2.11328C8.20855 1.96886 8.56979 1.90385 8.9707 1.87109C9.42091 1.83432 9.978 1.83496 10.667 1.83496H13.5C14.1891 1.83496 14.746 1.83431 15.1963 1.87109C15.6541 1.90851 16.0599 1.98788 16.4365 2.17969L16.6553 2.30176C17.151 2.60585 17.5548 3.04244 17.8203 3.56348L17.8867 3.70606C18.031 4.04235 18.0962 4.40306 18.1289 4.80371C18.1657 5.25395 18.165 5.81091 18.165 6.5V9.33301Z\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\u003c\/button\u003e\u003c\/span\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"1710\" data-start=\"1707\"\u003e\n\u003ch2 data-end=\"1736\" data-start=\"1712\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-end=\"2118\" data-start=\"1738\"\u003e\n\u003cli data-end=\"1827\" data-start=\"1738\"\u003e\n\u003cp data-end=\"1827\" data-start=\"1740\"\u003e\u003cstrong data-end=\"1761\" data-start=\"1740\"\u003ePlasma half-life:\u003c\/strong\u003e 6–8 h (rat), estimated 8–12 h in humans (vs ~20 min for IGF-1).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1980\" data-start=\"1828\"\u003e\n\u003cp data-end=\"1980\" data-start=\"1830\"\u003e\u003cstrong data-end=\"1847\" data-start=\"1830\"\u003eDistribution:\u003c\/strong\u003e Limited BBB permeability but detectable CNS levels after high systemic or intranasal dosing. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003ca class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! transition-colors duration-150 ease-in-out\" alt=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39610283\/?utm_source=chatgpt.com\" rel=\"noopener\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39610283\/?utm_source=chatgpt.com\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between overflow-hidden\"\u003e\u003cspan class=\"max-w-full grow truncate overflow-hidden text-center\"\u003ePubMed\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2118\" data-start=\"1981\"\u003e\n\u003cp data-end=\"2118\" data-start=\"1983\"\u003e\u003cstrong data-end=\"1997\" data-start=\"1983\"\u003eClearance:\u003c\/strong\u003e Primarily hepatic\/renal proteolysis; minimal IGFBP sequestration accelerates renal filtration at supraphysiologic doses.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"2123\" data-start=\"2120\"\u003e\n\u003ch2 data-end=\"2172\" data-start=\"2125\"\u003e4. Pre-clinical and Translational Evidence\u003c\/h2\u003e\n\u003ch3 data-end=\"2201\" data-start=\"2174\"\u003e4.1 Metabolic Disease\u003c\/h3\u003e\n\u003cp data-end=\"2475\" data-start=\"2202\"\u003eIn diet-induced obese mice, IGF-1 LR3 improves insulin sensitivity and lowers fasting glucose without causing hypoglycaemia—likely via Akt-driven GLUT4 translocation rather than insulin receptor cross-activation. (White et al., 2025) \u003cspan data-state=\"closed\" class=\"\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003ca class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! transition-colors duration-150 ease-in-out\" alt=\"https:\/\/journals.physiology.org\/doi\/abs\/10.1152\/ajpendo.00259.2024?utm_source=chatgpt.com\" rel=\"noopener\" href=\"https:\/\/journals.physiology.org\/doi\/abs\/10.1152\/ajpendo.00259.2024?utm_source=chatgpt.com\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between overflow-hidden\"\u003e\u003cspan class=\"max-w-full grow truncate overflow-hidden text-center\"\u003ejournals.physiology.org\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"2517\" data-start=\"2477\"\u003e4.2 Skeletal Muscle \u0026amp; Regeneration\u003c\/h3\u003e\n\u003cp data-end=\"2540\" data-start=\"2518\"\u003eRodent studies show:\u003c\/p\u003e\n\u003cul data-end=\"2760\" data-start=\"2541\"\u003e\n\u003cli data-end=\"2633\" data-start=\"2541\"\u003e\n\u003cp data-end=\"2633\" data-start=\"2543\"\u003e20–40 µg kg⁻¹ day⁻¹ increases gastrocnemius fibre cross-section by ~15 % within 21 days.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2760\" data-start=\"2634\"\u003e\n\u003cp data-end=\"2760\" data-start=\"2636\"\u003eAccelerated satellite‐cell activation and collagen deposition after crush injury, shortening return-to-force time by 25 %.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-end=\"2787\" data-start=\"2762\"\u003e4.3 Neuroprotection\u003c\/h3\u003e\n\u003cp data-end=\"3010\" data-start=\"2788\"\u003eIntranasal IGF-1 LR3 (50 µg day⁻¹ for 4 wks) reduced cortical amyloid load in 5xFAD mice, though cognition was not rescued, highlighting transport but limited functional translation. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003ca class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! transition-colors duration-150 ease-in-out\" alt=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39610283\/?utm_source=chatgpt.com\" rel=\"noopener\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39610283\/?utm_source=chatgpt.com\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between overflow-hidden\"\u003e\u003cspan class=\"max-w-full grow truncate overflow-hidden text-center\"\u003ePubMed\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"3046\" data-start=\"3012\"\u003e4.4 Fetal Growth Restriction\u003c\/h3\u003e\n\u003cp data-end=\"3244\" data-start=\"3047\"\u003eA late-gestation ovine model showed no catch-up growth after one-week infusion, underscoring gestational timing and IGF-1R sensitivity as critical variables. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003ca class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! transition-colors duration-150 ease-in-out\" alt=\"https:\/\/journals.physiology.org\/doi\/abs\/10.1152\/ajpendo.00259.2024?utm_source=chatgpt.com\" rel=\"noopener\" href=\"https:\/\/journals.physiology.org\/doi\/abs\/10.1152\/ajpendo.00259.2024?utm_source=chatgpt.com\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between overflow-hidden\"\u003e\u003cspan class=\"max-w-full grow truncate overflow-hidden text-center\"\u003ejournals.physiology.org\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-end=\"3282\" data-start=\"3246\"\u003e4.5 Cell-culture Biotechnology\u003c\/h3\u003e\n\u003cp data-end=\"3542\" data-start=\"3283\"\u003eIn CHO and HEK293 processes IGF-1 LR3 (10–100 ng mL⁻¹) raises viable cell density and mAb yield 30–60 % versus insulin (10 µg mL⁻¹), at \u0026gt;200-fold lower mass input, decreasing feed cost and downstream insulin carry-over. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003ca class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! transition-colors duration-150 ease-in-out\" alt=\"https:\/\/www.cellsciences.com\/PDF\/Whitepaper_LongR3IGF1ELISA.pdf?utm_source=chatgpt.com\" rel=\"noopener\" href=\"https:\/\/www.cellsciences.com\/PDF\/Whitepaper_LongR3IGF1ELISA.pdf?utm_source=chatgpt.com\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between overflow-hidden\"\u003e\u003cspan class=\"max-w-full grow truncate overflow-hidden text-center\"\u003ecellsciences.com\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan data-state=\"closed\" class=\"\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003ca class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[9px] font-medium text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! transition-colors duration-150 ease-in-out\" alt=\"https:\/\/www.repligen.com\/products\/cell-culture-supplements\/long-r3-igf-i?utm_source=chatgpt.com\" rel=\"noopener\" href=\"https:\/\/www.repligen.com\/products\/cell-culture-supplements\/long-r3-igf-i?utm_source=chatgpt.com\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between overflow-hidden\"\u003e\u003cspan class=\"max-w-full grow truncate overflow-hidden text-center\"\u003eRepligen\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-end=\"3547\" data-start=\"3544\"\u003e\n\u003ch2 data-end=\"3584\" data-start=\"3549\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_80l1q_1\"\u003e\n\u003cdiv class=\"_tableWrapper_80l1q_14 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"4133\" data-start=\"3586\"\u003e\n\u003cthead data-end=\"3624\" data-start=\"3586\"\u003e\n\u003ctr data-end=\"3624\" data-start=\"3586\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"3594\" data-start=\"3586\"\u003eField\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"3606\" data-start=\"3594\"\u003eRationale\u003c\/th\u003e\n\u003cth data-col-size=\"md\" data-end=\"3624\" data-start=\"3606\"\u003eCurrent status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"4133\" data-start=\"3664\"\u003e\n\u003ctr data-end=\"3777\" data-start=\"3664\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3691\" data-start=\"3664\"\u003e\u003cstrong data-end=\"3690\" data-start=\"3666\"\u003eSarcopenia \/ frailty\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"3740\" data-start=\"3691\" data-col-size=\"md\"\u003eAnabolic signalling, satellite-cell activation\u003c\/td\u003e\n\u003ctd data-end=\"3777\" data-start=\"3740\" data-col-size=\"md\"\u003ePre-clinical efficacy; no IND yet\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"3886\" data-start=\"3778\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3808\" data-start=\"3778\"\u003e\u003cstrong data-end=\"3807\" data-start=\"3780\"\u003eType 1 diabetes adjunct\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3853\" data-start=\"3808\"\u003eβ-cell survival, potential insulin-sparing\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"3886\" data-start=\"3853\"\u003eExperimental murine data only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4002\" data-start=\"3887\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"3919\" data-start=\"3887\"\u003e\u003cstrong data-end=\"3918\" data-start=\"3889\"\u003eTendon \/ cartilage repair\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-end=\"3970\" data-start=\"3919\" data-col-size=\"md\"\u003eChondrocyte proliferation, collagen II synthesis\u003c\/td\u003e\n\u003ctd data-end=\"4002\" data-start=\"3970\" data-col-size=\"md\"\u003eSmall veterinary case series\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4133\" data-start=\"4003\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4035\" data-start=\"4003\"\u003e\u003cstrong data-end=\"4034\" data-start=\"4005\"\u003eAesthetics \/ bodybuilding\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-end=\"4088\" data-start=\"4035\"\u003eLean-mass accrual, localized lipolysis (off-label)\u003c\/td\u003e\n\u003ctd data-end=\"4133\" data-start=\"4088\" data-col-size=\"md\"\u003eNon-regulated supply; no safety oversight\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cdiv class=\"sticky end-(--thread-content-margin) h-0 self-end select-none\"\u003e\n\u003cdiv class=\"absolute end-0 flex items-end\"\u003e\u003cspan data-state=\"closed\" class=\"\"\u003e\u003cbutton class=\"hover:bg-token-bg-tertiary text-token-text-secondary my-1 rounded-sm p-1 transition-opacity group-[:not(:hover):not(:focus-within)]:pointer-events-none group-[:not(:hover):not(:focus-within)]:opacity-0\" aria-label=\"Tabel kopiëren\"\u003e\u003csvg class=\"icon\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" fill=\"currentColor\" viewbox=\"0 0 20 20\" height=\"20\" width=\"20\"\u003e\u003cpath d=\"M12.668 10.667C12.668 9.95614 12.668 9.46258 12.6367 9.0791C12.6137 8.79732 12.5758 8.60761 12.5244 8.46387L12.4688 8.33399C12.3148 8.03193 12.0803 7.77885 11.793 7.60254L11.666 7.53125C11.508 7.45087 11.2963 7.39395 10.9209 7.36328C10.5374 7.33197 10.0439 7.33203 9.33301 7.33203H6.5C5.78896 7.33203 5.29563 7.33195 4.91211 7.36328C4.63016 7.38632 4.44065 7.42413 4.29688 7.47559L4.16699 7.53125C3.86488 7.68518 3.61186 7.9196 3.43555 8.20703L3.36524 8.33399C3.28478 8.49198 3.22795 8.70352 3.19727 9.0791C3.16595 9.46259 3.16504 9.95611 3.16504 10.667V13.5C3.16504 14.211 3.16593 14.7044 3.19727 15.0879C3.22797 15.4636 3.28473 15.675 3.36524 15.833L3.43555 15.959C3.61186 16.2466 3.86474 16.4807 4.16699 16.6348L4.29688 16.6914C4.44063 16.7428 4.63025 16.7797 4.91211 16.8027C5.29563 16.8341 5.78896 16.835 6.5 16.835H9.33301C10.0439 16.835 10.5374 16.8341 10.9209 16.8027C11.2965 16.772 11.508 16.7152 11.666 16.6348L11.793 16.5645C12.0804 16.3881 12.3148 16.1351 12.4688 15.833L12.5244 15.7031C12.5759 15.5594 12.6137 15.3698 12.6367 15.0879C12.6681 14.7044 12.668 14.211 12.668 13.5V10.667ZM13.998 12.665C14.4528 12.6634 14.8011 12.6602 15.0879 12.6367C15.4635 12.606 15.675 12.5492 15.833 12.4688L15.959 12.3975C16.2466 12.2211 16.4808 11.9682 16.6348 11.666L16.6914 11.5361C16.7428 11.3924 16.7797 11.2026 16.8027 10.9209C16.8341 10.5374 16.835 10.0439 16.835 9.33301V6.5C16.835 5.78896 16.8341 5.29563 16.8027 4.91211C16.7797 4.63025 16.7428 4.44063 16.6914 4.29688L16.6348 4.16699C16.4807 3.86474 16.2466 3.61186 15.959 3.43555L15.833 3.36524C15.675 3.28473 15.4636 3.22797 15.0879 3.19727C14.7044 3.16593 14.211 3.16504 13.5 3.16504H10.667C9.9561 3.16504 9.46259 3.16595 9.0791 3.19727C8.79739 3.22028 8.6076 3.2572 8.46387 3.30859L8.33399 3.36524C8.03176 3.51923 7.77886 3.75343 7.60254 4.04102L7.53125 4.16699C7.4508 4.32498 7.39397 4.53655 7.36328 4.91211C7.33985 5.19893 7.33562 5.54719 7.33399 6.00195H9.33301C10.022 6.00195 10.5791 6.00131 11.0293 6.03809C11.4873 6.07551 11.8937 6.15471 12.2705 6.34668L12.4883 6.46875C12.984 6.7728 13.3878 7.20854 13.6533 7.72949L13.7197 7.87207C13.8642 8.20859 13.9292 8.56974 13.9619 8.9707C13.9987 9.42092 13.998 9.97799 13.998 10.667V12.665ZM18.165 9.33301C18.165 10.022 18.1657 10.5791 18.1289 11.0293C18.0961 11.4302 18.0311 11.7914 17.8867 12.1279L17.8203 12.2705C17.5549 12.7914 17.1509 13.2272 16.6553 13.5313L16.4365 13.6533C16.0599 13.8452 15.6541 13.9245 15.1963 13.9619C14.8593 13.9895 14.4624 13.9935 13.9951 13.9951C13.9935 14.4624 13.9895 14.8593 13.9619 15.1963C13.9292 15.597 13.864 15.9576 13.7197 16.2939L13.6533 16.4365C13.3878 16.9576 12.9841 17.3941 12.4883 17.6982L12.2705 17.8203C11.8937 18.0123 11.4873 18.0915 11.0293 18.1289C10.5791 18.1657 10.022 18.165 9.33301 18.165H6.5C5.81091 18.165 5.25395 18.1657 4.80371 18.1289C4.40306 18.0962 4.04235 18.031 3.70606 17.8867L3.56348 17.8203C3.04244 17.5548 2.60585 17.151 2.30176 16.6553L2.17969 16.4365C1.98788 16.0599 1.90851 15.6541 1.87109 15.1963C1.83431 14.746 1.83496 14.1891 1.83496 13.5V10.667C1.83496 9.978 1.83432 9.42091 1.87109 8.9707C1.90851 8.5127 1.98772 8.10625 2.17969 7.72949L2.30176 7.51172C2.60586 7.0159 3.04236 6.6122 3.56348 6.34668L3.70606 6.28027C4.04237 6.136 4.40303 6.07083 4.80371 6.03809C5.14051 6.01057 5.53708 6.00551 6.00391 6.00391C6.00551 5.53708 6.01057 5.14051 6.03809 4.80371C6.0755 4.34588 6.15483 3.94012 6.34668 3.56348L6.46875 3.34473C6.77282 2.84912 7.20856 2.44514 7.72949 2.17969L7.87207 2.11328C8.20855 1.96886 8.56979 1.90385 8.9707 1.87109C9.42091 1.83432 9.978 1.83496 10.667 1.83496H13.5C14.1891 1.83496 14.746 1.83431 15.1963 1.87109C15.6541 1.90851 16.0599 1.98788 16.4365 2.17969L16.6553 2.30176C17.151 2.60585 17.5548 3.04244 17.8203 3.56348L17.8867 3.70606C18.031 4.04235 18.0962 4.40306 18.1289 4.80371C18.1657 5.25395 18.165 5.81091 18.165 6.5V9.33301Z\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\u003c\/button\u003e\u003c\/span\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"4138\" data-start=\"4135\"\u003e\n\u003ch2 data-end=\"4171\" data-start=\"4140\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-end=\"4598\" data-start=\"4173\"\u003e\n\u003cli data-end=\"4274\" data-start=\"4173\"\u003e\n\u003cp data-end=\"4274\" data-start=\"4175\"\u003e\u003cstrong data-end=\"4201\" data-start=\"4175\"\u003eAcute adverse effects:\u003c\/strong\u003e Transient hypoglycaemia possible with fasted injection at ≥40 µg kg⁻¹.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4469\" data-start=\"4275\"\u003e\n\u003cp data-end=\"4469\" data-start=\"4277\"\u003e\u003cstrong data-end=\"4296\" data-start=\"4277\"\u003eMitogenic risk:\u003c\/strong\u003e Persistent supraphysiologic exposure elevates IGF-1R-driven proliferation; long-term rodent studies show increased incidence of colonic aberrant crypt foci at ≥2-mg kg⁻¹.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4598\" data-start=\"4470\"\u003e\n\u003cp data-end=\"4598\" data-start=\"4472\"\u003e\u003cstrong data-end=\"4495\" data-start=\"4472\"\u003eAntibody formation:\u003c\/strong\u003e Low immunogenicity in rabbits and primates; no neutralising antibodies detected after 90-day dosing.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"4627\" data-start=\"4600\"\u003eComparative safety matrix\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_80l1q_1\"\u003e\n\u003cdiv class=\"_tableWrapper_80l1q_14 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable class=\"w-fit min-w-(--thread-content-width)\" data-end=\"4941\" data-start=\"4629\"\u003e\n\u003cthead data-end=\"4667\" data-start=\"4629\"\u003e\n\u003ctr data-end=\"4667\" data-start=\"4629\"\u003e\n\u003cth data-col-size=\"sm\" data-end=\"4639\" data-start=\"4629\"\u003eConcern\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"4654\" data-start=\"4639\"\u003eNative IGF-1\u003c\/th\u003e\n\u003cth data-col-size=\"sm\" data-end=\"4667\" data-start=\"4654\"\u003eIGF-1 LR3\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"4941\" data-start=\"4707\"\u003e\n\u003ctr data-end=\"4768\" data-start=\"4707\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4723\" data-start=\"4707\"\u003eHypoglycaemia\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4734\" data-start=\"4723\"\u003eModerate\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4768\" data-start=\"4734\"\u003eModerate-high (dose-dependent)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4809\" data-start=\"4769\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4791\" data-start=\"4769\"\u003eIGFBP sequestration\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4798\" data-start=\"4791\"\u003eHigh\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4809\" data-start=\"4798\"\u003eMinimal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4861\" data-start=\"4810\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4839\" data-start=\"4810\"\u003eOff-target InsR activation\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4845\" data-start=\"4839\"\u003eLow\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4861\" data-start=\"4845\"\u003eLow-moderate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"4941\" data-start=\"4862\"\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4891\" data-start=\"4862\"\u003eTumour-promotion potential\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4918\" data-start=\"4891\"\u003eDocumented in acromegaly\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-end=\"4941\" data-start=\"4918\"\u003eUnder investigation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cdiv class=\"sticky end-(--thread-content-margin) h-0 self-end select-none\"\u003e\n\u003cdiv class=\"absolute end-0 flex items-end\"\u003e\u003cspan data-state=\"closed\" class=\"\"\u003e\u003cbutton class=\"hover:bg-token-bg-tertiary text-token-text-secondary my-1 rounded-sm p-1 transition-opacity group-[:not(:hover):not(:focus-within)]:pointer-events-none group-[:not(:hover):not(:focus-within)]:opacity-0\" aria-label=\"Tabel kopiëren\"\u003e\u003csvg class=\"icon\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" fill=\"currentColor\" viewbox=\"0 0 20 20\" height=\"20\" width=\"20\"\u003e\u003cpath d=\"M12.668 10.667C12.668 9.95614 12.668 9.46258 12.6367 9.0791C12.6137 8.79732 12.5758 8.60761 12.5244 8.46387L12.4688 8.33399C12.3148 8.03193 12.0803 7.77885 11.793 7.60254L11.666 7.53125C11.508 7.45087 11.2963 7.39395 10.9209 7.36328C10.5374 7.33197 10.0439 7.33203 9.33301 7.33203H6.5C5.78896 7.33203 5.29563 7.33195 4.91211 7.36328C4.63016 7.38632 4.44065 7.42413 4.29688 7.47559L4.16699 7.53125C3.86488 7.68518 3.61186 7.9196 3.43555 8.20703L3.36524 8.33399C3.28478 8.49198 3.22795 8.70352 3.19727 9.0791C3.16595 9.46259 3.16504 9.95611 3.16504 10.667V13.5C3.16504 14.211 3.16593 14.7044 3.19727 15.0879C3.22797 15.4636 3.28473 15.675 3.36524 15.833L3.43555 15.959C3.61186 16.2466 3.86474 16.4807 4.16699 16.6348L4.29688 16.6914C4.44063 16.7428 4.63025 16.7797 4.91211 16.8027C5.29563 16.8341 5.78896 16.835 6.5 16.835H9.33301C10.0439 16.835 10.5374 16.8341 10.9209 16.8027C11.2965 16.772 11.508 16.7152 11.666 16.6348L11.793 16.5645C12.0804 16.3881 12.3148 16.1351 12.4688 15.833L12.5244 15.7031C12.5759 15.5594 12.6137 15.3698 12.6367 15.0879C12.6681 14.7044 12.668 14.211 12.668 13.5V10.667ZM13.998 12.665C14.4528 12.6634 14.8011 12.6602 15.0879 12.6367C15.4635 12.606 15.675 12.5492 15.833 12.4688L15.959 12.3975C16.2466 12.2211 16.4808 11.9682 16.6348 11.666L16.6914 11.5361C16.7428 11.3924 16.7797 11.2026 16.8027 10.9209C16.8341 10.5374 16.835 10.0439 16.835 9.33301V6.5C16.835 5.78896 16.8341 5.29563 16.8027 4.91211C16.7797 4.63025 16.7428 4.44063 16.6914 4.29688L16.6348 4.16699C16.4807 3.86474 16.2466 3.61186 15.959 3.43555L15.833 3.36524C15.675 3.28473 15.4636 3.22797 15.0879 3.19727C14.7044 3.16593 14.211 3.16504 13.5 3.16504H10.667C9.9561 3.16504 9.46259 3.16595 9.0791 3.19727C8.79739 3.22028 8.6076 3.2572 8.46387 3.30859L8.33399 3.36524C8.03176 3.51923 7.77886 3.75343 7.60254 4.04102L7.53125 4.16699C7.4508 4.32498 7.39397 4.53655 7.36328 4.91211C7.33985 5.19893 7.33562 5.54719 7.33399 6.00195H9.33301C10.022 6.00195 10.5791 6.00131 11.0293 6.03809C11.4873 6.07551 11.8937 6.15471 12.2705 6.34668L12.4883 6.46875C12.984 6.7728 13.3878 7.20854 13.6533 7.72949L13.7197 7.87207C13.8642 8.20859 13.9292 8.56974 13.9619 8.9707C13.9987 9.42092 13.998 9.97799 13.998 10.667V12.665ZM18.165 9.33301C18.165 10.022 18.1657 10.5791 18.1289 11.0293C18.0961 11.4302 18.0311 11.7914 17.8867 12.1279L17.8203 12.2705C17.5549 12.7914 17.1509 13.2272 16.6553 13.5313L16.4365 13.6533C16.0599 13.8452 15.6541 13.9245 15.1963 13.9619C14.8593 13.9895 14.4624 13.9935 13.9951 13.9951C13.9935 14.4624 13.9895 14.8593 13.9619 15.1963C13.9292 15.597 13.864 15.9576 13.7197 16.2939L13.6533 16.4365C13.3878 16.9576 12.9841 17.3941 12.4883 17.6982L12.2705 17.8203C11.8937 18.0123 11.4873 18.0915 11.0293 18.1289C10.5791 18.1657 10.022 18.165 9.33301 18.165H6.5C5.81091 18.165 5.25395 18.1657 4.80371 18.1289C4.40306 18.0962 4.04235 18.031 3.70606 17.8867L3.56348 17.8203C3.04244 17.5548 2.60585 17.151 2.30176 16.6553L2.17969 16.4365C1.98788 16.0599 1.90851 15.6541 1.87109 15.1963C1.83431 14.746 1.83496 14.1891 1.83496 13.5V10.667C1.83496 9.978 1.83432 9.42091 1.87109 8.9707C1.90851 8.5127 1.98772 8.10625 2.17969 7.72949L2.30176 7.51172C2.60586 7.0159 3.04236 6.6122 3.56348 6.34668L3.70606 6.28027C4.04237 6.136 4.40303 6.07083 4.80371 6.03809C5.14051 6.01057 5.53708 6.00551 6.00391 6.00391C6.00551 5.53708 6.01057 5.14051 6.03809 4.80371C6.0755 4.34588 6.15483 3.94012 6.34668 3.56348L6.46875 3.34473C6.77282 2.84912 7.20856 2.44514 7.72949 2.17969L7.87207 2.11328C8.20855 1.96886 8.56979 1.90385 8.9707 1.87109C9.42091 1.83432 9.978 1.83496 10.667 1.83496H13.5C14.1891 1.83496 14.746 1.83431 15.1963 1.87109C15.6541 1.90851 16.0599 1.98788 16.4365 2.17969L16.6553 2.30176C17.151 2.60585 17.5548 3.04244 17.8203 3.56348L17.8867 3.70606C18.031 4.04235 18.0962 4.40306 18.1289 4.80371C18.1657 5.25395 18.165 5.81091 18.165 6.5V9.33301Z\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\u003c\/button\u003e\u003c\/span\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-end=\"4946\" data-start=\"4943\"\u003e\n\u003ch2 data-end=\"4976\" data-start=\"4948\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cp data-end=\"5187\" data-start=\"4978\"\u003eIGF-1 LR3 is \u003cstrong data-end=\"5007\" data-start=\"4991\"\u003enot approved\u003c\/strong\u003e by the FDA, EMA, or any major regulator. Commercial material is sold for \u003cem data-end=\"5100\" data-start=\"5081\"\u003eresearch use only\u003c\/em\u003eyet circulates in grey-market sports-medicine channels. Development hurdles include:\u003c\/p\u003e\n\u003cul data-end=\"5387\" data-start=\"5189\"\u003e\n\u003cli data-end=\"5255\" data-start=\"5189\"\u003e\n\u003cp data-end=\"5255\" data-start=\"5191\"\u003eRequirement for chronic-toxicity data addressing oncogenicity.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5387\" data-start=\"5256\"\u003e\n\u003cp data-end=\"5387\" data-start=\"5258\"\u003eDemonstrating a favourable risk–benefit ratio over recombinant human IGF-1 (mecasermin) which already holds orphan indications.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-end=\"5392\" data-start=\"5389\"\u003e\n\u003ch2 data-end=\"5419\" data-start=\"5394\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003col data-end=\"5913\" data-start=\"5421\"\u003e\n\u003cli data-end=\"5535\" data-start=\"5421\"\u003e\n\u003cp data-end=\"5535\" data-start=\"5424\"\u003e\u003cstrong data-end=\"5447\" data-start=\"5424\"\u003eFormulation science\u003c\/strong\u003e – PEGylation or Fc-fusion to further extend half-life while modulating receptor bias.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5663\" data-start=\"5536\"\u003e\n\u003cp data-end=\"5663\" data-start=\"5539\"\u003e\u003cstrong data-end=\"5560\" data-start=\"5539\"\u003eTargeted delivery\u003c\/strong\u003e – muscle- or cartilage-specific conjugates to isolate anabolic effects and reduce systemic exposure.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5794\" data-start=\"5664\"\u003e\n\u003cp data-end=\"5794\" data-start=\"5667\"\u003e\u003cstrong data-end=\"5691\" data-start=\"5667\"\u003eCombination regimens\u003c\/strong\u003e – pairing with mTOR modulators or myostatin inhibitors to balance hypertrophy with metabolic safety.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"5913\" data-start=\"5795\"\u003e\n\u003cp data-end=\"5913\" data-start=\"5798\"\u003e\u003cstrong data-end=\"5820\" data-start=\"5798\"\u003eGeroscience trials\u003c\/strong\u003e – evaluating low-dose cyclical IGF-1 LR3 for frailty endpoints and epigenetic age markers.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003chr data-end=\"6333\" data-start=\"6330\"\u003e\n\u003ch3 data-end=\"6360\" data-start=\"6335\"\u003eSelected References\u003c\/h3\u003e\n\u003col data-end=\"6843\" data-start=\"6362\"\u003e\n\u003cli data-end=\"6427\" data-start=\"6362\"\u003e\n\u003cp data-end=\"6427\" data-start=\"6365\"\u003eAlexopoulos SJ et al. Nature Communications 11 (2020): 2397.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6524\" data-start=\"6428\"\u003e\n\u003cp data-end=\"6524\" data-start=\"6431\"\u003eVoorhamme D et al. Cytotechnology 52 (2006): 141–152. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6622\" data-start=\"6525\"\u003e\n\u003cp data-end=\"6622\" data-start=\"6528\"\u003eEngel MG et al. J Alzheimer’s Dis 103 (2025): 113–126. \u003cspan data-state=\"closed\" class=\"\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6737\" data-start=\"6623\"\u003e\n\u003cp data-end=\"6737\" data-start=\"6626\"\u003eRepligen Corp. LONG R³ IGF-I Cell Culture Supplement Data Sheet (2024). \u003cspan data-state=\"closed\" class=\"\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"6843\" data-start=\"6738\"\u003e\n\u003cp data-end=\"6843\" data-start=\"6741\"\u003eWhite A et al. Am J Physiol Endocrinol Metab (2025, in press). \u003cspan data-state=\"closed\" class=\"\"\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":52684871598418,"sku":null,"price":65.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/igf_1_lr3.png?v=1770834978"}],"url":"https:\/\/sciencepeptideslab.com\/collections\/gh-analogs-and-secretagogues.oembed","provider":"Science Peptides Lab","version":"1.0","type":"link"}